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Thesis abstract 
The present thesis includes five original studies focusing on body composition (BC) in non-
alcoholic fatty liver disease (NAFLD) patients, mainly in a clinical perspective, directed to clinical 
practice. The first study of this thesis aimed at analyzing the relation between body fat (BF) content 
and distribution, as assessed by dual energy x-ray absorptiometry (DXA), and cardiac autonomic 
control, more specifically with heart rate recovery after a maximal exercise test, which is an indirect 
clinical marker of parasympathetic reactivation, also known to be a strong risk factor for overall and 
cardiac mortality. The second study focused on the utility of waist circumference (WC) measurement, 
as a predictor of both BF content and distribution, and also on the comparison of different WC 
measurement protocols based on biological criteria, protocols’ precision and practical criteria, aiming 
to identify a preferential measurement protocol to be used in NAFLD patients. The third and fourth 
studies focused on the influence of using different WC measurement protocols in the relation of both 
waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) with BF content and distribution, as 
assessed by DXA, and aimed to identity a preferable measurement protocol. The fifth study focused 
on body indexes and circumferences usefulness as surrogates of BF content and distribution and 
aimed at identifying if there is a preferential clinical predictor of both BF content and distribution, as 
compared to the commonly used body mass index, in NAFLD patients. The results obtained 
confirmed the strong relation between BC and cardiac autonomic control and showed that BF 
distribution is more important than BF content in explaining cardiac autonomic control variation. It 
was also possible to conclude that WC measured just above the iliac crest seem preferable to be 
used in NAFLD patients, either singly or included in body indexes such as WHR or WHtR, mostly due 
to practical criteria but also because of it strong correlation with both BF content and distribution. 
WHtR appears to be the best BF content and distribution surrogate to be used in clinical practice 
with NAFLD patients. WC alone is a good practical alternative, when simplicity and time saving are 
important instrument/method selection criteria. 
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Resumo da tese 
A presente tese integra cinco investigações originais que se centram no estudo da 
composição corporal (CC) em pacientes com doença do fígado gordo não-alcoólico (DFGNA), numa 
perspetiva eminentemente clínica e direcionada para a prática. Um primeiro estudo visou analisar a 
relação da quantidade e distribuição da massa gorda corporal (MG), avaliada por densitometria por 
raio-X de dupla energia (DXA), com o controlo autonómico cardíaco, mais especificamente com um 
indicador indireto da reativação do sistema nervoso parassimpático, que é a frequência cardíaca de 
recuperação após um esforço máximo, que também é um forte fator de risco para mortalidade. O 
segundo estudo visou avaliar a utilidade da medição do perímetro da cintura, isoladamente, como 
preditor da quantidade e distribuição de MG, em pacientes com DFGNA, e comparar os resultados e 
os procedimentos da medição do perímetro da cintura realizada segundo diferentes protocolos de 
medição de modo a identificar um protocolo preferencial. O terceiro e quarto estudo pretenderam 
avaliar o impacto da utilização do perímetro da cintura obtido segundo diferentes protocolos de 
medição na performance da razão cintura/anca e da razão cintura/altura, enquanto indicadores 
clínicos, duplamente indiretos, de quantidade e distribuição de MG. O quinto e último estudo deste 
trabalho teve como objetivo avaliar a relação de perímetros e índices corporais com a quantidade e 
distribuição de MG, em pacientes com DFGNA, e procurou identificar a existência de alternativas 
preferenciais à utilização do índice de massa corporal. Os resultados encontrados no presente 
trabalho permitem confirmar que a CC está fortemente relacionada com o controlo autonómico 
cardíaco, em pacientes com DFGNA, e que, nessa relação, a distribuição de MG parece ser mais 
determinante do que a sua quantidade absoluta e relativa. Também foi possível concluir que o 
perímetro da cintura medido imediatamente acima da crista ilíaca parece ser a melhor metodologia 
para ser utilizada com esta população, sobretudo por razões de ordem prática, mas também pelo seu 
desempenho na relação com quantidade e distribuição de MG, quer quando utilizado isoladamente 
como quando integrado em índices corporais, como a razão cintura/ anca ou a razão cintura/ altura. 
A razão cintura/altura parece ser a melhor alternativa para ser usada como preditor da quantidade e 
distribuição de MG em pacientes DFGNA, sendo que o perímetro da cintura também é uma boa 
alternativa sobretudo por razões de ordem prática.  
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Chapter 1 – Introduction 
“Presentation of this thesis, including its main focus and purposes as well as its 
organization” 
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With the present thesis entitled “Body Composition in Non-Alcoholic Fatty Liver Disease 
Patients - Usefulness of Body composition and Fat Distribution Markers and their Relation with 
Autonomic Nervous System Cardiac Regulation” (Composição Corporal na Doença do Fígado Gordo 
Não-alcoólico – Utilidade de Indicadores de Composição e Distribuição de Gordura corporal e a sua 
Relação com a Regulação Cardíaca pelo Sistema Nervoso Autónomo), the author aims to obtain the 
Doctoral Degree in Human Kinetics in the specialty of Physical Activity and Health (Doutoramento no 
ramo de Motricidade Humana na especialidade de Atividade Física e Saúde) by the Faculty of Human 
Kinetics (Faculdade de Motricidade Humana) – University of Lisbon (Universidade de Lisboa), 
Portugal. The project for the present thesis was submitted to the Fundação para a Ciência e 
Tecnologia – Ministério da Educação e Ciência, for an individual doctoral scholarship, which was 
awarded (SFRH / BD / 41173 / 2007). The study was developed and conducted at the 
Interdisciplinary Center for the Study of Human Performance (CIPER), at the Faculty of Human 
Kinetics - University of Lisbon, Portugal. 
This work results from the will and effort to contribute to enlighten selected features of 
clinical routine assessments of body composition (BC) of patients diagnosed with Non-Alcoholic Fatty 
Liver Disease (NAFLD). In order to fulfill this purpose, a mix of laboratory and field methods was used 
for the assessment of BC and autonomic nervous system status. The relation of different body fat 
(BF) depots and ratios with a selected mortality and cardiovascular risk related autonomic nervous 
system marker was assessed, and therefore one perspective of the relevance of BC assessment in 
these patients was discussed. The usefulness of clinical methods and specific markers and indexes for 
the assessment of BC to use in daily clinical practice with the studied patients was then evaluated 
and discussed. Ultimately, suggestions were made concerning the inclusion of selected methods for 
efficient assessment of the BC in NAFLD patients in clinical settings.  
1.1. Research rationale 
NAFLD is an increasingly recognized condition that may progress to end-stage liver disease. 
The prevalence of NAFLD is estimated to range up to over 30% of general population in western 
countries tough accurate epidemiologic data are still not available in many countries (1-5). If we 
consider only the obese population, particularly in abdominal or in morbidly obesity, the prevalence 
raises significantly ranging up to 100% (1-3). Because of its’ strong association with obesity, mainly 
central obesity, and with impaired glucose metabolism, it is expected that NAFLD will increase 
strongly, establishing a parallel with the pandemic dimension of the mentioned metabolic disorders 
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(5, 6). NAFLD is also considered to be the hepatic manifestation of the metabolic syndrome (7), and it 
is known that NAFLD patients are at greater cardiovascular risk when compared with the general 
population (8).  
BC, particularly specific BF distribution adverse phenotypes (central, abdominal or visceral 
obesity), may be paramount in the aetiology of metabolic disorders such as  NAFLD (9), and is known 
to be associated to increased overall and cardiovascular mortality as well as mortality and 
cardiovascular risk factors (5, 10-17). Obesity seems to be also somewhat related to important 
mortality and cardiovascular risk related autonomic nervous system (ANS) markers (18). As a part of 
the human nervous system that has been shown to be responsible for many important metabolic 
body functions, including adipocyte, heart and liver functions (19, 20), the ANS may be an important 
piece of the puzzle in the understanding of metabolic disorders and may also be an important target 
of intervention. Data on the relation of BC and heart rate recovery (HRR), a selected marker of ANS 
functioning, is scarce, particularly in subpopulations such as NAFLD patients where it is mostly 
absent. Although being utmost important in the study of metabolic disorders, the study of BC is not 
much explored in the mentioned subpopulation, plus specific and comprehensive guidelines for the 
assessment of BC in NAFLD patients in the clinical setting are lacking. Most often the only BC marker 
studied is the body mass index (BMI) which, although easy to measure and proven useful in 
epidemiological approaches, has known limitations (21, 22). One important BC surrogate that arises 
as a good complement, and possibly an alternative, in BC assessment in clinical settings is the waist 
circumference (WC) (17, 23). However it has been difficult to standardize measurement procedures, 
particularly concerning the anatomical landmarks for the measurement. Other BC clinical markers 
are gaining importance but again, standardization may be a strong impediment for broad 
implementation. The recently suggested body adiposity index seems less exposed to the mentioned 
standardizations difficulties (24) however it has not yet proven significant predictive superiority as 
compared to existing surrogates (25).  These limitations may be restraining the implementation of 
additional or alternative measures in clinical BC appraisals. Any contribution to enlighten the 
mentioned miasmas in the current knowledge may be valuable contribution for the clinical 
management and possible prognostic of epidemic metabolic disorders such as NAFLD. Studies 
focusing on these miasmas are needed before recommendations and guidelines can be properly 
formulated.  
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1.2. Research questions 
Literature focusing on the study of human BC is abundant but studies focusing on the study 
of BC in NAFLD patients are not so. In order to contribute for the understanding of the importance of 
BC in NAFLD patients and to increase the information available to support comprehensive guidelines 
for BC assessment of NAFLD patients in the clinical setting, we sought to formulate the following 
questions: 
1 - Is BF content and distribution associated with ANS in NAFLD patients? 
2 - What is the best WC measurement protocol to be used in clinical practice as a surrogate 
of BF content and distribution in NAFLD patients? 
3 - What is the best WC measurement protocol to be used in clinical practice to calculate 
waist-to-high ratio as a surrogate whole and regional BF in NAFLD patients? 
4 - What is the best WC measurement protocol to be used in clinical practice to calculate 
waist-to-hip ratio as a surrogate of BF content and distribution in NAFLD patients’? 
5 - What are the best body index and/or circumference to be used in clinical practice as a 
surrogate of BF content and distribution in NAFLD patients? 
1.3. Purposes of this research 
The main purposes of this thesis were to contribute for the understanding of the importance 
of BC in NAFLD patients as well as to increase the information available for building comprehensive 
guidelines for BC assessment of NAFLD patients in the clinical setting. With this in mind we 
formulated the following specific purposes of the present study: 
1- To determine if, and to what extent, specific markers of BC and BF distribution, are 
related with a selected mortality and cardiovascular risk related ANS marker in NAFLD 
patients. 
2- To find which of the most used WC measurement protocol is preferable to be used in 
clinical practice with NAFLD patients. 
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3- To analyze whether the most used WC measurement protocol affect the strength of 
association between waist-to-height ratio and both, whole and central BF in NAFLD 
patients. 
4- To analyze whether the most used WC measurement protocol affect the strength of 
association between waist-to-hip ratio and BF content and distribution in NAFLD 
patients. 
5- To analyze how body circumferences and indexes perform as surrogate of whole and 
regional BF content and BF distribution in NAFLD patients; 
6- To find if any specific body index and/or circumference perform better than the 
commonly used body mass index (BMI) as surrogate of BC in NAFLD patients. 
1.4. Outline of this thesis 
The present thesis is composed of ten chapters, as subsequently presented. 
Chapter 1 – Introduction 
The introduction presents the rational for the present investigation. The studied problem is 
disclosed together with the general research questions and purposes of the thesis. The thesis outline 
is presented and a mention to funding source is also made at the end of this chapter.   
Chapter 2 – Review 
This chapter presents a succinct review of the literature aiming to display the state of the art 
concerning the studied topics and to present the biological plausibility of the purposes of this 
research. This chapter is divided into three main parts. The first part focuses briefly on NAFLD 
epidemiology, pathophysiology and health consequences. The second part focuses on BC and fat 
distribution, its´ assessment and implications on health. The third part presents an overview of the 
ANS, including a general description of its’ structure and function, cardiac regulation and respective 
interactions on metabolism, including BF regulations and other health and health risks implications. 
Chapter 3 – Methods 
This chapter provides a comprehensive description of the studied sample as well as the 
methods used for patients’ assessment and data record. The inclusion of this chapter in the present 
thesis allowed the avoidance of the repetition of the description of the methodology used in each 
study, which was mostly similar, particular in respect to the studied sample and the dependent 
variables. This chapter firstly presents the “sample” and “study design” subsections to describe how 
the study was conducted, how the patients were recruited and the general sample characteristics, 
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and then presents the description of the methodology used for patients’ assessment and data 
record, particularly BC and cardiac autonomic control. 
Chapter 4 – Study 1: “Is Body Composition and Body Fat Distribution Related to Cardiac 
Autonomic Control in Non-Alcoholic Fatty Liver Disease Patients?” 
This chapter presents study 1.  The aim of this study was to determine if, and to what extent, 
specific markers of BC and BF distribution, are related with a selected mortality and cardiovascular 
risk related ANS marker in NAFLD patients. The association of different variables of whole and 
regional BC as well as ratios between different BF depots, used as BF distribution markers, with HRR, 
a known cardiac autonomic control marker reflective of parasympathetic reactivation, is analyzed.  
Chapter 5 – Study 2: “Which is the Best Waist Circumference Measurement Protocol to use 
in Non-Alcoholic Fatty Liver Disease Patients?” 
This chapter presents study 2. The aim of this study was to find which of the most used WC 
measurement protocols is preferable to be used in clinical practice with NAFLD patients. Four of the 
most used protocols to measure WC were tested according to different criteria in the quest of finding 
which seems best suitable for use in clinical settings with NAFLD patients.   
Chapter 6 – Study 3: “Does the Wait Circumference Measurement Protocol Used Influences 
the Relation Between Waist-to-Height Ratio and Body Composition in Non-Alcoholic Fatty Liver 
Disease Patients?” 
This chapter presents study 3. The aim of this study was to analyze whether the most used 
WC measurement protocols affect the strength of association between waist-to-height ratio (WHtR) 
and both, whole and central BF in NAFLD patients. In the literature WHtR was initially suggested 
using a specific WC measurement protocol (WCmp) however this ratio has been, most often, 
calculated using a different WCmp from the initially suggested. In this study four of the most used 
protocols to measure WC were used to calculate WHtR ratio and the results were compared in their 
association level with criterion whole and regional BC markers. 
Chapter 7 – Study 4: “Does the Waist Circumference Measurement Protocol Used Influences 
the Relation Between Waist-to-Hip Ratio and Body Fat Content and Distribution in Non-Alcoholic 
Fatty Liver Disease Patients?” 
This chapter presents study 4. The aim of this study was to analyze whether the most used 
WC measurement protocols affect the strength of association between waist-to-hip (WHR) ratio and 
BF content and distribution in NAFLD patients. In the literature WHR was initially suggested using WC 
measured at the minimal waist still this ratio has most often been calculated using a different WCmp 
from the initially suggested. In this study four of the most used protocols to measure WC were used 
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to calculate WHR ratio and the results were compared in their association level with criterion whole 
and regional BC and BF distribution markers. 
Chapter 8 – Study 5: “Are Body Indexes and Circumferences useful as Surrogates of Body Fat 
content and distribution in Non-Alcoholic Fatty Liver Disease Patients as compared with the 
commonly used Body Mass Index?” 
This chapter presents study 5. The aim of this study was twofold: (1) to analyze how body 
circumferences and indexes perform as surrogates of whole and regional BF content and BF 
distribution in NAFLD patients; (2) to find if any specific body index and/or circumference perform 
better than the commonly used BMI as surrogate of BC in NAFLD patients. The strength of 
associations between the clinical BC markers, comprising all studied body indexes and 
circumferences, and criterion BC and BF distribution dependent variables were tested. All correlation 
coefficients were compared to those obtained using BMI to identify alternative clinical markers.   
Chapter 9 – Conclusions 
This chapter presents the final conclusions of the present thesis. All studies are linked into 
one single research project and the main conclusions are presented in three separate sections: the 
first main conclusions concern the strength and limitations recognized in the overall research that is 
being presented; secondly the main findings of the present thesis are presented along with the 
respective practical implications; ultimately some recommendations and future directions of 
research are presented.   
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The present chapter will present the state of the art concerning the studied topics, aims and 
instruments of the research being reported. This chapter is divided into three main parts. Firstly we 
will present a description of non-alcoholic fatty liver disease (NAFLD), its’ pathophysiology, causes 
and consequences, and a characterization of the population diagnosed with this disease. Secondly 
we will make a review on body composition (BC) and body fat (BF) distribution, its´ assessment and 
implications on health. In the end we will present an overview of the autonomic nervous system 
(ANS), including a general description of it’s structure and function, cardiac regulation and its’ 
interactions on metabolism, including BF regulations and other health and health risks implications.  
2.1. Non-Alcoholic Fatty Liver Disease  
NAFLD is a rising metabolic condition that is under considerable discussion. Excess BF and 
particular BF accumulation patterns seem to be strongly linked to NAFLD and possibly play an 
important role in the disease aetiology, progression and consequences. This section outlines the 
pathophysiology and epidemiology of NAFLD, with a special focus on the importance specific 
metabolic disorders (insulin resistance and obesity) in the etiology of NAFLD.  
2.1.1. General Overview of Non-Alcoholic Fatty Liver Disease 
NAFLD is a rising recognized condition that has caught a growing focus over the last years 
(16, 26). The pathological picture of NAFLD resembles that of alcohol-induced liver disease, but it 
occurs in patients without an alcohol intake capable of injuring the liver (>20g/d for men and >30g/d 
for women) (16, 27-29). A diverse terminology has been used to characterize NAFLD, such as: fatty-
liver hepatitis; nonalcoholic Laënnec’s disease; diabetes hepatitis; alcohol-like liver disease and 
nonalcoholic steatohepatitis (16). The name non-alcoholic fatty liver disease has been considered 
preferable, encompassing the full spectrum of non-alcoholic, fat related, liver disease stages (16, 
30). 
There is not complete agreement on criteria for diagnosis of NAFLD, even though it has been 
suggested that it encompasses two basic histological lesions: (I) hepatic steatosis and (II) non-
alcoholic steatohepatitis (NASH) (30-32). Hepatic steatosis consists of fat accumulation in 
hepatocytes mostly resulting from metabolic disorders (32). The degree of liver fat accumulation in 
NAFLD can be graded according to the percentage of hepatocytes with fat deposits: mild NAFLD 
involves less than 30% hepatocytes, moderate NAFLD up to 60%, and severe NAFLD above 60% (33), 
though a slightly different classification has been suggested by Brunt and colleagues (34). NASH is 
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characterized by hepatic inflammation and macrovisicular steatosis along with a constellation of 
other disturbances (32). The term NASH was introduced over three decades ago in the description of 
a group of Mayo Clinic patients, mostly obese and/or with diabetes mellitus, with an unnamed 
disease associated with a fatty liver histology, with elevated liver enzymes along with inflammation 
and fibrosis mimicking alcoholic hepatitis, but in the absence of alcohol intake (35). A proposal for 
grading and staging the histological lesions present in NASH was long presented by Brunt and 
colleagues (34). NASH can evolve to advanced fibrosis, cirrhosis and hepatocellular carcinoma (16, 
30). Fat in the liver can be quantified by image methods [e.g. ultrasound of the liver has a high 
sensitivity and specificity, nearly 90%, for detection of fatty infiltration (36)] but the degree of 
inflammation and fibrosis, as well as other histological features of NASH can only be diagnosed by 
liver biopsy (16, 26, 37). Angulo and colleagues (38) have recently developed a scoring system to 
identify NAFLD patients with and without advanced fibrosis. By applying this model they were able to 
identify 90% of advance fibrosis using only routine measured and readily available clinical and 
laboratory data. In their study Angulo and colleagues (38) could have avoided 75% of performed liver 
biopsies. It is likely that other simple markers, strongly associated with NAFLD, will arise from 
research, and give significant information to estimate disease status.  
The prevalence of NAFL D is estimated to range up to over 30% of general population in 
western countries, though accurate epidemiologic data are still not available in many countries (1-4). 
NASH occurs in up to 5.7% of the general population, in western countries (5, 39). Progression to 
cirrhosis can occur in 15 to 20% of NASH patients (40). In many countries more than 80% of NAFLD 
patients have an increased BMI and obesity has been found present in 25 up to nearly 60% of NAFLD 
patients (3, 41-44). Approximately 50% of NAFLD patients show signs of insulin resistance (IR) and 
20-30% have type 2 diabetes,  80% present hyperlipidemia while arterial hypertension is present in 
about 30-60% (44). If we consider only the obese population, particularly in abdominal or in morbidly 
obesity, the prevalence NAFLD may range up to 100% (1-3, 26). Because of this strong association 
with obesity, mainly central obesity, and with impaired glucose metabolism, it is expected that 
NAFLD will strongly increase, establishing a parallel with the pandemic dimension of the mentioned 
metabolic disorders (6). Bottom line NAFLD is strongly associated to obesity, mostly that of the trunk 
(2, 16, 45, 46), to dyslipidemia, as mentioned before, mainly hypertriglyceridemia (39, 47), and to 
diabetes and IR (39, 46, 48), thereby NAFLD is also considered to be the hepatic manifestation of the 
metabolic syndrome (7, 41, 49). Given the close association between NAFLD and classical 
cardiovascular risk factors it is not surprising to find that patients with NAFLD have a higher 
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prevalence and risk of cardiovascular disease (CVD), as consistently shown by Targher and colleagues 
(8, 50-53).  
2.1.2. NAFLD pathophysiology 
NAFLD, in most cases, is a consequence of an imbalance between factors that promote liver 
fat increase (uptake and synthesis of fatty acids) and factors that promote liver fat reduction 
(secretion and oxidation of fatty acids) (16, 54). It has been suggested a “two-hit” hypothesis for the 
progression of NAFLD (55). The first hit, as mentioned, would be an imbalance in hepatic lipid 
metabolism favouring liver fat increase resulting in hepatic steatosis. The “Two-hit” hypothesis 
proposes that a second hit (oxidative stress and cytokine induction) is needed for inflammation to 
take place resulting in NASH (55, 56).   
The increased level of lipids, mostly in the form of triglycerides, within hepatocytes in 
patients with NAFLD, results from an imbalance between the mechanisms that promote the uptake 
and synthesis of fatty acids and those that promote the oxidation and export of fatty acids (16). The 
accumulation of fat in the liver may be mediated by IR, regardless the fitness level of the patients 
(57). In fact, IR appears to be the most consistent explanation of the development of NAFLD (16, 32, 
46). Two main mechanisms may be involved in the IR mediated hepatic fat accumulation: 
hyperinsulinemia and lipolysis (16). In healthy humans insulin stimulates adipocyte fat uptake and 
inhibits lipolysis (as explained in more detail in subsection 2.3.3.2 in this chapter), therefore reducing 
fatty acids flux from these cells. However, when cells present IR, insulin action is somewhat blunted 
and therefore lipolysis may be increased, resulting in increased fatty acid flux from adipocytes (58). 
The increased flux of fatty acids trough the portal vein towards the liver will result in high liver fatty 
acid uptake that will lead to mitochondrial β-oxidation overload, with the consequent accumulation 
of fatty acids within hepatocytes (16). IR initiates a compensatory effect by the pancreas β-cells that 
will increase insulin production leading to hyperinsulinemia (13) which in turn increases fatty acid 
synthesis in hepatocytes, by increasing glycolysis (32), and also favors the accumulation of fat within 
hepatocytes by decreasing the production of apolipoprotein 100, one main component of very low 
density lipoproteins (VLDL) (32, 59). In summary it is reasonable to assume that IR increases 
hepatocyte fat accumulation by favoring the hepatic metabolic pathways that promote lipid uptake 
and synthesis, limiting those that promote lipid degradation and secretion. 
BC has an important role in the etiology of NAFLD (9) and might as well be a central cause of 
NAFLD. BF distribution may be even more crucial than whole BF in the etiology of NAFLD (5, 16). 
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Excess BF, observed in overweight and obese, besides being an important risk factor for developing 
NAFLD, is also strongly associated with IR and diabetes and may thereby contribute also indirectly for 
the development of NAFLD (5). The relation of increased BF with both IR and NAFLD, besides being a 
statistical relationship, has gained increased biological support. It has been observed that increased 
visceral adipocyte size is a strong predictor of increased triglycerides in the blood (60). More 
specifically, when visceral adipocytes are increased, they are predicted to contribute to nearly 50% of 
portal vein non-esterified fatty acids (NEFA) flux to the liver, as compared to only 5 to 10% observed 
in lean individuals (61). Together, this evidence supports the potential role of obesity, particularly 
abdominal obesity, in the development of excessive lipolysis related metabolic disorders, such as 
NAFLD. Moreover obese individuals, particularly the abdominal obese, display an adverse secretion 
pattern of several cytokines or adipokines, such as C-reactive protein (CRP), tumor necrosis factor-α 
(TNF- α), interleukin-6 (IL-6) and other which can alter lipolysis and insulin sensitivity (62-65), 
reproducing all the metabolic imbalances previously described to be associate to IR alone, that may 
lead to NAFLD. A quite recent study, conducted in rats, even showed significant elevation of hepatic 
triglycerides to precede the presence of IR (66). This is consistent with the assumption that obesity, 
particularly central obesity may be a key factor in NAFLD pathogenesis.  
The so called “two hit” theory states that a second hit, after liver fat accumulation leading to 
simple liver steatosis (just discussed), is needed for NAFLD to progress to NASH (55). The second hit 
has been suggested to include mitochondrial dysfunction and lipid peroxidation (55, 56). Yet, 
mitochondrial dysfunction, quite recently, has been suggested to have a much more central role in 
the development of NAFLD,  preceding hepatic fat accumulation (66) and therefore having a role in 
the development of steatosis (67) and this has been suggested to be somewhat linked to physical 
inactivity (68). The precise step that triggers simple steatosis to move to NASH is not completely 
understood. Visceral adipose tissue was found to be a risk factor for the presence of NASH, and may 
play a role (46). Mitochondria are the main cellular source of reactive oxygen species (ROS) and 
therefore have been suggested to be a major contributor to the progression of NAFLD (56). ROS are 
normal cellular end-products of oxygen metabolism, and are important signaling substances for 
redox balance or activation of defense mechanisms, however, high concentrations of ROS may be 
detrimental for cell metabolism and even for cell survival (69).  As mentioned earlier hepatic 
steatosis occurs in the presence of mitochondrial β-oxidation overload, along with other metabolic 
impairments. Overloaded mitochondrial β-oxidation, present in steatotic hepatocytes generates 
increased opportunities for the formation of ROS which along with increased availability of fatty acid 
within hepatocytes, create an enriched cellular environment for lipid peroxidation. Lipid peroxidation 
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alters lipids integrity in a chain reaction way that may disrupt structural lipids (membrane lipids from 
organelles as mitochondria or from cell membrane itself) if not stopped (e.g. by anti-oxidants) (69). 
Peroxidation of mitochondrial structural lipids causes or increases mitochondrial dysfunction leading 
to higher formation of ROS, and vice-versa, increasing oxidative stress, which may end up causing 
hepatocyte apoptosis (programed cell death) or, in more adverse cases, necrosis (69). Ultimately 
these disturbances may lead to liver fibrosis and cirrhosis (55, 56, 70).  
Bottom line, BC has an important role in the etiology of NAFLD (9). BF distribution may be 
even more essential than whole BF in the etiology of NAFLD (5, 16). Excess BF, observed in 
overweight and obese, and adverse BF distribution, besides being important risk factors that may 
contribute directly for developing NAFLD, are also strongly associated with IR and diabetes and may 
thereby contribute also indirectly for the development of NAFLD as well (5). Additional liver 
disturbances may be needed for NAFLD to progress to more adverse stages and outcomes (55).  
2.2. Body Composition 
The study of BC is strongly associated to, and sometimes confused for the study of obesity, 
though BC includes the study of body components far beyond fat mass alone. Nevertheless, in the 
present study, the focus will be mostly on BF content and distribution. BC is considered to be a 
component of health related fitness and it has proven to have physical, morphological and 
particularly important health implications (71, 72). In this section it will be presented a general 
overview of BC and its’ health implications and a focus on BC assessment with some emphasis on BC 
clinical markers.  
2.2.1. Body composition overview 
The study of BC is a fascinating branch of the biological sciences. Imagining the alterations 
occurring in living body mass, from conception throughout lifespan cannot let anyone dispassionate. 
The field of BC research was suggested to be organized in three interconnecting areas: (I) BC levels 
and their organizational rules, (II) BC methodology, as well as (III) BC biological effects (73, 74). The 
first area involving the study, definition and links of the components themselves in each level of the 
suggested five-level model (described ahead in this subsection, see figure 2.1). The second area 
focuses on the study of BC measurement techniques to assess the various components in vivo. These 
include sophisticated laboratory methods as well as practical clinical methods and instruments. The 
third area involves the study of the influence of biological factors on BC, including those related to 
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both physiological and pathological conditions. Specific research topics included in this area of 
research comprises growth, development, aging, race, nutrition, hormonal effects, physical activity 
as well as diseases and medications that may influence BC. Even though this was not clear in the 
terminology proposed by Wang and colleagues for the organization of BC research, in the present 
thesis it was assumed that the influence of biological factors on BC (the third area of the proposed 
terminology) can be observed in both directions, meaning BC may be sometimes viewed as a 
determinant and/or as a consequence of abnormal or pathological conditions. Over the years a wide 
variation could be observed in the terminology and methodology used in the study of BC. The 
terminology and the five-level model suggested by Wang and colleagues (see figure 2.1) was 
milestone in the field of BC research and is still fairly consensual, despite the technology advances 
occurred. In the five-level model,  it is assumed that each component within each level is mutually 
exclusive and the sum of all components in the same level is equivalent to whole body mass (73).  
 
Figure 2.1 – The five-level model in body composition suggested by Wang and colleagues. Adapted from Shen and 
colleagues (74), pp 4. N: nitrogen; CHO: carbohydrates. 
The atomic level includes eleven major components, including oxygen, hydrogen, carbon and 
nitrogen which all together account for more than 96% of whole body mass (74). The mentioned 
atoms constitute molecules including water, lipid, carbohydrates, proteins, lipids, bone minerals and 
soft tissue minerals, which are the six major components at the molecular level (74). This is probably 
one of the most considered level in BC analysis. At the molecular level it is possible to use 
multicomponent models: such as the widely used two compartment model (BF + fat free mass) which 
can be assessed by most methods available; or the three compartment model (eg. BF + bone mineral 
content + lean soft tissue) as can be assessed by dual energy x-ray absorptiometry (DXA); or the 
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common gold standard four compartment model (eg. Fat mass + total body water + total body 
protein + minerals) which needs to be assessed with a combination of methods (74). The cellular 
level includes three components: extracellular solids; extracellular fluids and cells, which include 
both fat and body cell mass. The tissue-organ level results from the differentiation of cells into 
tissues and organs, including adipose tissue, skeletal muscle, visceral organs and bone. At this level it 
is important to distinguish between adipose tissue and the wide studied BF or even from lipids, the 
latest both assessed at the molecular level (see figure 2.2) (74). Lipids include all of such molecules in 
the body, including non-fat lipids (lipids that are not in the form of triglycerides), both in adipose and 
other tissues, lipids stored within the adipose tissue in the form of triglycerides, and lipids in the form 
of triglycerides stored in other tissues. The commonly used word “fat” may be used interchangeably 
with BF and refers to triglycerides, which are the molecular form in which lipids are stored in the 
body. BF can be stored in the adipose tissue and in other tissues as well. Adipose tissue comprises BF 
and non-fat lipids, such as phospholipids, but includes also other components essential to the 
survival and function of adipose tissue cells. About 80% of adipose tissue is fat and the remainder 
20% are water, proteins and minerals (75). The fifth level, the whole-body level, can be assessed 
using simple measures of weight or height, and can also be divided into regions such as the head, 
limbs and trunk, which can be assessed with various anthropometric techniques, such as 
circumferences, skinfolds and lengths. 
 
Figure 2.2 – The relationships between molecular-level components lipid and fat and the tissue-organ-level component 
adipose tissue. Adapted from Shen and colleagues (74), pp 12.  
Shen and colleagues (75) presented a classification of adipose tissue location, based on 
image methods, which was very important to give some coherence to the wide terminology that was 
being used by then. In general adipose tissue is divided into subcutaneous and internal adipose 
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tissue. Subcutaneous may be divided into superficial and deep subcutaneous adipose tissue. Recently 
it has been given some importance to this division of subcutaneous adipose tissue (17). Internal 
adipose tissue can then be divided into visceral and non-visceral and these can subsequently be 
divided in many other specific fat depots, all according to their specific location (75). Sometimes BF 
may be stored in the visceral region, outside of adipocytes, near the organs. This is called ectopic fat 
and seems to have important health implications (76-78). Though this terminology was developed 
using image methods, DXA, despite being considered an image method, cannot assess all of the 
mentioned adipose tissues. DXA assesses BF in the whole body or body regions but cannot identify 
adipose tissue. Some attempts, however, were made to estimate visceral adipose tissue using DXA 
(79, 80) and found coefficients of correlation over 0.85, which is considered to be high. Yet DXA can 
only give precise estimates of whole BF, as does air displacement plethysmography (81), additionally 
DXA also estimates BF of specific regions or segments of the body, including the upper and lower 
limbs, the trunk or the abdominal regions, and other customized regions if intended (82). The 
present thesis adopts the terminology recommended by Sardinha and Teixeira (77): whole BF refers 
to whole body; regional BF represents a single variable of a body region, as in total abdominal fat; BF 
distribution refers to the measurement of one variable in relation to another so that a dichotomous 
fat distribution type can be identified (e.g., a contrast or a ratio), as is expressed in Vague’s pioneer 
observations on this topic (83, 84). Never the less it is recognized that the expressions “regional BF” 
and “BF distribution” have been commonly used interchangeably (77). 
BF distribution analysis started with the study of body shape (13). In the beginning of the 20th 
century, after World War II, insurance companies identified a higher risk of mortality related to 
certain BF distribution Phenotypes (11). In the conviction that fat accumulation in different regions of 
the body could have different predictive values, classifications of BF distribution were developed, 
such as Vague’s classification (83, 84) that distinguished central BF accumulation (android) from 
peripheral, preferentially lower, BF accumulation (gynoid). BF distribution has long been shown to be 
related with other adverse outcomes, including diabetes, CVD, some forms of cancer and mortality 
(11). BF distribution markers have been suggested to be more consistent and strong predictors of 
CVD in healthy men and women, as compared to whole body markers of generalized adiposity (85), 
and the potential usefulness of such BF distribution clinical markers for public health has been 
recognized (86). BF distribution has also been shown to be particularly related to other metabolic 
impairments such as NAFLD (2, 16, 45, 46), as mentioned and explained in the previous subsection of 
the present work. More than six decades after Vague’s preliminary publication, BF distribution is still 
receiving increased attention and related publications (17, 78). Image methods have been assumed 
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as criterion in the study of BF distribution, yet computerized axial tomography (CT) and magnetic 
resonance imaging (MRI), often used as reference methods to quantify adipose tissue (87, 88), do not 
assess BF (75). DXA assesses BC in a three compartment model within the molecular level and can 
estimate whole and regional BF content and distribution (82). Studies using DXA have however 
showed that BF from specific regions of interest (ROI) may be considered acceptable predictors of 
visceral adipose tissue (79, 80, 89, 90). Studies using ratios between DXA assessed ROI have also 
been able to predict MRI assessed visceral adipose tissue (91). BF can also be quantified by magnetic 
resonance spectroscopy (MRS) in various tissues-organs, such as the liver (92) or the muscle (93). 
Another image method often used to estimate liver fat content is ultrasound (94). Many clinical 
markers of BF content and distribution have been suggested, including simple anthropometric 
measurements and resulting calculated body indexes, as discussed ahead in the present chapter. 
These anthropometric variables and indexes assess BC at a whole-body level to evaluate body 
dimensions and morphology, and often are used as BF content and distribution surrogates.  
2.2.2. Body Composition and obesity 
The study of overweight and obesity has been overwhelming in the field of human BC 
research, maybe because of both the pandemic dimension of its prevalence in developed countries 
(95, 96) and the associated health implications of such widespread condition (14, 97, 98). The study 
of BC in specific subpopulations, such as NAFLD patients, is not so well explored as in the general 
population or in other specific subpopulations but is giving consistent steps and growing. Obesity has 
been defined as an excess of adipose tissue (71) however adipose tissue is difficult to assess, 
requiring expensive and limited access imaging methods such as computed tomography or magnetic 
resonance imaging (75). Obesity has also been referred to as an excess of BF (17, 99), which should 
be easier to estimate than adipose tissue. However the most widely used definition of obesity is “a 
state of excessive weight” mostly because of the simple and inexpensive marker recommended by 
most prominent organizations (72, 100-102) and most often used for the diagnosis of obesity: the 
body mass index (BMI = weight [kg] / height [m]2). As mentioned, obesity is an important health 
concern and is linked to many other diseases and morbidities and ultimately, to higher mortality 
rates (11, 103), but the problem in obesity seem to be more related to altered metabolism of surplus 
fat and enlarged adipocytes, along with other metabolic impairments (17, 104, 105), rather than just 
an excess of body weight alone (106). Therefore whenever obesity is mentioned, in the present work, 
it should be referring to excess BF. The link between BF and related morbidities, or the detailed 
physiologic pathway that links them, are not still completely disclosed. Nevertheless it seems rather 
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consistent that the altered metabolism associated to excessive BF, either circulating fat as 
generalized intracellular fat, may play the pathological role in obesity (46, 104, 107-109).  Obesity has 
been shown to be particularly linked to an increase in CVD, especially coronary artery disease, and 
this seemed to be mediated by other obesity related risk factors (e.g. diabetes, dyslipidemia, 
hypertension or sedentary lifestyle) (12, 15), however, in the Framingham Heart Study obesity was 
shown to be an independent risk factor of CVD, in both men and women (103, 110, 111), and in 1998 
obesity was classified as a primary risk factor for CVD by the American Heart Association (112). 
Several excellent scientific reviews have been published focusing on the causes and health 
consequences of obesity, including all obesity related pathophysiological and pathogenic specificities 
(113-121). It is not the aim of the present work to replace these publications. 
2.2.3. Clinical markers of body composition/obesity 
This subsection focus on the clinical markers studied in the present thesis. This includes 
established and promising body indexes as well as body circumferences. A description and review 
regarding each studied clinical marker will be presented in the following subsections. To better 
organize the information, this subsection is divided in three parts: the first part regards the well-
established BMI; the second part regards the selected body circumferences; the third part focus on 
body indexes, other than BMI.   
2.2.3.1. Body mass index  
BMI, calculated as weight, in kg, divided by squared height, in meters (BMI = weight [kg] / 
height [m]2), is a simple marker of excess body weight, easy to measure, highly precise and strongly 
associated with overall fat (122) thus has been shown to explain 74% and 55% of the variation of 
whole absolute and relative BF (as assessed by Dual Energy X-ray Absorptiometry), respectively 
(123). BMI has also been shown to be particularly highly related with whole and subcutaneous 
adipose tissue, besides being strongly related with body circumferences and Waist-to-height ratio 
(WHtR) (discussed ahead in this subsection) (124). BMI has been massively used and endorsed by 
prominent institutions/organizations for the diagnosis of overweight and obesity (72, 100-102, 125). 
BMI however assesses BC at a whole body level, considering Wang’s five-level model (73), and does 
not assess any specific BC component, though having, as mentioned, a significant association with 
generalized fatness (122). Therefore, when assessing obesity, BMI may be deceptive (17). The 
limitations of BMI have long been reported (21, 99, 126), several other markers have been advocated 
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(23, 127, 128), and new markers are being suggested regularly (17, 24, 129). Even though the 
usefulness of BMI may be accepted in the assessment of secular trends of the prevalence of obesity 
at the population level, BMI has been suggested to only provide a crude measurement of total 
adiposity and do not accurately diagnose obesity, at least at the individual level (126, 130). The 
endorsement of the use of BMI as a marker for obesity has relied recurrently on same arguments, 
including: BMI measurement is simple, non-invasive, reliable and inexpensive (131); BMI is 
associated with BC, particularly to fat (132), and BMI is also related with mortality and morbidity 
(133-136), including with the prevalence of NAFLD (137). The first argument may be very well applied 
to other markers, such as WC, which has been suggested to be as much or even more simple, non-
invasive, reliable and inexpensive as compared to BMI (23). The second and third arguments have 
also shown fragilities and are somewhat interrelated (21). The BMI has been shown to be highly 
related with whole BF assessed by DXA (138), which is the most important body component in 
determining obesity, and has even been shown to be associated with abdominal BF depots, 
particularly subcutaneous adipose tissue (139). However BMI is also related to other body 
components of the lean tissue, such as muscle or bone (21). Ultimately a person with high levels of 
muscle mass and bone mineral density may be classified as overweight or obese, even if he/she does 
not have excess BF or related metabolic disorders. On the opposite direction, subjects with normal 
BMIs are often shown to have excess BF and related metabolic disorders. Individuals with the later 
mentioned phenotype are often referred to as metabolically obese normal-weight individuals (45). 
BMI does not take into account the heterogeneity of regional BF deposition (140), which has been 
identified as an important correlate leading to CVD (13) and possibly to NAFLD (5, 16). Frankenfield 
and colleagues (99) found that 30% of men and 46% of women with BMI under 30kg/m2 had obesity 
levels of fat, as defined by results over 25% or 30% of BF for men and women respectively. The under 
prediction of obesity has been considered a greater error than its over prediction because the risk is 
higher for the development of co-morbidities in under predicted obese patients, which may also skip 
or delay important therapy (126). In specific subpopulations, such as CVD patients (141), dialysis 
patients (142) or even elder individuals (143), increasing BMI seems to be protective, which is 
completely against the concept of obesity. This underlies the concept of the “obesity paradox”, firstly 
introduced over ten years ago by Gruberg and colleagues (144) and was further studied and 
consolidated, particularly by Lavie and colleagues (145-164). A fairly recent report by Coutinho and 
colleagues (141) helped enlighten this topic and should hopefully spur further studies to consider 
going beyond the BMI to assess the morbidity/mortality risk associated with excess adiposity in 
specific subpopulations such as that of patients with CVD. The mentioned report provides robust 
evidence that anthropometric correlates of body shape, such as WC and the WHR, matter a lot more 
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than the BMI, which is only an index of relative body size and not of BC /BF distribution, in the 
subpopulation of CVD patients. The recent study by the same research group (165) showed that the 
highest mortality risk in CVD patients was found in subjects with a BMI of 22kg/m2 and a WHR of 
0.98, which means a normal weight person with central fat accumulation. This may lead to the 
assumption suggested by Despres, that the so called “obesity paradox” may rather be a “BMI 
paradox” (130). Other subpopulations should be tested for the usefulness of BMI and alternative 
tools should be standardized at least when BMI proves deceptive.  
2.2.3.2. Body circumferences 
Over the years a considerable amount of tools and markers have been advocated for the 
assessment of BC and the associated health risks, either alternatively and/or complimentary to BMI. 
In the present work some of the most conspicuous proposals were studied. Body circumferences 
have been shown to be less skill dependent and have lower inter-observer variation, as compared 
with skinfold measurement (166, 167). Body circumferences, sometimes called body girths (168), 
have been also widely used and recommended (23, 72, 86, 102, 125, 167, 169-173), for use in clinical 
settings. WC measurement has been extensively used in different settings and populations (23, 86, 
169), including the subpopulation of NAFLD patients (174). WC is considered a risk factor for NAFLD 
(175, 176) and was found to be related with CVD related morbidity, with diabetes and with 
cardiovascular as well as all-cause mortality irrespectively of WC measuring site (23, 177, 178). WC 
cut off values to assess overweight and obesity, as well as increased cardiovascular risk, have been 
developed for different ethnic groups (179), however the most commonly used cutoffs are those 
defined by Lean and colleagues (180, 181) (overweight = 94 cm and 80 cm; obesity = 102 cm and 88 
cm; for men and women, respectively), derived from a cross-sectional population predominantly 
from European origin, yet worldwide accepted cut off values are yet upcoming (86). Specific WC cut 
off values have been developed for Japanese workers (85 cm for men and 80 cm for women) above 
which was recommended that everyone should be referred for fatty liver appraisal through 
abdominal ultrasound (182). In NAFLD patients WC has been found to be associated with several 
metabolic impairments including IR (183, 184) as well as liver fat (174) and NAFLD severity (185, 186). 
Moreover high WC was also found to be related to increased health-care costs (187). WC has been 
considered a proper surrogate of BC, particularly when focusing on regional BF or in BF distribution, 
in the general population and in selected subpopulations (139, 169, 188), showing high correlations 
with most body circumferences, particularly with arm and hip circumferences (hip-C) (r2=0.89 and 
0.84, respectively), and also with visceral, subcutaneous and whole adipose tissues, in addition to 
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both BMI and WHtR (124). Observations using computed tomography showed that WC was better 
predictor than both BMI and WHR, of overall abdominal BF depots, including intraperitoneal and 
retroperitoneal adipose tissues plus anterior and posterior abdominal subcutaneous adipose tissues 
(139). WC was also found a very good predictor of both trunk and waist BF, as assessed by DXA (138). 
Conversely, the relation of WC with NAFLD patients’ BF content and distribution has been 
overlooked. Also, even with the robust evidence concerning WC as a strong BC marker and a 
predictor of the risk of numerous diseases and adverse outcomes, and also despite the widespread 
usage of WC, there is currently no optimal and uniquely recommended WC measurement protocol 
(WCmp) to be used in clinical practice, either in general population as in specific higher risk 
subpopulations. Several WCmp have been recommended by sound authorities, such as the World 
Health Organization (WHO) (125) or the International Society for the Advancement of 
Kineanthropometry (ISAK) (168), but scientific rational is lacking to recommend one single protocol 
(23, 189). The suggested protocols differ mainly on the anatomical landmarks and correspondent 
measuring sites (see table 2.1). The most frequent WC measurement sites found in the literature 
were at the midpoint between the lowest rib and the iliac crest, as suggested by the WHO, at the 
minimal waist (as suggested by ISAK) and at the umbilicus, still a fourth measurement site has also 
been used and endorsed by the National Institute of Health of the United States and also by the 
Canadian Society of Exercise Physiology, which is measured just above the iliac crest (23, 102, 171, 
190). Nevertheless several other measuring sites have been sparsely used (23).  
Table 2.1 – Waist circumference measurement landmarks and references. 
References Protocol 
ISAK (168); ASRM (170); ACSM (72)  Measured at the level of the narrowest site of the torso (minimal waist). 
NIH/CDC (171, 190);  CSEP  (189) Measured right above the iliac crest. 
WHO (86, 125, 191) Measured at the mid-distance between the last rib and the top of the iliac crest. 
Commonly used, including in studies 
on NAFLD (51, 68)  
Measured at the level of the umbilicus. 
ISAK – The International Society for the Advancement of Kinanthropometry; ASRM – Anthropometric Standardization Reference Manual; ACSM 
– American College of Sports Medicine; NIH – National Institute of Health; CDC – Centers for Disease Control and Prevention; CSEP – Canadian 
Society of Exercise Physiology; WHO – World Health Organization. 
Besides WC, other body circumferences have been used and suggested for the study of 
human morphology and BC (168, 170-173), yet the volume of the knowledge and publications 
concerning these other body circumferences are not comparable to that of WC. Unlike WC 
measurement protocol, the protocol for hip-C measurement, at the maximum extension of the 
buttocks, is fairly consensual (168, 170-172). Smaller hip-C seems to be associated with an adverse 
metabolic profile, including increased features of the metabolic syndrome (192) and with higher 
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intima-media thickness (193), in obese women. Still small hip-C seem to decrease survival in both 
men and women, however physical activity may counterbalance, at least partially, the adverse effect 
of small hips (194). Larger hip-C, conversely, were shown to be associated with a lower risk of type 2 
diabetes, lower glycemia and better lipid profiles, independently of BMI, age, and WC (195-199). 
These seem to be true particularly for women, when adjusting for WC (200, 201). This inverse 
association of larger hip-C with diabetogenic and atherotrombotic profile, for any given WC, was 
confirmed in our laboratory, in obese women (202). Ethnicity was argued to be irrelevant in the 
inverse relation between hip-C and hazardous outcomes (196), however, opposite results have also 
been found in specific populations, such as the Australian aborigines and Chinese (203, 204). In a 
recent cohort of both men and women, first degree relatives of diabetic patients, hip-C was neither a 
positive nor negative risk factor for incidence of diabetes (205). A recent meta-analysis by the same 
authors, however, confirmed the inverse relationship between hip-C and risk of type 2 diabetes in 
both men and women (206). Also quite recently, hip-C was found important for the assessment of 
mortality risk and it was suggested that central obesity related risk, as assessed by WC, may be 
seriously underestimated if hip-C is not taken into account (207). Hip-C was found among the highest 
correlates for the percentage of whole BF, as well as for BMI and WC (24). Hip-C has been shown to 
be associated with subcutaneous adipose tissue and, to a much lesser extent, with skeletal muscle 
and with visceral adipose tissue, in both men and women, as opposed to WC which seems more 
related to visceral adipose tissue (124, 208). Hip-C was also found to be correlated with the other 
body circumferences as well as with BMI and WHtR (124). Hip-C correlates in NAFLD patients are 
unknown. A model for calculating BMI based on WC and Hip-C measurements was developed with 
promising results, meaning whenever circumference measurements are available, the measurement 
of both weight and height to calculate of BMI may be redundant (209). Recently the measurement of 
both waist and hip-C were recommended to be considered together, but not as a ratio, to improve 
risk prediction models for cardiovascular and other hazardous outcomes (210).  
Another common body circumference described in the literature is the thigh circumference 
(thigh-C). Thigh-C measurement protocol, though not as inconsistent as WC measurement protocol, 
is also not as consensual as the protocol for hip-C measurement, as there are varying terminology 
and references for its assessment. In a milestone publication launched over two decades ago, thigh-C 
measurement was suggested in three different ways, each using its’ own landmarks and measuring 
sites: proximal thigh-C; mid-thigh-C and distal thigh-C (170). Most authors and 
institutions/organizations used and endorsed mid-thigh-C measurement (167, 172) also called mid-
thigh girth (168) or simply thigh-C (173) as will be called throughout the present work. Smaller thigh-
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C were shown to be associated with increased risk of CVD, IR and premature death (211-213). As 
with hip-C, larger thigh-C were shown to be associated with a lower risk of type 2 diabetes, 
independently of BMI, age, and WC (195). Thigh-C was shown to be associated to subcutaneous 
adipose tissue, and seem to have also a moderate relation with skeletal muscle and whole adipose 
tissue, though being associated with other body circumferences (124, 208). Associations with whole 
BF were also found in girls (214). Thigh-C has also been shown a strong association with both BMI 
and WHtR, though not as strong as that obtained between other body circumferences and the same 
body indexes (124).  
Arm circumference (arm-C) measurement, occasionally called arm relaxed girth (168) or mid-
upper arm-C (172, 215) or even mid-arm-C (216, 217), has been described according to two 
mainstream measurement protocols. One arm-C measurement protocol was standardized about 25 
years ago, as described in the Anthropometric Standardization Reference Manual (170), is widely 
used in the United States of America and is endorsed by the National Institutes of Health (171, 190) 
and others (167, 172, 173), which is measured at the mid distance between the acromion and the 
olecranon, measured with the elbow in a 90⁰ flexed position. The other prominent arm-C 
measurement protocol soundly endorsed by the ISAK (168) is measured at the mid-distance between 
the acromiale and the radiale landmarks, with the arms hanging by the sides in a relaxed position. 
Arm-C has been used for decades in the assessment of malnutrition in diverse populations, including 
children and underdeveloped countries population, particularly in emergency settings (215, 218-
221). Also for some decades now arm-C has also been known to influence blood pressure 
measurement and the diagnosis of hypertension (216, 222-224). Arm-C was later found to be 
positively correlated to hypertension related cardiac left ventricle abnormalities, yet showing a small 
effect size (225). Low arm-C was associated to poor prognosis in advanced cancer patients (226) and 
seems a better predictor of long term mortality risk, as compared to BMI, in older adults (220, 227). 
Arm-C seems highly reproducible and related with body weight, therefore it has been recommended 
that it should be used more often in nutritional studies (217, 228). It has been shown to be a good 
measure, capable of detecting variations as small as 2.2%, particularly when assessed always by the 
same observer (229). Arm-C seems particularly related with skeletal muscle, in addition to 
subcutaneous and whole adipose tissue, and was found to be related also with the other body 
circumferences, as well as with both BMI and WHtR (124). Arm-C correlates in NAFLD are unknown.  
Also occasionally used is calf circumference (calf-C), also called calf girth (168), which 
measures the widest circumference of the leg. Calf-C has been widely used in India for the 
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assessment of low birth weight (230-235). Calf-C has also been used to assess Duchenne dystrophy, 
which is characterized by increased calf volume, despite progressive muscle weakness (236). In 
elderly individuals low calf-C has been related to muscle disability, limited physical function (237) as 
well as nutritional status (238-241). An inverse association was found between calf-C and 
atherosclerosis, suggesting a protective effect of increasing calf-C, but this was only observed in 
elderly (242) and in type 2 diabetes Korean patients (243). Nevertheless calf-C seems to be positively 
related to insulin sensitivity in type 2 diabetes Korean patients (213). Low calf-C was found 
somewhat predictive of mortality in elderly individuals (177, 227, 244). Calf-C was found to be 
particularly related with skeletal muscle, in addition to subcutaneous and whole adipose tissue (124). 
Calf-C also showed strong correlations with the other body circumferences as well as with both BMI 
and WHtR (124). Calf-C correlates in NAFLD are unknown. 
2.2.3.3. Alternative body indexes 
In addition to BMI and single anthropometric measurements, other composed variables, 
often called indexes, have been developed and have also been shown to be of value in the 
assessment of BC, BF distribution and related health risks (24, 91, 129, 138, 245). One of such body 
indexes was the WHR, calculated as WC divided by hip-C, both in centimeters (WHR = WC [cm] / HC 
[cm]). WHR has been suggested mainly as a BF distribution surrogate and has been used to predict BF 
distribution related risk (86). WHR has been consistently linked to metabolic disorders, including type 
2 diabetes, hypertension and dyslipidemia, in diverse populations (178, 246-249) and to the 
respective outcomes, particularly cardiovascular (247, 250, 251), and was also shown to be closely 
related to the occurrence of NAFLD (252). Increased WHR has also been linked to a higher specific, 
particularly cardiovascular, and all-cause mortality (141, 253-258) however opposite results have also 
been found (259, 260). Still cut off values of 0.95 for men and 0.80 for women were defined for the 
identification of high WHR (261). WHR was found positively correlated with intraperitoneal and 
retroperitoneal adipose tissues as well as with anterior and posterior abdominal subcutaneous 
adipose tissues, yet WC performed better than WHR in predicting the later (139). Plus WHR was 
found to be moderately related with DXA derived BF ratios, including trunk BF-to-total BF ratio and 
trunk BF-to-appendicular BF ratio (262). Though, strong association have also been found between 
WHR and both DXA assessed trunk BF-to-appendicular BF ratio and waist BF-to-hip BF ratio (138). 
WHR correlates in NAFLD patients needs further attention. Even though WHR was initially suggested 
to be calculated using measurements of WC at the minimal waist (261), the WC measured at the mid 
distance between lowest rib and iliac crest has been the most used protocol (179). The considerable 
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variation in methodology and results found in the literature may be limiting, to some extent, a wider 
usage of this body index, however it is not known if this influences WHR correlation with BC, BF 
distribution and related health risk. WHR is assumed to reflect the distribution of fat throughout the 
body and a high WHR should represent a preferential abdominal or central accumulation of BF (128) 
and it has generally proven to be so (91, 138, 139) yet conflicting results have also been found (263). 
The importance of using one consensual standardized measurement protocol to calculate WHR was 
soon identified (264, 265). Yet no single consensual measurement protocol in recognized and a wide 
diversity of methods for the measurement and calculus of WHR can be found in the literature (179). 
Another promising body index is the waist-to-height ratio (WHtR), calculated as WC divided 
by height, both in centimeters (WHtR = WC [cm] / height [cm]) (129). WHtR is an index of abdominal 
obesity initially suggested by Hsieh and Yoshinaga in the mid-nineties (266, 267). By then WHtR was 
suggested to be a better predictor of multiple coronary heart disease risk factors than other obesity 
and fat distribution indexes in both men (267) and women (266). A cut of value of 0.5 was suggested 
for the diagnosis of high WHtR in both male and female individuals from different ethnic groups (245, 
268, 269). This cutoff value has been argued to support a strong public health message: “keep your 
waist to less than half your height”! Heymsfield and colleagues (124) presented data providing the 
conceptual foundation, based on a geometrical model, to support the relation of body 
circumferences with body size and composition, specifically in relation to height, which is the rational 
for WHtR. Additionally WHtR has been suggested to be preferable to other indexes and clinical 
assessments, including BMI, WC and WHR, to predict individual and clustering cardiovascular risk 
factors, including diabetes, hypertension and lipidemia, in different ethnic and age groups (129, 270-
274) tough comparable results have also been found (247, 270, 275) particularly with WC (276). 
Besides being associated with traditional cardiovascular risk factors high WHtR has been shown to be 
associated uric acid, C-reactive protein, and liver function enzymes (aminotransferases) (277). WHtR 
was also considered marginally preferable to BMI, WC and WHR in the longitudinal identification of 
incidence of CVD and related events (247) as well as to all-cause mortality (254). WHtR has been 
advocated to be a good alternative to BMI in the assessment of obesity related risk, and strong 
arguments have been putted out, including the fact that it is more sensitive than BMI as an early 
warning of health risk; it is cheaper and easier to calculate as compared to BMI; the cutoff value of 
0.5 may be used in males and females from different ethnic and age groups, including children, which 
is not true for BMI (269). To our knowledge only one study focused on NAFLD patients using WHtR 
(252). WHtR seems elevated in NAFLD patients but was not a better prognostic factor of NAFLD than 
were BMI or WHR. Additional research concerning in NAFLD patients is needed to establish 
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unequivocal usefulness of WHtR in this sub-population. WHtR has been studied mainly in relation to 
metabolic abnormalities and cardiovascular risk however some observations have also showed WHtR 
to be at least similarly associated to abdominal fat as is WC, and better than both BMI and WHR (278, 
279). WHtR was found to be more associated to visceral than to subcutaneous adipose tissue, as 
assessed by MRI (91, 275) however higher correlations with subcutaneous and whole adipose tissue 
was also found (124). WHtR was shown to be related with overall body circumferences, as well as 
with BMI (124). Despite some rather robust body of evidence regarding the study of WHtR, there is 
still some inconsistency considering the WCmp used to calculate WHtR (280). Scientific rational is 
lacking to recommend one single WCmp among the several protocols that have been suggested and 
endorsed by sound authorities, and used by prominent authors (23, 169, 189). Using different WCmp 
result in different WC magnitudes and therefore are not interchangeable (23). WHtR was initially 
suggested using WC measured at the umbilicus (266, 267). In a recent review (280) on WHtR, WC 
measured midpoint between the lowest rib and iliac crest was found to be used in 50% of the 
reviewed papers, and for that reason its routine use was encouraged. 
A novel body index was suggested rather recently, and claimed to be a better predictor of 
whole body adiposity than other already established common body indexes (24). Yet conflicting 
results were promptly disclosed (281) and have been reported since (25, 282, 283).  The body 
adiposity index (BAI), calculated as the hip-C, in centimeters, divided by height, in meters, to the 1.5 
power minus eighteen (BAI = (Hip-C [cm] / height [m] 1.5) – 18), was shown to predict percentage of 
BF (%BF), as assessed by DXA, with highly concordance (24), and it has generally proved to do so, in 
different populations (284, 285). Some studies however countered the argument that BAI is superior 
to other indexes, such as the BMI (25, 281), but also this counterargument has not been consistent 
(286). Of notice is the fact that hip-C measurement protocol is quite standardized and therefore this 
body index does not have the limitation reported for WHR and WHtR, which is the inconsistency 
regarding WCmp. BAI, though seemingly predictor of %BF, has been suggested to be ineffective to 
cardiovascular risk (282, 287-289). This is not surprising if taken into account the available 
information concerning the link between hip-C, a key component of BAI, and cardiovascular risk 
(described earlier in this subsection). Accordingly BAI was found to be inferior to BMI in the 
prediction of most cardiovascular risk factors (275, 290, 291). No studies could be found, using BAI, 
neither related to NAFLD, nor conducted in NAFLD patients. 
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2.3. Autonomic Nervous System 
The human nervous system comprises an ensemble of structures and a load of functions, 
many of them still under discussion. The autonomic nervous system is considered to be an important 
part of the human nervous system that strongly contributes for the dynamic maintenance of body’s 
homeostasis. A general overview of the human nervous system and a specification of the anatomy 
and functions of the ANS, particularly those related with lipid metabolism with possible important 
implications in body composition, will be presented here.  
2.3.1. General overview of the human nervous system 
The Human nervous system comprises two main groups of structures with different 
functions: the central nervous system (encompassing the brain and the spinal cord) and the 
peripheral nervous system (including the efferent and the afferent divisions) (292). The ANS is part of 
the efferent division of the peripheral nervous system and is involved in the innervation of all tissues 
other than skeletal muscle (292). The ANS includes the enteric nervous system as well as both the 
sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS). The enteric 
nervous system is a specialized nerve network in the wall of the intestinal tract and will not be 
further discussed here.  
2.3.2. The Autonomic Nervous System Divisions  
Both SNS and PNS have some similitudes, e.g. both have two-neuron connections between 
central nervous system and the effector cells, the first neuron has its cell body in the central nervous 
system and ends in an autonomic ganglion were it synapses with a second neuron that leads the 
stimulus to the effector cell or organ (292). However there are important differences between both 
SNS and PNS that makes possible for these two structures to have such distinct and unique functions. 
One such difference is in the communication with effector cells and organs: in the synapse between 
the first neuron (preganglionic fiber) and the second neuron (postganglionic fiber), both SNS and PNS 
use mainly the same neurotransmitter which is acetylcholine, however, in the SNS, the major 
neurotransmitter between the post ganglionic fiber and the effector cells is norepinephrine while in 
the PNS it is still acetylcholine (292). This underlies one major difference between both ANS divisions, 
that is crucial for the distinct, many times opposite, effects exerted in effector cells and related 
organs. Another important difference relies on the anatomical arrangements of both divisions: SNS, 
to some extent, has an entire system tied together so that it can act as a single unit, despite some 
small independent regulations; PNS, in contrast, is made up of relatively independent components, 
making it possible to have more variable responses, more tailored to specific demands (292). One 
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last difference discussed here is that SNS has two input pathways to target effector cells and organs: 
(I) a normal neuronal pathway through its’ neurotransmitter (norepinephrine) released by 
postganglionic fibers and (II) an adrenergic pathway through the adrenal medulla which is a set of 
postganglionic specialized neurons that never develops axons, instead, when activated by 
preganglionic fibers, release epinephrine (about 80%), norepinephrine, plus small amounts of other 
substances as dopamine and ATP, directly to the bloodstream (292). These substances, called 
hormones rather than neurotransmitters, are them transported via the blood to the effector cells 
and organs that may or may not be near SNS neurons and still be activated by circulating epinephrine 
and norepinephrine. The PNS only reaches effector cells and organs through its’ postganglionic 
fibers.  
The ANS is controlled by the central nervous system however the regulation of autonomic 
functions is highly dependent on visceral sensory feedback conveyed from the receptors located in 
overall organs to the central nervous system including a network of visceral sensory neurons which 
constitute the central autonomic network (CAN) (293). The CAN helps controlling and is affected by 
several physiologic factors such as blood pressure, respiration or the circadian cycle and has a tonic, 
reflex and adaptive control over autonomic (294). A description of the CAN components and 
function, particularly concerning cardiac autonomic control, is well summarized elsewhere (294, 
295). Because the activity of both divisions of the ANS is somewhat controlled by the CAN, disorders 
involving the CAN may manifest themselves as autonomic hyperactivity or as autonomic failure 
resulting in abnormal outcomes in different organs and bodily functions leading to metabolic 
disorders such as obesity or essential hypertension, depending on in each direction and each of the 
ANS division is most altered (294). 
2.3.3. Functions of the autonomic nervous system 
This section will discuss ANS functions, particularly those related to cardiac control and 
metabolic control, especially lipid and adipocyte metabolism. The ANS has many functions that 
concur for homeostasis (also known as dynamic constancy) including smooth muscle and cardiac 
regulation and secretory gland control (292, 293). The SNS and the PNS have different, sometimes 
opposing, functions in the body. Generally the SNS increases body’s response under conditions of 
stress (e.g. exercise), increases energy expenditure generating a so called “catabolic state” (fight-or-
flight response) whereas the PNS is dominant in resting vegetative functions, promotes energy 
storage supporting a typically “anabolic state” (rest-or-digest state) (293). In the present document 
the focus will be mainly on cardiac and adipocyte autonomic regulation. 
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2.3.3.1. Cardiac autonomic control 
This section centers on the control of heart function by the ANS, particularly that related to 
exercise, and the consequent recovery from such physiological challenge. The ANS is involved in 
cardiac autonomic control at rest and in response to challenges such as orthostasis, thermic 
regulation or exercise (293, 295). PNS exerts an inhibitory effect, through the vagal nerve, which 
reduces heart rate and ventricular contractility so that the heart is not exposed to excessive 
unnecessary work (20). At rest PNS is dominant in the control of cardiac function, which causes 
sinoatrial node to decrease heart rate (292). In the complete absence of any influence, neither 
hormonal nor neural, the sinoatrial node pace is about 100 beats per minute, however, at rest most 
humans have lower heart rates due to PNS action (292). At the onset of exercise, many times even 
before the start of actual exercise, heart rate increases in response to decreases in PNS activity to the 
vagal nerve, affecting the sinoatrial node and ventricular muscle of the heart, which reduces the 
tonic suppressive effect of the vagal cardiac stimulation on heart rate and ventricular contractility 
(20). Subsequent and complementary activation of the SNS nerves to the heart plus the SNS 
stimulated released of epinephrine in the adrenal medulla, to the blood, will result in additional 
increases in heart rate and ventricular contractility during exercise, primarily via stimulation of B-
adrenergic receptors in the heart both by neural (mostly norepinephrine) and endocrine (mostly 
epinephrine) catecholamines (20, 292). In summary, heart rate increases in response to exercise 
through a combined action of SNS and PNS. At exercise cessation the increased heart rate rapidly 
decreases throughout exercise recovery. This rapid recovery is mediated mainly by PNS reactivation 
and seems to be important in reducing excessive cardiac work after exercise (296).   
Specific disturbances in the ANS have been identified as strong risk factors for cardiac 
disease, morbidity and mortality (297-302). The relation of ANS and mortality was initially 
hypothesized by Schwartz and colleagues (303). Since the findings by Imai and colleagues (296) 
suggesting early heart rate recovery (HRR) as a parasympathetic reactivation marker, as later 
confirmed (304), several studies have shown poor parasympathetic cardiac control, as assessed by 
HRR, to be strong and independently related to higher risk of mortality and other hazardous 
cardiovascular and metabolic outcomes, either in general population referred for symptom limited 
graded exercise test (297-299, 305-307) as in patients with established cardiovascular (308, 309) or 
metabolic diseases (18, 310, 311) (table 2.2). 
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Table 2.2 – Studies examining the usefulness of heart rate recovery as a prognostic marker. 
Reference Setting Purpose Sample Exercise 
protocol 
HRR protocol HRR Cutoff values Main conclusions 
Cole et al. 
(299) 
 
Cleaveland 
Clinic 
Foundation
.   
 
Examine the 
usefulness of HRR 
as a prognostic 
marker of overall 
mortality. 
n = 2428 
Adults referred 
to for a first 
symptom 
limited test.  
Standard and 
modified 
Bruce 
Protocols. 
HR recorded at 
maximum 
exercise and at 1 
minute of 
recovery; 
Recovery: 
- In treadmill;  
- 1.5 mph;  
- 2.5% incline. 
Low HRR1’ ≤ 
12bpm  
A low HRR after 
maximal exercise is 
a powerful and 
independent 
predictor of the risk 
of death. 
Nishime et 
al. (305) 
Cleaveland 
Clinic 
Foundation
.   
 
To examine the 
importance of 
SPECT perfusion 
abnormalities 
relative to 
functional 
capacity and HRR 
for prediction of 
all-cause 
mortality. 
n = 9554  
Adults  ≥30yr 
Consecutive 
patients 
referred 
specifically for 
exercise ECG. 
Standard and 
modified 
Bruce 
Protocols. 
HR recorded at 
maximum 
exercise and at 1 
minute of 
recovery; 
Recovery: 
- In treadmill;  
- 1.5 mph;  
- 2.5% incline. 
Low HRR1’ ≤ 
12bpm 
HRR is an 
independent 
predictor of 
mortality.  
 
Shetler et al. 
(312) 
Veterans 
Affairs Palo 
Alto 
Medical 
Centers.   
 
To validate HRR 
as prognostic tool 
for all-cause 
mortality, 
evaluate its 
diagnostic value 
for coronary 
artery disease 
and clarify some 
of the 
methodological 
issues 
surrounding its 
use. 
n = 2193 males  
(age = 59±10yr) 
Patients who 
underwent 
exercise testing 
and coronary 
angiography 
between 1987 
and 1998, 
without cardiac 
disease. 
Treadmill 
protocol from 
the U.S. Air 
Force School 
of Aerospace 
Medicine 
Or an 
Individualized 
Treadmill 
ramp 
protocol. 
 
 HR recorded at 
maximum 
exercise and at 1, 
2 3 and 5 minutes 
of recovery; 
 
Recovery: 
- passive recovery;  
- In supine 
position. 
Low HRR2’ ≤ 
22bpm 
HRR at 2 minutes 
had prognostic 
value for all-cause 
mortality but not 
diagnostic value for 
coronary artery 
disease.  
 
Diaz et al. 
(308) 
Cleaveland 
Clinic 
Foundation
.   
 
To examine the 
importance of 
SPECT perfusion 
abnormalities 
relative to 
functional 
capacity and HRR 
for prediction of 
all-cause 
mortality. 
n = 7163  
(25% women). 
Adults ≥ 30yr.  
Consecutive 
patients 
referred 
for symptom-
limited exercise 
testing with 
SPECT imaging. 
Standard and 
modified 
Bruce 
Protocols. 
HR recorded at 
maximum 
exercise and at 1 
minute of 
recovery; 
Recovery: 
- In treadmill;  
- 1.5 mph;  
- 2.5% incline. 
Low HRR1’ ≤ 
12bpm 
Myocardial 
perfusion defects 
independently 
predict all-cause 
death, even after 
accounting HRR and 
other potential 
confounders. 
 
HRR – heart rate recovery; HR – heart rate; SPEC - thallium201 single photon emission computed tomography; ECG – Electrocardiogram; CAD – 
coronary artery disease; CVD – cardiovascular disease; DM – diabetes mellitus; CV – cardiovascular; T2DM – type 2 diabetes mellitus; CHD – coronary 
heart disease. 
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Table 2.2 – Studies examining the usefulness of HRR as a prognostic marker (continuation). 
Reference Setting Purpose Sample Exercise 
protocol 
HRR protocol HRR Cutoff values Main conclusions 
Watanabe et 
al. (306) 
Cleaveland 
Clinic 
Foundation
.   
 
To determine 
whether the 
predictive value 
for mortality of 
HRR persisted 
even after 
considering 
estimated left 
ventricular 
ejection fraction. 
n = 5438  
Adults ≥ 30yr.  
Consecutive 
patients referred 
for exercise stress 
echocardiography 
Standard and 
modified 
Bruce 
Protocols. 
HR recorded at 
maximum 
exercise and at 1 
minute of 
recovery; 
Recovery: 
- passive recovery;  
- In supine 
position. 
Low HRR1’ ≤ 
18bpm with 
stress 
echocardiography
. 
HRR is a powerful 
and independent 
predictor of death, 
even after 
accounting for left 
ventricular systolic 
function. 
Vivekananth
an et al. 
(307) 
Cleaveland 
Clinic 
Foundation
.   
 
To determine 
whether 
abnormal HRR 
predicts mortality 
independent of 
the angiographic 
severity of 
coronary disease. 
n = 7163      
(25% women). 
Consecutive 
patients ≥ 30yr, 
referred for 
symptom-
limited exercise 
testing with 
SPECT imaging. 
Standard and 
modified 
Bruce 
Protocols. 
HR recorded at 
maximum 
exercise and at 1 
minute of 
recovery; 
Recovery: 
- 1 minute; 
- In treadmill;  
- 1.5 mph;  
- 2.5% incline. 
Low HRR1’ ≤ 
12bpm 
Or 
Low HRR1’ ≤ 
18bpm with 
stress 
echocardiography
. 
HRR is 
independently 
predictive of 
mortality, even 
when controlled for 
angiographic 
severity of CAD, left 
ventricular function, 
and exercise 
capacity. 
Lipinski et al. 
(298) 
Veterans 
Affairs Palo 
Alto 
Medical 
Centers.   
 
To determine 
whether 
abnormal HRR 
predicts mortality 
independent of 
the angiographic 
severity of 
coronary disease. 
n = 2193 men 
Patients who 
underwent 
exercise testing 
and coronary 
angiography 
between 1987 
and 1998, 
without cardiac 
disease.  
Treadmill 
protocol from 
the U.S. Air 
Force School 
of Aerospace 
Medicine 
Or an 
Individualized 
Treadmill 
ramp 
protocol. 
 
 HR recorded at 
maximum 
exercise and at 1, 
2 3 and 5 minutes 
of recovery; 
 
Recovery: 
- passive recovery;  
- In supine 
position. 
Low HRR1’ ≤ 
12bpm 
and 
Low HRR2’ ≤ 
22bpm  
Decreased HRR at 2 
minutes, is a strong 
predictor of 
mortality 
independent of 
other variables, and 
predicts also the 
presence of CAD. 
Cheng et al. 
(310) 
Aerobics 
Center 
Longitudin
al Study 
(ACLS), at 
The Cooper 
Clinic in 
Dallas.   
 
To evaluate 
whether slow 
HRR after 
maximal exercise 
predicts 
cardiovascular 
disease (CVD) and 
all-cause 
mortality among 
these diabetic 
men. 
n = 2333 men 
Patients with 
documented 
diabetes 
mellitus (DM) 
(mean age 49.4 
years) diagnosed 
between 1970 
and 1996.  
Modified 
Balke 
Treadmill 
Protocol 
 
 HR recorded at 
maximum 
exercise and at 5 
minutes of 
recovery; 
 
Recovery: 
- Description of 
recovery protocol 
not available. 
Quartile 1:  
<55 bpm; 
Quartile 2: 
55 – 66 bpm; 
Quartile 3: 
67 – 75 bpm; 
Quartile 4: 
>75 bpm. 
Men with DM and 
slow HRR at 5 min 
following a maximal 
exercise test had a 
higher risk of CVD 
and all-cause 
mortality, even 
after controlling for 
cardiorespiratory 
fitness and other 
confounders. 
HRR – heart rate recovery; HR – heart rate; SPEC - thallium201 single photon emission computed tomography; ECG – Electrocardiogram; CAD – 
coronary artery disease; CVD – cardiovascular disease; DM – diabetes mellitus; CV – cardiovascular; T2DM – type 2 diabetes mellitus; CHD – coronary 
heart disease. 
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Table 2.2 – Studies examining the usefulness of HRR as a prognostic marker (continuation). 
Reference Setting Purpose Sample Exercise 
protocol 
HRR protocol HRR Cutoff values Main conclusions 
Arena et al. 
(309) 
Heart 
Failure 
program 
at the 
Medical 
College of 
Virginia in 
Richmond
.  
To assess the 
prognostic value 
for mortality of 
HRR, 
independently 
and in 
combination with 
other 
cardiopulmonary 
exercise testing 
variables, in a 
group of subjects 
diagnosed with 
compensated 
Heart Failure. 
n = 87 (35 
female) 
Consecutive 
patients 
diagnosed with 
heart failure and 
left ventricle 
dysfunction.  
Modified 
ramping 
Treadmill 
protocol. 
 
HR recorded at 
maximum 
exercise and at 1 
minute of 
recovery; 
 
Recovery: 
- no less than 
1’30’’ recovery;  
- In treadmill; 
- 1.0 mph;  
- 0% incline.. 
Not presented.  HRR have significant 
prognostic value for 
cardiac death and 
hospitalization in 
patients with heart 
failure. 
Myers et al. 
(297) 
Veterans 
Affairs 
Palo Alto 
Medical 
Centers.   
 
To assess the 
relative 
prognostic utility 
of chronotropic 
incompetence 
and HRR in 
predicting 
cardiovascular 
mortality in 
patients referred 
for exercise 
testing for clinical 
reasons. 
n = 1910  
Patients who 
underwent 
maximal 
exercise testing 
for clinical 
reasons.  
Individualized 
Treadmill 
ramp 
protocol. 
 
 HR recorded at 
maximum 
exercise and at 1, 
2 3 and 5 minutes 
of recovery; 
 
Recovery: 
- passive recovery;  
- In supine 
position. 
Low HRR2’ < 
22bpm  
Both chronotropic 
incompetence and 
HRR predict 
cardiovascular 
mortality in patients 
referred for exercise 
testing for clinical 
reasons.  
Chacko et al. 
(311) 
Appropria
te Blood 
Pressure 
Control in 
Diabetes 
(ABCD) 
trial. 
To evaluate the 
relationship of 1- 
and 2-min HRR 
and the incidence 
of all-cause and 
CV mortality, and 
CV events in 
patients with 
T2DM who had 
exercise treadmill 
testing performed 
on a screening 
basis. 
n = 871 (63% 
male)  
Asymptomatic 
patients with 
type II diabetes 
mellitus (T2DM) 
from ABCD trial 
evaluated 
between 1991 
and 1993.  
Individualized 
Treadmill 
ramp 
protocol. 
 
HR recorded at 
maximum 
exercise and at 1 
and 2 minutes of 
recovery; 
 
Recovery: 
- 2’ recovery;  
- In treadmill; 
- 1.2 mph;  
- 0% incline.. 
Low HRR1’ < 
12bpm  
Slowed HRR at 1 
and 2 min are useful 
in assessing risk of 
mortality and CV 
events in T2DM 
patients. Therapies 
directed at 
normalizing HRR in 
this high-risk group 
of patients should 
be pursued.  
HRR – heart rate recovery; HR – heart rate; SPEC - thallium201 single photon emission computed tomography; ECG – Electrocardiogram; CAD – 
coronary artery disease; CVD – cardiovascular disease; DM – diabetes mellitus; CV – cardiovascular; T2DM – type 2 diabetes mellitus; CHD – coronary 
heart disease. 
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Table 2.2 – Studies examining the usefulness of HRR as a prognostic marker (continuation). 
Reference Setting Purpose Sample Exercise 
protocol 
HRR protocol HRR Cutoff values Main conclusions 
Carnethon et 
al. (18) 
The 
Coronary 
Artery 
Risk 
Developm
ent in 
Young 
Adults 
(CARDIA) 
study.  
To investigate the 
association of a 
comprehensive 
set of 
sociodemographi
c characteristics, 
health behaviors, 
and clinical 
characteristics 
with the 
development of 
slow HRR in 
healthy young 
adults who were 
followed during 
20 yr. 
n = 2730 (56% 
female) 
(age=25,1±3,6 at 
baseline)  
Young adults 
from a healthy 
cohort followed 
for 20 years.  
Modified 
Balke 
Treadmill 
protocol. 
 
 HR recorded at 
maximum 
exercise and at 2 
minutes of 
recovery; 
 
Recovery: 
- 2’ recovery; 
- Active walking;  
- In treadmill. 
Low HRR2’ < 
22bpm  
Higher risk for 
mortality associated 
to HRR is modulated 
by the presence and 
development of 
CHD risk factors. 
The characteristics 
most strongly 
associated with the 
odds of having slow 
HRR in middle age 
are modifiable.  
HRR – heart rate recovery; HR – heart rate; SPEC - thallium201 single photon emission computed tomography; ECG – Electrocardiogram; CAD – 
coronary artery disease; CVD – cardiovascular disease; DM – diabetes mellitus; CV – cardiovascular; T2DM – type 2 diabetes mellitus; CHD – coronary 
heart disease. 
2.3.3.2. Autonomic nervous system and adipocyte lipid metabolism  
This section focus on some aspects of metabolic autonomic control that helps understand 
the link between ANS and BC, along with some co-morbidities. The ANS is directly involved in 
regulation of cardiovascular system and secretory glands (including endocrine) and, therefore, can 
have an important contribution in energy balance. The activation of the SNS is associated to an 
increase of the metabolic rate, favoring catabolism, which is dominant in stress situations such as 
exercise or exercise testing, therefore it is often referred to as the ‘flight or fight’ response therefore 
can significantly increase energy expenditure (293). On the opposite direction, the PNS affects 
metabolism favoring anabolism, which is important and mostly dominant in a resting state, therefore 
it is often referred to as the ‘rest and digest’ response and so has an important role in energy saving 
and storing (293). The “Mona Lisa Hypothesis” (an acronym for “Most Obesities kNown Are Low In 
Sympathetic Activity”) as a possible explanation for obesity, was suggested more than two decades 
ago (313), and still the link and contribution of the ANS on BF content and distribution is under 
constructive and growing discussion.  
Previous reports have already shown ANS imbalance to be linked to obesity (313, 314) and 
higher BF accumulation (315, 316), diabetes (317-319) and other (320-323), all of which contribute to 
mortality. On the other way around, BF distribution may also be an important factor, more than 
whole BF, for the development of ANS imbalance (315, 324, 325). 
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Adipocyte lipid turnover is an important feature of lipid metabolism which involves adipocyte 
fatty acids secretion and β oxidation (lipolysis or adipocyte fat catabolism) and fatty acid uptake and 
de novo synthesis (lipogenesis or adipocyte fat anabolism) (326, 327). To stimulate lipolysis of 
triglycerides within the adipocytes and fatty acids release from adipocytes into the bloodstream, 
resulting in adipocyte lipid content reduction, a cascade of cellular signals must take place. Lipolysis 
of adipocyte triglycerides is highly mediated by hormone sensitive lipase (HSL) which, once 
phosphorylated and activated, moves to the surface of the lipid droplet within the adipocyte cytosol 
and participates in triglycerides hydrolysis into three fatty acids and one glycerol (328). On the 
reverse direction, for lipogenesis to take place and increase adipocytes fatty acids uptake, resulting in 
adipocyte lipid content augmentation, a different cellular signaling cascade must occur. Adipocyte 
lipogenesis is highly mediated by lipoprotein lipase (LPL) which is synthetized in and secreted by 
adipocytes, and then migrates to the lumen of adipocytes capillary where, once activated, it can 
move to the surface of the lipid droplet in the blood to hydrolyze it into NEFA and glycerol (329). 
Plasma NEFA will then move into adipocytes while the glycerol will flow to the liver to be converted 
into glycogen (19).  
The ANS action is key in adipocyte lipid metabolism regulation, either in the anabolic 
lipogenesis as in the catabolic lipolysis (326, 327, 330). The ANS can assure adipocyte lipid 
metabolism regulation by two main mechanisms: (I) the endocrine and (II) the neural input.  
2.3.3.2.1. Autonomic nervous system related endocrine regulation of adipocyte lipid 
metabolism  
Both catecholamines (epinephrine and norepinephrine) and insulin are the major plasma 
hormones responsible for the endocrine regulation of lipolysis and lipogenesis in human adipocytes 
(326).  
Catecholamines are released as hormones by the endocrine glands at the adrenal medulla, 
and are regulated by SNS activation (292). Catecholamines can both increase adipocyte lipolysis, by 
stimulating β-adrenergic receptors (also called adrenoceptors), and can decrease adipocyte lipolysis, 
by stimulating α-adrenoceptors (326). Albeit seaming physiologically contradictory how 
catecholamines can stimulate both contrary effects in the same adipocyte cell, it has been suggested 
a reasonable explanation for such apparent paradox. Both α and β-adrenoceptors have different 
affinities (different levels of tendency to form a chemical bond with a ligand) and desensitization 
(inability to be activated after being stimulated for long time) onsets to catecholamine stimulation 
(331). Accordingly adipocyte α-adrenoceptors (particularly α2) seam to express higher affinity to 
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catecholamines at low catecholamine concentration, as usually observed at rest. In higher 
catecholamine concentration situations, such as exercise or exercise testing, α mediated antilipolytic 
actions seems absent of lipolysis regulation. Catecholamines act also directly on adipocyte β-
adrenergic receptors, on the plasma membrane of adipocytes, to activate lipolysis so that adipocyte 
fatty acids can be mobilized into the blood to be used as energy substrate (326). Three different β-
adrenoceptors have been reported present in adipocytes and, as mentioned before, the different β-
adrenoceptors have also been shown to have different affinities and desensitization onsets to 
catecholamines (table 2.3).  
Table 2.3 – Adipocyte adrenoceptors affinities and desensitization characteristics, adapted from Lafontan and 
colleagues (331). 
Catecholamines 
Adrenoceptors affinities Adrenoceptors desensitization resistance  
Epinephrine α2 > β2 > β1 > β3 α2 = β3 > β2 ≥ β1 
Norepinephrine α2 > β1 ≥ β2 > β3  
In summary the receptor with the lowest affinity to catecholamines (β3) will remain active in 
response to prolonged catecholamine exposure and, consequently, may be important in prolonged 
stimulation (such as during prolonged exercise), after the other β-adrenergic receptors become 
desensitized. Also important is the fact that β-adrenergic receptors have a heterogeneous 
distribution throughout adipocytes from different body regions and this may be a key feature in 
regional lipolysis regulation and determinant for BF distribution (326). Because adipocytes from 
different body regions can have different β adrenoceptors they will respond to stimulation in 
different ways: visceral adipocytes have β adrenoceptors more easily stimulated but tend do 
desensitize quite rapidly when being continuously stimulated whereas peripheral/limbs adipocytes 
have higher expression of β3 adrenoceptors that are more difficult to activate but can be stimulated 
during longer periods of time without reducing catecholamine sensitivity (326). The other key 
hormone in the regulation of lipolysis, insulin, is released by pancreatic β-cells, which are regulated 
by several inputs, including both SNS and PNS post-ganglionic innervation (19). The SNS activation 
has an inhibitory effect on insulin secretion while PNS activation will stimulate insulin secretion 
resulting in increased blood insulin concentration (292). Adipose tissue is very sensitive to changes in 
insulin concentration. Small increases in plasma Insulin concentration may inhibit lipolysis up to 50% 
below basal levels by reducing the signaling cascade responsible by activating HSL (326). Besides 
having an anti-lipolytic effect, Insulin stimulates also LPL activity, which in turn will hydrolyze 
Body Composition in Non-Alcoholic Fatty Liver Disease 
Chapter 2 – Review 
Nuno Manuel Queiroz Pimenta de Magalhães  37 
chylomicron and very-low density lipoprotein triglycerides, in the blood, increasing blood NEFA 
concentration (329, 332). Insulin also stimulates NEFA esterification within adipocytes which means 
that, together with HSL suppression, insulin can significantly reduce NEFA concentration within 
adipocytes (329). This insulin stimulated NEFA concentration increase in the blood and decrease in 
the adipocytes will create a concentration gradient favoring NEFA flow from the blood into 
adipocytes where they are re-esterified (329). As in the muscle cells, insulin also stimulates GLUT4 in 
adipocytes, increasing glucose uptake (19). Fatty acids entering into the adipocyte will then be 
converted in triglycerides when associated with one glycerol, while glucose will be either catalyzed 
into acetil-COA and ultimately converted into fatty acids that will be stored as triglycerides as well 
(de novo lipogenesis) or transformed into α-glycerol phosphate to form triglycerides (because 
adipocytes are not able to phosphorylate glycerol and therefore has to form glycerol from glucose) 
(19, 333).  
Catecholamines and insulin are recognized as the major plasma hormones regulating lipolysis 
however other hormones can also influence lipolysis and lipogenesis as well. Growth hormone along 
with thyroid hormones and cortisol seam to increase the catecholamine stimulated lipolysis (326, 
334). Other factors like insulin-like growth factor-1, prostaglandin, adenosine and neuropeptide Y 
seem to have an inhibitory effect, synergic to insulin, on adipocyte lipolysis (326, 334). 
Bottom line the SNS can mainly stimulate lipolysis either by augmenting norepinephrine and 
epinephrine release at the adrenal medulla or by the inhibition of insulin production at the pancreas. 
PNS can modulate lipolysis by stimulating insulin secretion to the bloodstream. Lipogenesis is mainly 
controlled by insulin, and insulin release rate into the blood results from the balance between SNS 
and PNS activation. The ANS can also modulate adipocyte metabolism by its’ neuronal input rather 
than exclusively by an endocrine pathway as discussed ahead.  
2.3.3.2.2. Autonomic nervous system neuronal regulation of adipocyte lipid metabolism  
ANS innervation of adipose tissue and its’ importance is not yet a consensual topic. Two main 
discussions concerning ANS innervation of adipose tissue seem presently pinnacling: (I) the 
importance of the ANS in controlling lipid metabolism in adipocytes, as compared to endocrine 
regulation (335); (II) the existence of parasympathetic innervation in adipose tissue (335-337). It has 
been accepted that both catecholamines and insulin are the major regulators of adipocyte lipid 
metabolism. However this knowledge is being challenged by the possibility that an important 
participation of the ANS may directly regulate lipid metabolism through its’ neural terminations on 
adipocytes (335). Timothy Bartness is one prominent researcher, among others, who have been 
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arguing that the participation of ANS neural regulation in the control of lipolysis might be more 
important than the regulation of lipolysis by adrenal epinephrine (330). Arguments for this rely on 
experiments that showed, in animal models, that lipid mobilization from adipocytes was almost 
unaffected in the absence of epinephrine, which occurred after removing its’ source (bilateral 
adrenodemedullation) (338). Thus evidences of direct neuroanatomical projections of post ganglionic 
neurons from SNS to adipocytes have been presented (339). Furthermore, the presented evidences 
on SNS innervation of adipose tissue, seams to support the existence of a significant distinction in 
post-ganglionic neurons, within the SNS, that innervate distinct BF depots (e.g. Inguinal adipocytes vs 
epididymal adipocytes) (339). Such evidences of diverse innervation in different BF depots have been 
further detailed (337). As a result it has been showed that fatty acids are preferentially recruited 
from internally located adipocytes, whereas the more externally located subcutaneous adipocytes 
are relatively spared, in response to different photoperiods (day lengths) which is considered to have 
a modulation effect on SNS (339). Previous studies had already suggested an effect on BF distribution 
resulting from the lesion of different regions of the hypothalamus (340). Together these findings 
suggest a strong possible role of the ANS in modulating BF distribution. Overall these results support 
a key contribution of the ANS in the neuronal regulation of adipocyte lipid metabolism and also in BF 
distribution.  
The presence of PNS innervation in adipocytes was considered to be absent or irrelevant 
(330, 341). Nevertheless Kreier and colleagues (336) had shown, and later substantiated (337) and 
enlightened (342), that PNS input is present in adipose tissue and may have a direct modulatory 
effect on adipocyte lipid metabolism. Still this is not yet consensual (335). Nevertheless, Kreier and 
colleagues (336) showed that PNS denervation of adipocytes impressively reduced insulin dependent 
uptake of circulating glucose and free fatty acids, and increased the activity of HSL, meaning PNS can 
influence adipocyte lipid metabolism un an anabolic way. Plus, the results by Kreier and colleagues 
(336) suggest that intra-abdominal and subcutaneous BF depots seem to be innervated by different 
PNS neurons meaning PNS may have a important role in BF distribution, as was earlier reported for 
SNS innervation (339). A follow up study confirmed the presence of separated groups of neurons 
projecting either to the intraabdominal or to the subcutaneous BF depots (337). 
The involvement of the ANS in the etiology of obesity and excess BF has long been suggested 
(the MONA LISA hypothesis) (313). ANS may also be involved in the modulation of BF distribution, as 
different BF depots were found to be innervated by different selective groups of neurons from both 
the PNS (337) and the SNS (339), and may, to same extent, be involved in the etiology of adverse BF 
distribution profiles. The neuroanatomical evidence for a reciprocal influence of BF and ANS, 
presented by Kreier and colleagues (337), supports a possible novel mechanism for ANS control of fat 
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metabolism, but also sets a rational for the contribution of BF accumulation, particularly that of the 
abdominal region, for ANS imbalance. Based on these findings it was hypothesized that ANS 
imbalance as a consequence of excess BF content, particular that of the intra-abdominal region, may 
affect autonomic control of biological functions such as cardiac function, glucose metabolism or even 
liver fat metabolism (337). Some metabolic impairments, particularly IR and obesity (main risk factors 
for hepatic steatosis), have been shown to precede the presence of slow HRR (18, 343). The 
distribution of fat throughout the body appears to be particularly important for cardiac autonomic 
control (315, 324). These evidences arisen the importance, particularly in higher risk subpopulations, 
of finding clinical non-invasive morphologic and metabolic markers, and potential therapy targets, 
related to cardiac autonomic control, a known strong independent risk factor for death and other 
hazardous outcomes.  
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Chapter 3 – Methods 
“Sample, instruments and methods used for the study of body composition and 
cardiac autonomic control, in the present thesis.” 
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The present chapter provides a comprehensive description of the studied subjects as well as 
the methodology used for subjects’ assessment and data record. The purpose of this is to avoid 
repetitions of methods descriptions in the subsequent chapters, concerning each conducted study. 
So, the following chapters will mention the studied variables, referring the present chapter for 
methods description. Also data analysis description is specific of each individual study within the 
present research and therefore will only be briefly mentioned in the present chapter and will be 
presented in detail in each of the following chapters, regarding each study.  
This chapter is divided into two main parts. The first part includes “sample” and “study 
design” subsections and present a description of the sample and how patients were recruited. The 
Second part focuses on the description of the methodology used for patients’ assessment and data 
record and analysis, including “body composition”, “body fat distribution”, “cardiac autonomic 
control” and “statistics” subsections. Even though the full assessment protocol is mentioned in the 
description of study design, only the methods used to collect data concerning the variables that were 
studied in the present research were described in detail in the current thesis.  
3.1. Sample 
To be selected for the present study individuals had to be diagnosed with non-alcoholic fatty 
liver disease (NAFLD), through liver biopsy or ultrasound, over 18 years of age, without history of 
hepatotoxic substances intake (eg. steroids) and tobacco consumption. Exclusion criteria included 
alcohol consumption over 20g/day; the presence of other potential causes for fatty liver disease, 
including viral hepatitis, auto-immune disease and others; any physical and/or mental disabilities or 
any condition that constituted an absolute restriction to exercise, or other diagnosed diseases, 
except for metabolic and cardiovascular diseases (insulin resistance, hypertension or dyslipidemia), 
with mandatory specific pharmacologic therapy.  
Medical doctors from Santa Maria Hospital and Curry Cabral Hospital were contacted to 
participate in the present research project. Two doctors accepted the challenge. A general outline of 
the present research project was presented to the patients diagnosed with NAFLD by their medical 
doctor. After knowing about the research project patients were asked if they would like to be 
contacted by the researcher to receive more detailed information.  A phone call was made to all 
patients who gave their verbal consent. In every phone call the researcher presented himself, 
presented the project outline, the main goals, as well as the preparation procedures for the 
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assessments and asked if patients were able and willing to participate. To those who responded 
affirmatively two visits to the Exercise and Health Laboratory (LabES) were scheduled. There were 59 
consecutive patients enrolled in the present study by their medical doctors, based on initial selection 
criteria; 37 of the selected patients accepted to participate and 28 were found eligible to enter the 
study, after exclusion criteria was considered. We studied 28 NAFLD patients (19 males, 51 ± 13 yrs, 
and 9 females, 47 ± 13 yrs), recruited from the outpatient medical departments in Santa Maria 
Hospital and Curry Cabral Hospital, in Lisbon (Portugal). Subjects were taking one or more of the 
following medication: platelet inhibitors, angiotensin-converting enzyme inhibitors, nitrates, statins, 
ezetimibe, nicotinic acid and biguanides with similar use among male and female patients. 
3.2. Study design 
This study was conducted at the LabES, from the Interdisciplinary Centre for the Study of 
Human Performance (CIPER) at the Faculty of Human Kinetics, University of Lisbon (Portugal). It 
consisted of a crossectional study aiming at investigating associations between variables that can 
help to understand their usefulness in the clinical setting. Data collection was conducted using 
equipment from four different laboratories within the CIPER: the body composition (BC) assessment 
laboratory, the cardiorespiratory assessment laboratory, both part of the LabES, and also the human 
biology laboratory and the biochemistry laboratory. The present research also benefited from the 
collaboration of different technicians and professionals in data collection: a chemical analysis 
technician for venous puncture and saliva collection; an anthropometry technician, certified by the 
International Society for the Advancement of Anthropometry (ISAK), for BC assessment; a 
cardiologist for the maximal exercise testing and an exercise physiologist who participated in the 
load and gas analysis monitoring of the maximal treadmill exercise testing, in the resting metabolic 
rate assessment, in strength assessment, in the physical activity assessment as well as in the 
nutritional assessment.  
Medical doctors from Santa Maria Hospital and Curry Cabral Hospital were contacted to 
participate in the present research project. Two doctors accepted the challenge. A general outline of 
the present research project was presented to the patients diagnosed with NAFLD by their medical 
doctor. After knowing about the research project patients were asked if they would like to be 
contacted by the project manager to receive more detailed information.  A phone call was made to 
all patients who gave their verbal consent. In every phone call the project manager presented 
Body Composition in Non-Alcoholic Fatty Liver Disease 
Chapter 3 – Methods 
 44  Nuno Manuel Queiroz Pimenta de Magalhães 
himself, presented the project outline, the main goals, the preparation procedures for the 
assessments and asked if patients were able and willing to participate. To those who responded 
Two visits to the LabES were scheduled, to all patients how agreed to participate in this 
study, with a maximum of two weeks interval between the two visits. On the first day we assessed 
resting metabolic rate (using gas analysis), BC, including Dual Energy X-ray Absorptiometry (DXA) and 
anthropometry, strength (using both Biodex and Jamar handgrip), physical activity and nutrition 
(using questionnaires), by the mentioned order. Subjects were allowed to eat a morning snack after 
strength assessment. On the second visit patients underwent blood and saliva collection followed by 
a graded maximal exercise testing on a treadmill. On both days patients arrived at the laboratories at 
8h in the morning, after an overnight 12-hour fast. All participants signed an informed consent on 
the first day, before being included in the present study and undergoing any study procedure. All 
methods used in the present study comply with ethics and Portuguese laws and were approved by 
Faculty of Human Kinetics institutional review board for human studies. The present investigation 
also complies with the principles outlined in the Declaration of Helsinki. A detailed description will be 
presented only for the methods used in data collection concerning variables included in the studies 
enclosed in the present thesis.  
3.3. Body composition 
BC was assessed using both laboratory and field/clinical methods. The selected laboratory 
method was DXA, which was used to assess whole and regional BC (described in subsection 3.3.1). 
DXA assessed body fat (BF) compartments were included into ratios to assess BF distribution 
(described in subsection 3.3.2). The field/clinical methods used in the present study consisted of 
anthropometric measurements. A detailed description of all anthropometric measurements and 
assessments, as well as the resulting calculated body indexes, are presented in subsection 3.3.3.  
3.3.1. Whole and regional body composition assessment 
BC was assessed using both DXA and anthropometry. DXA is an image laboratory method, 
minimally invasive, used for indirect assessment of BC at the molecular level, in a three compartment 
model. DXA is validated for the assessment of whole and regional BC, providing precise estimates of 
three specific body compartments: BF, bone, and lean soft tissue (82, 344, 345). DXA has also been 
used as a reference method in the validation of other BC assessment methods and techniques (24, 
346-348), despite presenting some assumptions and often neglected limitations, particularly in the 
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Figure 3.1 – DXA scan image with 
marked regions of interest. R1 – 
region of interest 1, as defined by 
the area within the upper edge of 
the second lumbar vertebra and de 
lower edge of the fourth lumbar 
vertebra.; R2 – region of interest 2 
defined as defined as R1 but limited 
by the rib cage on both sides. 
assessment of lean soft tissue (82). Unlike fat and mineral, who have fairly stable densities, the 
density of lean soft tissue may vary as a result of the variation of the percentage of its components, 
which are mainly water and protein (82). In-depth comprehensive information concerning the use of 
DXA as a method for the assessment of BC may be found elsewhere (82). Whole body DXA scans 
(Explorer W, Hologic; Waltham, MA, USA; Fan bean mode) were performed to assess patients’ whole 
and regional BC as well as BF distribution (Figure 3.1). Previously conducted repeated measurements 
in 18 young adults, to assess the instrument/methods’ 
precision, allowed the calculation of the coefficient of variation 
(COV) for the studied variables obtained from DXA 
measurements in our Laboratory (Table 3.1). 
Quality control of DXA equipment and software was 
made every morning with spine phantom before patients’ 
arrival to the LabES. Also, once a week, every week, quality 
control included step phantom analysis. All scans were made in 
the morning after: an overnight 12-hour fast; arriving to the 
LabES at 8h in the morning; signing an informed consent and 
undergoing resting metabolic rate assessment (using gas 
analysis). Before the scan patients were asked to wear light 
clothes and remove all metallic objects they might have on 
them, including jewelry, metallic zippers, bras with metal parts, 
removable prosthesis and other. Patients were positioned on 
the DXA table, for the whole body DXA scan, in a supine 
position, and all related procedures, were conducted according 
to the standard guidelines (349). By default DXA software (QDR 
for windows, version 12.4) estimates whole and regional BC, 
including the head, trunk, arms and legs, both left and right, 
regions fat content, according to a three-compartment model 
(BF mass, bone mass, and lean soft tissue).  The trunk region of 
interest (ROI) includes chest, abdomen and pelvis. Appendicular 
ROI includes both arms plus both legs. A list and description of 
DXA variables is available on table 3.1. All scans analyses were performed, analyzed and submitted to 
additional analysis by ROI to assess fat content of the abdominal (Abd) and central abdominal (CAbd) 
regions, by the same observer (Figure 3.1). The abdominal and central abdominal regions were  
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Table 3.1 – Description and coefficients of variation of variables obtained in 18 young adults, using Dual Energy X-ray 
Absorptiometry. 
DXA variables Description COV 
Whole BF body fat of the whole body 0.017 
Whole %BF Percentage of fat in whole body = (total BF/Weight) x 100 0.015 
Trunk BF Sum of body fat from chest, abdominal and pelvis regions  0.005 
Trunk %BF Percentage of fat in the trunk = (trunk BF/trunk mass) x 100 0.005 
Appendicular BF Sum of body fat from both arms and both legs 0.004 
Appendicular %BF Percentage of fat in the appendages = (appendicular 
BF/appendicular mass) x 100 
0.004 
Abdominal BF Includes all fat of the torso comprised between the upper border of 
L2 and the lower border of L4. 
0.010 
Abdominal %BF Percentage of fat in the abdominal region = (abdominal 
BF/abdominal mass) x 100 
0.010 
Central Abdominal BF Includes all fat as in abdominal BF but excluding lateral 
subcutaneous BF, as delimited by the rib cage. 
0.001 
Central Abdominal %BF Percentage of fat in central abdominal region = (central abdominal 
BF/central abdominal mass) x 100 
0.001 
DXA – Dual energy x-ray absorptiometry; COV – coefficient of variation; BF – body fat; L2 – second lumbar vertebra; L4 – fourth lumbar 
vertebra. 
determined as we have described elsewhere (350, 351), to access abdominal (Abd) BF and central 
abdominal (CAbd) BF in accordance to previous works (79, 80). In detail, the upper and lower limits 
of the abdominal and central abdominal ROI were determined as the upper edge of the second 
lumbar vertebra to the lower edge of the fourth lumbar vertebra, respectively (79, 80, 350, 351). The 
sides’ limits of the abdominal ROI were determined as to include all trunk length, but exclude any 
upper limb scan area (79, 350, 351), whereas the vertical sides of central abdominal ROI were the 
continuation of the lateral sides of the ribs cage, as to exclude the lateral subcutaneous fat of the 
trunk, including the anterior and posterior subcutaneous abdominal fat, as well as the intra-
abdominal fat (80), as can be observed in figure 3.1. The selected ROI assessed by DXA have been 
shown to be highly correlated to visceral fat, assessed by magnetic resonance imaging (79, 80). All 
results concerning the absolute and relative BF content variables were registered to the nearest 
0.01kg and 0.1%, respectively. 
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3.3.2. Body fat distribution 
BF distribution variables were calculated using ratios between BF content absolute values of 
different BF depots, obtained by DXA, as we reported before (351). The trunk BF-to-appendicular BF 
ratio, also called trunk-to-extremity fat ratio (91) or central-to-peripheral fat mass ratio (263), was 
calculated as the trunk BF content divided by the sum of  the BF content of the upper and lower 
limbs, both left and right. This ratio has been used to assess BF distribution and it intends to identify 
if BF is more accumulated in the periphery, including both arms and legs, also known as appendages, 
or if BF is more centrally distributed in the body, particularly in the trunk. This variable has been used 
even as a criterion marker of BF distribution in order to assess BF distribution prediction capacity of 
clinical instruments and techniques (263) and have been found among the best correlates to visceral 
and subcutaneous abdominal fat, in adolescent girls (91). The abdominal BF-to-whole BF was 
calculated as the selected abdominal ROI BF content divided by the whole BF. This intended to assess 
how much of whole BF is deposited in the abdominal region. The abdominal BF-to-trunk BF ratio was 
calculated as the fat content of the selected abdominal ROI divided by the trunk BF. This variable 
intended to assess the BF distribution within the trunk, in other words, to see the proportion of trunk 
BF that is centered in the abdominal region. The abdominal BF-to-trunk BF ratio and the abdominal 
BF-to-Total BF ratio have been used to assess BF distribution changes (351). Ratios were registered to 
the nearest 0.01. Some of the anthropometric measurements and indexes, included in the present, 
may also be considered BF distribution surrogates, particularly waist-to-hip ratio (WHR), however, for 
matters of convenience, all anthropometric variables were presented in the following subsection of 
the present thesis (see subsection 3.3.3).  
3.3.3. Anthropometry and body indexes 
As mentioned before, patients also benefited from an anthropometric assessment. 
Anthropometric measurements included weight, height, skinfolds, lengths and body circumferences. 
The present thesis includes only body mass, referred here as weight; stature, mentioned here as 
height and body circumferences, together with resulting body indexes. The studied anthropometric 
measurements are described in detail in tables 3.2 to 3.8. The choice for such selected 
anthropometric instruments and techniques was based on the aims and main focus of the present 
research, which are directed for the clinical practice. So the choice relied on the instruments and 
assessment techniques that have been suggested to possibly be more easily accepted by 
professionals for routine practice in clinical settings (23, 102, 166, 167, 169). Body circumferences 
consisted of arm circumference (arm-C), Hip circumference (hip-C), thigh circumference (thigh-C), 
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calf circumference (calf-C) and the WC measured according to four different measurement protocols 
(see tables 3.4 to 3.8). Some standardization procedures were taken into account, as recommended 
by Agarwal and colleagues (352), latter recommended by the World Health Organization (WHO) 
(191), to avoid any bias in the measurements, therefore all anthropometric measurements were 
made with subjects in a standing comfortable position, in their underwear, in over 12-hour fasting 
state. All measurements were made by the same technician, who was a trained level 2 technician, 
certified by the International Society for the Advancement of Kinanthropometry (ISAK). All subjects 
were able to stand without support and were measured in an upright position (168, 170, 353). Body 
weight was measured to the nearest 0.1 kg, and height was measured to the nearest 0.1 cm, on a 
digital scale (model 701, Seca; Hamburg, Deutschland) with an attached telescopic stadiometer 
(model 220, Seca; Hamburg, Germany), The measurement of body circumferences was conducted 
using an inelastic flexible metallic tape (model W606PM, Lufkin; Vancouver, Canada) and with the 
help of a segmometer (model segmometer 4, Rosscraft; Canada) to determine some measuring sites. 
All circumferences measurements were made with the tape parallel to the floor, in the case of both 
waist and hip-C, or perpendicular to the long axis of the limb, in the case of arm, thigh and calf-C. 
Body circumference measurements were taken after a tidal expiration, to the nearest 0.1 cm. Height 
was measured after a deep inhalation.  
Table 3.2 – Description of weight measurement 
Weight - measurement description (167, 168, 171, 353) 
Definition: 
Measured as body mass assessed in a standard gravitational field, and referred to as weight.  
1- Positioning the patient: 
Patients were standing on the center of the scale, without support and with weight distributed evenly on both 
feet. 
2- Measurement: 
After the patient was correctly positioned the observer recorded the stable digital readout of the scale. 
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Table 3.3 – Description of height measurement 
Height - measurement description (167, 171, 353) 
Definition: 
Measured as the distance between the highest point of the cranium (vertex) and the horizontal surface where 
the patients’ feet are standing, in an upright position.  
1- Positioning the patient: 
Patients were standing with heels together and toes apart with feet forming a 60
o
 angle, with heels, buttocks 
and scapulae touching the vertical plane of the stadiometer, and head in the Frankfort plane. 
2- Measurement: 
After the patient was correctly positioned the observer lowered the stadiometer horizontal head piece to the 
patients head compressing the hair. The observer recorded the result after instructing the patient to stand as tall 
as possible and to take a deep breath. 
Table 3.4 – Description of arm circumference measurement 
Arm circumference - measurement description (72, 167, 171, 353)   
Definition: 
Measured as the circumference of the arm, perpendicular to the long axis of the arm.  
1- Positioning the patient: 
Patients were standing in an upright position, with the observer facing his/her right side, and the arms hanging 
freely at the sides of the trunk with the palms facing the thighs. 
2- Measuring site: 
Measured at the midpoint of the arm with the patient standing erect, with the arms hanging freely at the sides 
of the trunk with the palms facing the thighs. The observer located the superior lateral tip of the acromion and 
marked it with a pen on the patients’ skin. The observer then located the midpoint of the olecranon process, 
with the elbow flexed at 90
o
 and measured the distance between both mentioned landmarks with a 
segmometer. The observer calculated the mid-distance and marker it on the patients’ skin with the help of a pen 
and the segmometer. Midpoint of the arm was located at the mid-distance between the superior lateral tip of 
the acromion and the midpoint of the olecranon process with the elbow flexed at 90
o
. 
3- Measurement: 
The observer held the measuring tape case in the left hand and uncoiled the tape so that it passed behind the 
arm of the subject. The case of the tape changed to the right hand and the tip changed to the left, so that the 
zero end of the tape was placed below the measurement value, when both ends were crossed at the front of 
the lateral face of the arm, wrapped around the arm, positioned perpendicular to the long axis of the arm and 
fitting tight around the arm without compressing the skin. The observer asks the patient to breath normally and 
records the result attained after a normal exhalation. 
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Table 3.5 – Description of waist circumference measurement 
Waist circumference - measurement description 
Definition: 
Measured as the circumference of the waist in a horizontal plane.  
1- Positioning the patient: 
Patients were standing in an upright position facing the observer, with the arms crossed over his/her chest. 
2- Measuring site: 
Waist circumference (WC) was measured at four distinct sites:  
WC1 – Also called minimal waist. Measured at the level of the observed narrowest part of the torso. This is the 
protocol endorsed by the International Society for the Advancement of Kinanthropometry (ISAK) (168); by the 
Anthropometric Standardization Reference Manual (170); by the American College of Sports Medicine (ACSM) 
(72); and others (167).  
WC2 – Measured at the level of the uppermost lateral border of the iliac crest. The observer stood on the 
patients right side to palpate the iliac crest and draw a horizontal line just above the uppermost lateral border of 
the iliac crest, crossed this horizontal mark with a vertical midaxillary line. This is the protocol endorsed by the 
National Institute of Health (NIH) and the Centers for Disease Control and Prevention (CDC) of the United States 
of America, to be used in the National Health and Nutrition Examination Survey (NHANES) (171, 190); and by the 
Canadian Society of Exercise Physiology (CSEP) (102, 189)   
WC3 – Measured at the mid-distance between the lowest rib and the top of the iliac crest. The observer stood 
on the patients’ right side to palpate the iliac crest and draw a horizontal line just above the uppermost lateral 
border of the iliac crest. Then the observer palpated lowest rib on the right side of the torso. With a 
segmometer, the observer measured the distance between both marks and calculated the mid distance, to draw 
a correspondent horizontal line on the right side of the patients’ torso. This is the protocol endorsed by the 
WHO (86, 125, 191)  
WC4 – Measured at the level of the umbilicus. This protocol is among the most used protocols and has been 
used in studies regarding NAFLD (51, 68).  
3- Measurement: 
The observer held the measuring tape case in the left hand and uncoiled the tape so that it passed behind the 
torso of the subject. The case of the tape changed to the right hand and the tip changed to the left, so that the 
zero end of the tape was placed below the measurement value, when both ends were crossed at the front of 
the torso, wrapped around the waist. The tape was positioned over the identified measuring site, on a 
horizontal plane around the waist, fitting tight without compressing the skin. The observer asks the patient to 
breath normally and records the result attained after a normal exhalation. 
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Table 3.6 – Description of hip circumference measurement 
Hip circumference - measurement description (72, 167, 168, 353)  
Definition: 
Measured as the gluteal circumference at the level of their greatest posterior protuberance, on a horizontal plane.  
1- Positioning the patient: 
Patients were standing in an upright position with the arms crossed over their chest. The observer faced the 
patients’ right side. 
2- Measuring site: 
Measured horizontally at the level of the observed maximum posterior protuberance of the buttocks. 
3- Measurement: 
The observer held the measuring tape case in the left hand and uncoiled the tape so that it passed behind the 
torso of the subject. The tape was positioned over the left hip, buttocks and pelvic regions, with the observer 
standing on the patients’ right side. The tape was positioned at the visible maximum posterior protuberance of the 
buttocks. The tape case changed to the right hand and the tip changed to the left, so that the zero end of the tape 
was placed below the measurement value, when both ends were crossed over the right hip so that it was wrapped 
around the hips, on a horizontal plane, fitting tight without compressing the skin. The observer asked the patient 
to breathe normally and records the result attained after a normal exhalation. 
Table 3.7 – Description of thigh circumference measurement 
Thigh circumference - measurement description (72, 167, 168, 170) 
Definition: 
Measured as the mid-thigh circumference, perpendicular to the long axis of the thigh.  
1- Positioning the patient: 
Patients were standing in an upright position facing the observer, with feet about 10 cm apart. 
2- Measuring site: 
Measured at the mid distance between the midpoint of the inguinal crease and the proximal border of the patella. 
Patients sat erect with the knees flexed to about 90
o
. The observer found both mentioned landmarks and 
measured the distance between them with a segmometer. The observer then calculated and marked on the 
patients’ thigh the mid-distance between both landmarks.  
3- Measurement: 
The observer holds the measuring tape case in the left hand and uncoils the tape with the right hand so that it 
passes behind the thigh of the subject. The tape was positioned perpendicular to the long axis of the thigh. The 
case of the tape changed to the right hand and the tip changed to the left, so that the zero end of the tape was 
placed below the measurement value, when both ends were crossed over the front of the thigh, with the tape 
wrapping around the thigh, fitting tight without compressing the skin. The observer asks the patient to breath 
normally and records the result attained after a normal exhalation. 
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Table 3.8 – Description of calf circumference measurement 
Calf circumference - measurement description (72, 167, 168, 170) 
Definition: 
Measured as the maximum circumference between the knee and the ankle.  
4- Positioning the patient: 
Patients were standing in an upright position facing the observer, with feet about 20 cm apart and weight 
distributed equally on both feet. 
5- Measuring site: 
Measured the maximum circumference between the knee and the ankle.   
6- Measurement: 
The observer holds the measuring tape case in the left hand and uncoiled the tape with the right hand so that it 
passed behind the calf of the subject. The tape was positioned perpendicular to the long axis of the leg. The case 
of the tape changed to the right hand and the tip changed to the left, so that the zero end of the tape was 
placed below the measurement value, when both ends were crossed over the front of the leg, so that the tape 
was wrapped around the leg, fitting tight without compressing the skin. The observer asks the patient to breath 
normally and records the result attained after a normal exhalation. 
WC measurement was conducted with four different protocols in each patient (figure 3.2). 
The selected protocols for WC measurement are the most used protocols found in the literature and 
endorsed by prominent authors and institutions/organizations (23, 169). Time length of each WC 
measurement, including all procedures, 
from brief initial instruction results 
registering, was recorded in seconds, to 
the nearest 1 second, with a standard 
watch chronometer (model RS800, 
Polar, Oulu, Finland). Body weight was 
measured to the nearest 0.1 kg, and 
height was measured to the nearest 0.1 
cm, on a scale with an attached 
stadiometer (model 770, Seca; 
Hamburg, Germany), according to a 
standardized protocol (353). All 
anthropometric measurements were 
repeated two times and the limits for 
the difference between the first and 
Figure 3.2 – Simulation of waist circumference measuring sites. 
WC1 – waist circumference measured at minimal waist; WC2 - 
waist circumference measured just above iliac crest; WC3 – waist 
circumference measured at mid-distance between lowest rib and 
iliac crest; WC4 – waist circumference measured at the umbilicus. 
WC 1 
WC 3 
WC 4 
WC 2 
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second measurements were defined, as presented in table 3.9. Whenever the second measurement 
differed more than the established limit from the first measurement, a third measurement was 
carried out. We always considered the result obtained in the second measurement unless a third 
measurement was carried out. When a third measurement was taken we considered the mode or, if 
mode was absent, the median value of all three measurements. By using this procedure we sought to 
always use the most suitable value that was actually measured on the subjects (instead of mean 
values). 
Table 3.9 – Established limits for the difference between first and second anthropometric measurements  
Anthropometric variable Limits for accepted difference between first and second measurements 
Weight  0.5 kg 
Height  1.0 cm 
Arm-C 0.2 cm 
WC 1.0 cm 
Hip-C 1.0 cm 
Thigh-C 0.5 cm 
Calf-C 0.2 cm 
Arm-C – arm circumference; WC – waist circumference; Hip-C – hip circumference; Thigh-C – thigh circumference; Calf-C – calf 
circumference. 
Several body indexes were calculated, using anthropometric measurements, as surrogates of 
general BF as well as morphology and fat distribution. Body indexes in the present research included 
body mass index (BMI), body adiposity index (BAI), WHtR and WHR (table 3.10). Both weight and 
height were used to calculate the subjects’ BMI, by dividing the weight, in kg, by the squared height, 
in meters (BMI = weight [kg] / height [m]2) (125). The novel BAI, suggested to be a better marker of 
body adiposity than overall commonly used body indexes, was calculated as hip-C, in cm, divided by 
height powered to 1.5, in meters, minus eighteen (BAI = (Hip-C [cm] / height [m] 1.5) - 18) (24); WHtR 
was calculated as WC divided by height, both in centimeters (WHtR = WC [cm] / height [cm]) (266, 
267) and WHR was calculated as WC divided by HC, both in centimeters (WHR = WC [cm] / HC [cm]) 
(179).  
  
Body Composition in Non-Alcoholic Fatty Liver Disease 
Chapter 3 – Methods 
 54  Nuno Manuel Queiroz Pimenta de Magalhães 
Table 3.10 – Assessed body indexes 
Body Indexes Calculus 
BMI weight [kg] / height [m]2 
BAI (Hip-C [cm] / height [m] 1.5) – 18 
WHtR WC [cm] / height [cm] 
WHR WC [cm] / Hip-C [cm] 
BMI – body mass index; BAI – body adiposity index; WHtR – waist-to-height ratio; WHR – 
waist –to-hip ratio; Hip-C – hip-Circumference; WC – waist circumference. 
3.4. Cardiac Autonomic Control 
Cardiac autonomic control was studied using heart rate recovery (HRR) after a maximal 
exercise test. Cardiac autonomic control is one feature of the autonomic nervous system (ANS), 
consequently HRR was the chosen as a marker of ANS function but also, to a lesser extent, as a risk 
assessment marker. HRR is suggested to be mostly reflective of parasympathetic reactivation, thus 
providing scarce information about the sympathetic nervous system functioning (296, 304). Slow 
HRR, however, has been shown to be independently related to higher risk of cardiovascular and all-
cause mortality and other cardiovascular and metabolic outcomes (18, 298, 299, 307-311). The next 
subsections present the description of the exercise protocol as well as the recovery protocol and 
respective HRR data collection. 
3.4.1. Exercise Testing 
All subjects underwent a treadmill (model Q-65, Quinton, Cardiac Science Corp; Bothell, WA, 
USA) graded exercise test (GXT) using Bruce standard protocol (354). All GXT were monitored using a 
12 lead electrocardiogram PC-based acquisition module (model PCE-210, Welch-Allyn, Welch Allyn 
Inc.; Skaneateles Falls, NY, USA) and the data, including heart rate (HR), were monitored and 
recorded using Welch Allyn CardioPerfect software (Welch Allyn Inc.; Skaneateles Falls, NY, USA). 
Oxygen uptake was monitored during GXT using a metabolic cart (model CPX Ultima cardio, 
Medgraphics, Cardio Medical Graphics Corp; St Paul, MN, USA) and data was recorded using Breeze 
Suite software (version 6.4.1, Medical Graphics Corp; St Paul, MN, USA). Subjects exercised until at 
least two of the following test termination criteria were reached (355): (1) subjects volitional fatigue; 
(2) respiratory exchange ratio reached 1.1 or higher; (3) subjects reached predicted maximal HR 
(HRmax); (4) oxygen uptake did not increase in spite of increasing work load.  
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3.4.2. Heart rate recovery 
Several different protocols have been used to assess HRR, including different exercise 
protocols and different resting protocols, as can be observed in table 2.2 in the previous chapter. The 
most commonly used protocol to assess HRR was chosen to be used in the present thesis. When GXT 
termination criteria were reached patients started exercise recovery with a speed of 1.5 mph (≈2.4 
km/h) and incline of 2.5% on the treadmill. Subjects remained walking with the recovery treadmill 
mechanical load for 2 minutes. After 2 minutes of recovery the treadmill was stopped and subjects 
continued their recovery seated in an armless standard chair. HR was recorded beat-by-beat and was 
averaged at 15 seconds intervals for identifying HRmax. HR at the end of the first and second 
recovery minutes were identified and recorded from beat-by-beat records (HR1 and HR2, 
respectively). HRR was calculated as the difference between observed HRmax and HR1 (HRR1 = 
HRmax – HR1) and HR2 (HRR2 = HRmax – HR2). Cut off value for identifying slow HRR was considered 
12 bpm for HRR1 (299, 307, 308, 311). The 22 bpm cut off value for identifying slow HRR2 was 
developed using a supine recovery protocol (298, 312), however it has been used with diverse 
exercise recovery protocols, including seated (356) and walking (18) recovery protocols  and 
therefore was adopted in the present study for descriptive purposes only.   
3.5. Statistics 
 Considering this is a cross-sectional research, all of the purposes of each study were largely 
linked to association analysis between variables. For this purpose the statistical analysis consisted 
mainly of two correlational methods named “partial correlation” and “semipartial correlation”. In 
order to accomplish a statistical power of 80% (β = 0.20) at a statistical significance level of 5% (α = 
0.05), as has been used as a convention (357), a sample of over 84 individuals were needed, 
therefore 90 patients were coveted to be included in the present sample in the initial research 
project. This would allow coefficients of correlation as low as 0.3, traditionally corresponding a 
moderate effect size, to be considered significant and unexposed to type I and II errors (357). 
Unfortunately, despite all efforts on behalf of everyone involved this research project, only 28 NAFLD 
patients could be recruited. In order to maintain the statistical power and significance level at the 
same agreed level, only coefficients of correlation equal or superior to 0.5, corresponding to a large 
effect size, may be considered unexposed to type I and II errors (357). Other statistical variables and 
techniques will be used rather consistently, such as coefficient of variance to assess data collection 
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accuracy, and z statistics for the comparison of different coefficients of correlation. Detailed 
description of data analysis is further provided in the next chapters, regarding each study. 
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“Is Body Composition and Body Fat Distribution Related to Cardiac Autonomic 
Control in Non-Alcoholic Fatty Liver Disease Patients?”1 
  
                                                          
1
 Pimenta, N, Santa-Clara, H, Cortez-Pinto, H, Silva-Nunes, J, Rosado, M, Sousa, P, Calé, R, Melo, X,
 
Sardinha, L, Fernhall, B (2013), European Journal of Clinical Nutrition (published online, ahead of print), DOI: 
10.1038/ejcn.2013.249. 
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Abstract 
Background: Heart rate recovery (HRR), a cardiac autonomic control marker, has been shown 
to be a predictor of morbidity and mortality. HRR has been shown also to be related to body 
composition (BC), yet this was not tested in Non-Alcoholic Fatty Liver Disease (NAFLD) patients.  
Purpose: The aim of this study was to determine if, and to what extent, markers of BC and 
body fat (BF) distribution are related with cardiac autonomic control in NAFLD patients.  
Methods: BC was assessed with Dual Energy X-ray Absorptiometry in 28 NAFLD patients (19 
males, 51 ± 13 yrs, and 9 females, 47 ± 13 yrs). BF depots ratios were calculated to assess BF 
distribution. Subjects’ HRR was recorded 1 (HRR1) and 2 minutes (HRR2) immediately after a 
maximum graded exercise test.  
Results: BC and BF distribution were related to HRR, particularly weight, trunk BF, central 
abdominal BF as well as trunk BF-to-appendicular BF ratio showed a negative relation with HRR1 (r=-
0.61; r=-0.60; r=0.55 and r=-0.55; respectively, p<0.01), and trunk BF-to-appendicular BF ratio was 
the only also associated with HRR2 (r=-0.59; p<0.01, respectively). Age seems to be somewhat 
related to both HRR1 and HRR2 except when controlled for BF distribution. The preferred model in 
multiple regression should include trunk BF-to-appendicular BF ratio and BF to predict HRR1 
(r2=0.55; p<0.05), and trunk BF-to-appendicular BF ratio alone to predict HRR2 (r2=0.43; p<0.001).  
Conclusions: BC and BF distribution were related to HRR in NAFLD patients. Trunk BF-to-
appendicular BF ratio was the best independent predictor of HRR and therefore may be best related 
to cardiovascular increased risk, and possibly act as a mediator in age related cardiac autonomic 
control variation. 
Keywords: Regional Body Fat; Dual Energy X-ray Absorptiometry; Hepatic Steatosis; Heart 
Rate Recovery; Parasympathetic Reactivation. 
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4.1. Introduction 
Heart rate recovery (HRR) after exercise is a recognized cardiac autonomic control marker 
reflective of parasympathetic reactivation (296, 304). Slow HRR is independently related to higher 
risk of mortality and other cardiovascular and metabolic outcomes (18, 298, 299, 307-311). 
Autonomic nervous system (ANS) imbalance, including blunted HRR, has also been linked to obesity 
(313), higher body fat (BF) accumulation (315, 316) and other metabolic disturbances (320, 358). The 
autonomic nervous system is also known to influence adipocyte metabolism and rather recently 
Kreier and colleagues (337) presented a neuroanatomical evidence for a reciprocal influence of 
adipocytes, particularly intra-abdominal, and ANS, and suggested a pathway for ANS mediated 
imbalance in several other biological functions including liver fat metabolism. Insulin resistance and 
obesity (main risk factors for hepatic fat accumulation) have been shown to precede the presence of 
slow HRR (18, 343). Thus, the distribution of BF appears to be particularly important for cardiac 
autonomic control (315, 324). The relation between BF content and distribution may constitute one 
missing piece of the puzzle in the link between body composition (BC) and metabolic abnormal 
outcomes. However this hypothesis needs further research, particularly in specific higher risk 
subpopulations as are non-alcoholic fatty liver disease (NAFLD) patients. NAFLD is a consequence of 
imbalanced hepatic fat metabolism and encompasses several stages, from initial hepatic steatosis 
(hepatocyte fat accumulation), to hepatic inflammation (non-alcoholic steatohepatitis) along with a 
constellation of other disturbances, that ultimately can lead to advanced fibrosis, cirrhosis, liver 
failure and death (16). BF distribution, besides being strongly associated with NAFLD is also 
associated with other metabolic disorders that can also increase the risk of NAFLD, therefore may be 
an important factor in the etiology of both NAFLD (5, 16) and ANS imbalance (315, 324, 325).  
Very few studies have focused on BF distribution and HRR associations and it is unknown if 
such a relationship exists in NAFLD patients. The purpose of the present study was to determine if, 
and to what extent, specific markers of BC and BF distribution, are related with reduced 
parasympathetic reactivation following maximal exercise, as assessed by HRR, in NAFLD patients. 
4.2. Methods 
In the present study we analyzed two groups of variables as listed in table 4.1: BC variables 
and ANS variables.  
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Table 4.1 – List of Studied variables in study 1 
Variable Unit of measurement Abbreviations Described in subsection 
Age years -- 3.1 
Sex -- -- 3.1 
Whole body composition variables    
Weight kg -- 3.3.3 
Stature cm -- 3.3.3 
Body mass index kg/m
2
 BMI 3.3.3 
Whole body fat kg Whole BF 3.3.1 
Whole percentage of body fat % Whole %BF 3.3.1 
Whole fat free mass kg Whole FFM 3.3.1 
Whole percentage of Fat free mass % Whole %FFM 3.3.1 
Regional body composition variables    
Trunk body fat kg Trunk BF 3.3.1 
Trunk percentage of fat mass % Trunk %BF 3.3.1 
Trunk fat free mass kg Trunk FFM 3.3.1 
Trunk percentage of fat free mass % Trunk %FFM 3.3.1 
Appendicular body fat kg Append BF 3.3.1 
Appendicular percentage of fat mass % Append %BF 3.3.1 
Appendicular fat free mass kg Append FFM 3.3.1 
Appendicular percentage of fat free mass % Append %FFM 3.3.1 
Abdominal body fat kg Abd BF 3.3.1 
Abdominal percentage of body fat % ABD %BF 3.3.1 
Central Abdominal body fat kg CAbd BF 3.3.1 
Central Abdominal percentage of body fat % CAbd %BF 3.3.1 
Body fat distribution variables    
Trunk BF-to-Appendicular BF -- -- 3.3.2 
Abdominal BF-to-whole BF -- -- 3.3.2 
Abdominal BF-to-trunk BF -- -- 3.3.2 
Autonomic nervous system variables    
Heart rate recovery at 1’ bpm HRR 1 3.4 
Heart rate recovery at 2’ bpm HHR 2 3.4 
DXA – dual energy x-ray absorptionmetry; bpm – beats per minute; Máx. GXT – maximal graded exercise test; ECG - electrocardiogram. 
BC variables, including whole and regional BC, were assessed by DXA, and BF distribution 
markers were calculated (as described in subsections 3.3.1 and 3.3.2 of this thesis, respectively); and 
HRR after a maximal exercise test was used as an ANS function marker (soundly detailed in section 
3.4 of this thesis), in the studied sample of 28 NAFLD patients (described in section 3.1 of chapter 3).  
Descriptive statistics are presented as mean ± sd and range for all analyzed variables. The 
Gaussian distribution of the data was assessed with the Shapiro-Wilk goodness-of-fit test. Partial and 
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part, also called semipartial (357), correlations were performed to assess the relations between 
dependent and independent variables controlling for age and sex. When age was an independent 
variable the correlation was controlled for sex and fat distribution. Only correlation coefficients equal 
or above 0.50 were considered to be significant at a significance level of 5% and a statistical power of 
80% (357). Multiple linear regressions were conducted, using Enter method, between dependent 
variables and correlated independent variables to analyze r square change when using two 
predictors in the model. Stepwise regressions were performed to find preferred models for the 
prediction of both dependent variables (HRR1 and HRR2). The level of significance was set at P<0.05 
(two-tailed). Statistical calculations were performed using the IBM SPSS Statistics version 19 (SPSS, 
inc, Chicago, IL, USA). 
4.3. Results 
Mean values for all studied variables are presented in Table 4.2.  No clinical test interruption 
criteria, such as electrocardiogram signs of ischemia, new onset of arrhythmias, or excessive 
hypotensive/hypertensive response, were observed in any GXT. All subjects met termination criteria 
for ending the GXT. From among the 28 studied NAFLD patients slow HRR1 was present in 6 (22.2%, 
2 were female) and slow HRR2 in 5 (18.5%, 2 were female) patients. Neither HRR1 nor HRR2 were 
different between men and women (p=0.754 and p=0.631 obtained in an independent samples t test 
comparison, respectively). Mean body mass index (BMI) of the studied sample was in the overweight 
category, with no differences between sexes (p=0.075 on independent samples t test). BMI was also 
not related with age (r= -0.22; p=0.285 on Pearson correlation). 
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Table 4.2 – Descriptive data of the studied sample in study 1 
 NAFLD Patients (n=28) 
Variables Mean + sd *  Min. – Max. 
Age, yr (median, yr) 48.6 ± 12.8 (49)  25 – 68  
Sex, n female (% female)  9 (32.1)    
HRR1, bpm  19.4 ± 10.1   -4.0 – 37.0  
HRR2, bpm  35.9 ± 16.7   -8.0 – 67.0  
Whole Body Analisys      
Weight, kg  88.0 ± 12.8   66.2 – 115.8  
Height, cm  167.3 ± 9.2   149.5 – 183.7  
BMI, kg/m2 (% obese) 29.1 ± 4.0 (32.1)  22.6 – 42.2  
Whole BF, kg (%) 27.5 ± 9.3 (31.52 ± 8.29)  13.7 – 51.2 (18.84 – 46.28) 
Whole FFM, kg (%) 58.8 ± 9.2 (68.48 ± 8.29)  39.6 – 77.7 (53.72 – 81.16) 
Regional Body Analisys      
Trunk BF, kg (%) 15.2 ± 5.2 (33.37 ± 7.71)  7.4 – 25.0 (20.87 – 48.01) 
Trunk FFM kg (%) 29.9 ± 4.0 (66.63 ± 7.31)  21.1 – 38.6 (51.99 – 79.13) 
Append BF, kg (%) 10.8 ± 4.8 (30.42 ± 10.39)  5.2 – 25.7 (13.63 – 50.40) 
Append FFM, kg (%) 28.5 ± 5.1 (80.40 ± 6.56)  19.2 – 36.7 (68.64 – 90.66) 
Abdominal BF, kg (%) 3.5 ± 1.2 (37.57 ± 6.59)  1.7 – 6.3 (26.09 – 49.40) 
Central Abdominal BF, kg (%) 2.9 ± 0.8 (35.82 ± 5.70)  1.6 – 5.0 (24.28 – 44.64) 
Body Fat Distribution (Ratios)      
Trunk BF-to-Append BF ratio  1.478 ± 0.371   0.958 – 2.547  
Abdominal BF-to-whole BF ratio 0.130 ± 0.025   0.045 – 0.185  
Abdominal BF-to-Trunk BF ratio 0.231 ± 0.039   0.095 – 0.299  
* results are presented as mean ± standard deviation, unless otherwise noted; BF – body fat; BMI – body mass index; FFM – fat free mass; 
Append . appendicular; HRR1 – heart rate recovery at 1 min.; HRR2 – heart rate recovery at 2 min.; Máx. – highest observed value; Min. – 
lowest observed value. 
Table 4.3 shows the results for partial and semipartial correlations between each 
independent variable and each dependent variable (HRR1 and HRR2), controlled for sex and age 
(unless otherwise noted). Only BF compartments, not fat free mass, were related to HRR. On a whole 
body analysis only weight was found negatively correlated with HRR1 (p=0.002), in both partial 
correlations and semipartial correlations. The regional BC analysis showed that trunk BF (p=0.003) 
and central abdominal (CAbd) BF (p=0.009) were negatively correlated with HRR1 but not with HRR2, 
both in partial and semipartial correlations, independently of sex and age. The analysis of BF 
distribution indicated that the trunk BF divided by appendicular BF was the only studied BF 
distribution marker related to HRR1 (p=0.008) and the only studied independent variable to be 
related to HRR2 (p=0.003) in both partial and semipartial correlations, when controlled for sex and 
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age. Age, when controlled for sex and BF distribution, was not related to neither HRR1 nor HRR2 
(p=0.596 and p=0.483, respectively). 
Table 4.3 – Partial and semipartial correlations between dependent and independent 
variables of study 1 
 HRR 1  HRR 2 
Variables r 
†
 r 
‡
  r 
†
         r 
‡
 
Age - 0.12 § - 0.09 ¶   - 0.154 §   - 0.12 ¶ 
Whole Body Analisys 
Weight  - 0.61 * - 0.57 *   - 0.484    - 0.44  
Height  - 0.18 - 0.16   - 0.16   - 0.15 
BMI - 0.33 - 0.30   - 0.16   - 0.15 
Whole BF - 0.49  - 0.43   - 0.31   - 0.29 
Whole %BF - 0.24 - 0.22   - 0.07   - 0.06 
Whole FFM - 0.19 - 0.17   - 0.14   - 0.13 
Whole %FFM   0.24   0.21     0.19     0.17 
Regional Body Analisys 
Trunk BF  - 0.60 * - 0.55 *   - 0.45    - 0.41  
Trunk %BF - 0.36 - 0.33   - 0.23   - 0.21 
Trunk FFM - 0.21 - 0.19   - 0.15   - 0.14 
Trunk %FFM   0.29   0.26      0.26     0.23 
Append BF - 0.27 - 0.25   - 0.10   - 0.09 
Append %BF - 0.02 - 0.02     0.19     0.17 
Append FFM - 0.18 - 0.16   - 0.14   - 0.13 
Append %FFM   0.17   0.16      0.14     0.13 
Abdominal BF - 0.49  - 0.45    - 0.27   - 0.24 
Abdominal %BF - 0.30 - 0.27   - 0.09   - 0.09 
Central Abdominal BF - 0.55 * - 0.51 *   - 0.34   - 0.30 
Central Abdominal %BF - 0.38 - 0.35   - 0.17   - 0.15 
Body Fat Distribution (Ratios) 
Trunk BF-to-append BF ratio  - 0.55 * - 0.50 *   - 0.59 *   - 0.54* 
Abdominal BF-to-whole BF ratio - 0.15 - 0.14   - 0.04   - 0.04 
Abdominal BF-to-trunk BF ratio   0.09 - 0.08       0.26     0.24 
BMI – body mass index; BF – body fat; %BF – percentage of body baf; FFM – fat free mass; %FFM – 
percentage of fat free mass; Append – appendicular; HRR1 – heart rate recovery at 1 min.; HRR2 – heart 
rate recovery at 2 min.; † – partial correlations controlling for age and sex (except when age was an 
independent variable); ‡ – semipartial correlations removing the effect of age and sex (except when age 
was an independent variable); § – partial correlation controlling for trunk BF-to-appendicular BF ratio and 
sex; ¶ – semipartial correlation removing the effect of trunk BF-to-appendicular BF ratio and sex. * - 
significant for p<0.05 and β=0.20. 
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All independent variables that showed significant relation with HRR in partial and semipartial 
correlations were included in multiple linear regression analysis shown in table 4.4. Regressions were 
performed using only trunk BF-to-appendicular BF ratio and age, which has been suggested to 
influence HRR in healthy adults (18), as predictors of either HRR1 or HRR2, and also between pairs of 
independent variables to predict HRR1. Because trunk BF-to-appendicular BF ratio was the only 
independent variable correlated with both dependent variables, it was chosen as a fixed 
independent variable in multiple linear regressions. The higher r square change in the prediction of 
HRR1 seems to be that obtained by adding weight to trunk BF-to-appendicular BF ratio in the 
prediction model. In the prediction of HRR2 Trunk BF-to-appendicular BF ratio alone was found to 
predict over 40% of the variation of HRR2, in this sample of NAFLD patients. 
Table 4.4 – Linear regressions with R square change analysis (Enter method) between dependent and related 
independent variables of study 1. 
 
Variables 
 
Model † 
 
R 
 
R square 
R square 
change 
 
P 
HRR 1 ‡      
Trunk BF-to-Appendicular BF ratio  0.62 0.38 -- 0.001 ** 
 Weight, kg 0.74 0.55 0.17 0.012 * 
 Trunk BF, kg 0.72 0.52 0.14 0.020 * 
 C Abd BF, kg 0.66 0.44 0.06 0.138 
 Age, yr 0.63 0.39 0.01 0.346 
HRR 2 ‡      
Trunk BF-to-Appendicular BF  ratio †  0.66 0.43 -- 0.000 *** 
 Weight, kg 0.71 0.50 0.07 0.087 
 Age, yr 0.67 0.44 0.01 0.467 
BF – body fat; C Abd BF – central abdominal body fat; HRR1 – heart rate recovery at 1 min.; HRR2 – heart rate recovery at 2 
min.; † – Regressions using pairs of independent variables, which include always Trunk BF-to-Appendicular BF ratio plus one of 
the listed variables; ‡ – Dependent variable in the following regressions. * – significant for p<0.05; ** – significant for p<0.01; 
*** – significant for p<0.001. 
4.4. Discussion 
To our knowledge this is the first study to focus on the association between HRR, and BC 
and/or BF distribution, in NAFLD patients. Most studies on HRR focus primarily on cardiovascular 
outcomes and have not included BC variables (299, 304, 307-309). Some previous population-based 
reports showed slower HRR in patients with higher BMI (343, 359). Nilsson and colleagues found 
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similar results in elders (325). In a recent report, BMI showed the highest odds ratio for slow HRR2 
(OR=6.58) over a 20 yr period, after controlling for baseline HRR (18). In our sample, after controlling 
for age and sex, BMI was not associated with either HRR1 or HRR2. Similar results had also been 
found in a sample of type 2 diabetes mellitus patients (311). These discrepancies may be explained 
by differences in studied samples as well as in research protocols, including different HRR record 
timing criterion as well as considerable exercise protocol differences either in the effort as in the 
recovery phase. Nevertheless the development of slow HRR seems more likely in those who have 
more BF accumulation (18, 343, 356).  
A recent study reported that the sum of skinfolds accounted for the greatest variance of both 
HRR1 and HRR2, as compared with BMI, WC and maximal oxygen consumption (316). They used 
mainly skinfolds from the trunk region, including the abdominal skinfold, which can reinforce the 
importance of central BC for appropriate ANS function. In accordance to Esco and colleagues the 
present results showed trunk BF and Central Abdominal (CAbd) BF to be significantly correlated with 
HRR1, independent of age and sex. Few studies could be found using different BC markers, besides 
BMI, when focusing on HRR, nevertheless some investigations have used WC to assess central 
obesity or central as well as whole BF accumulation and found concordant results to ours (18). Mean 
WC has been shown to be higher in patients with slow HRR (18, 343). The association between slow 
HRR and WC has been shown to be stronger than with BMI (adjusted for age, race and sex) (343) as 
well as with all metabolic syndrome components (325). In the present study the results on central BF 
variables, particularly abdominal fat and central abdominal fat, also show a negative correlation with 
HRR1, but not with HRR2. Kim and colleagues (315) found somewhat concordant results concerning 
the relation between visceral fat, particularly that around the myocardium, and both HRR1 and 
HRR2. The only study we found focusing on HRR and regional BC analysis using DXA showed no 
differences in HRR between overweight young adults and lean control subjects, in a sample of 
overnight sleep apnea patients, even though overweight subjects were significantly heavier, and had 
higher BMI, %BF and central abdominal BF (360). Lindmark and colleagues (358), using heart rate 
variability (HRV) to assess ANS function, found that increased visceral adipose tissue, but not 
subcutaneous adipose tissue, as assessed by computed tomography, was strongly associated with 
ANS imbalance.  
In the present study Trunk BF-to-Appendicular BF ratio was the only BF distribution marker 
that was related to HRR, moreover this BF distribution marker was the only studied independent 
variable to show correlation magnitudes with both HRR1 and HRR2 that correspond to a large effect 
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size, even after removing the effect of sex and age. Multiple regression also revealed that other BC 
variables added little predictive capacity to Trunk BF-to-Appendicular BF ratio. These results 
emphasize that BF distribution may be more important for ANS function than the absolute or relative 
amount of BF. Because HRR has been considered a powerful predictor of cardiovascular, as well as 
overall, mortality (297, 299, 305, 307, 310, 311, 361, 362), the present results suggest that a central 
BF distribution, particularly Trunk BF-to-Appendicular BF ratio, can possibly relate more strongly to 
cardiovascular increased risk. The importance of a central distribution of BF was noticed before, 
using HRV to assess ANS function (324). In that study, abdominal-to-peripheral fat distribution, 
assess by dividing abdominal by thigh DXA estimated fat contents, was found to explain a significant 
variation of HRV (324). Carnethon and colleagues (18) showed an association of HRR with aging. In 
our cross-sectional study the relation of HRR1 and HRR2 with patient’s age, was absent if controlled 
for BF distribution. Christou and colleagues (324) had long suggested that the changes in fat 
accumulation pattern that occurs with aging, resulting in BF distribution changes, may contribute to 
the ANS variation attributed to aging. This is a matter that needs to be confirmed either in the 
general population as in specific subpopulations such as the NAFLD patients and other metabolic 
impaired subpopulations. 
The prevalence of slow HRR in the present study is in accordance with most of the published 
data, including that from the Cleveland Clinic Foundation (299, 307, 308) that focused on patients 
referred for symptom-limited exercise testing, as well as in patients with metabolic impairments 
(310, 311) or in even more heterogeneous populations (343). However, when confronted with 
healthy cohort data, as shown recently by Carnethon and colleagues (18) the prevalence of slow HRR 
in the present sample was fairly high. The prevalence of high levels of BMI, including obese and 
morbidly obese patients, in the present sample was expected since obesity, along with insulin 
resistance, have been identified as the strongest risk factors for NAFLD, and therefore highly 
prevalent in this subpopulation (2-4, 6). 
In conclusion, in the present study BF content and distribution were important contributors 
to HRR in NAFLD patients. Excess BF accumulated in the trunk or abdominal regions was associated 
with poor HRR. BF distribution appears to be more important than overall BF accumulation in 
explaining the variation of HRR and therefore can possibly be a better predictor of cardiovascular risk 
in NAFLD patients. The present results may also support an important role of BF distribution in the 
link between aging and slowing HRR.  
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Chapter 5 – Study 2:  
“Which is the Best Waist Circumference Measurement Protocol to use 
in Non-Alcoholic Fatty Liver Disease Patients?”2 
  
                                                          
2
 Pimenta, N, Santa-Clara, H, Cortez-Pinto, H, Silva-Nunes, J, Sardinha, L (2013) Nutrition Journal, 
(Submited). 
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Abstract 
Background: Body Fat (BF), particularly central fat accumulation, is related to Non-alcoholic 
Fatty Liver Disease (NAFLD). Waist circumference (WC) measurement has been widely used in NAFLD 
patients as a marker of body composition (BC), particularly central BF, but no single WC 
measurement protocol (WCmp) is consensually accepted.  
Purpose: The aim of the present investigation was to find which of the most used WCmp is 
preferable to be used in clinical practice with NAFLD patients.  
Methods: Total and regional BF were assessed through Dual Energy X-ray Absorptiometry 
(DXA) in 28 NAFLD patients (19 males, 51 + 13 yrs, and 9 females, 47 + 13 yrs), who were diagnosed 
by liver biopsy or ultrasound, after exclusion of other potential causes of liver disease. All subjects 
also underwent anthropometric evaluation including the measurement of WC using four different 
WCmp (WC1: minimal waist; WC2: iliac crest; WC3: mid-distance between iliac crest and lowest rib; 
WC4: at the umbilicus).  
Results: All WC measurements were correlated particularly with central BF depots, including 
trunk BF (r=0.78; r=0.82; r=0.82; r=0.84; respectively for WC1, WC2, WC3 and WC4) abdominal BF 
(r=0.78; r=0.78; r=0.80; r=0.72; respectively for WC1, WC2, WC3 and WC4) and central abdominal BF 
(r=0.76; r=0.77; r=0.78; r=0.68; respectively for WC1, WC2, WC3 and WC4), even after controlling for 
age, sex and body mass index. There were no differences between the correlation coefficients 
obtained between all studied WC measurements and each whole and central analyzed BF variable.  
Conclusions: A preferable WCmp in these NAFLD patients could not be clearly established 
based on biological criteria or on protocols’ precision. The WC measured at the superior border of 
the iliac crest may be a better choice for use in clinical practice based on practical criteria.  
Keywords: Regional Body Fat; Dual Energy X-ray Absorptiometry; Hepatic Steatosis; Clinical 
Body Composition Assessment; Anthropometry. 
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5.1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is a rising recognized condition that has caught a 
growing attention. In an advanced stage NAFLD can ultimately lead to advanced fibrosis, cirrhosis, 
liver failure and death (16, 30). In most cases NAFLD is a consequence of an imbalance in hepatic fat 
metabolism, favouring factors that promote liver fat increase (uptake and synthesis of fatty acids) 
against factors that promote liver fat reduction (secretion and oxidation of fatty acids) (16, 54). While 
insulin resistance (IR) seems to be the most consistent and replicable explanation of liver fat 
accumulation (16, 32), both central body fat (BF) and IR have been found to increase the risk of 
NAFLD (363), furthermore whole and particularly central BF may also increase the risk for NAFLD by 
its strong association with IR (5, 183). Excess both whole and central BF accumulation are also known 
cardiovascular risk factors. These evidences arisen the importance, particularly in this higher risk 
subpopulation, of finding clinical non-invasive surrogates, and potential therapy targets, of risk 
related body composition (BC). 
Waist circumference (WC) measurement is widely used in different settings and populations 
(23, 86, 169), including the subpopulation of NAFLD patients (174). WC has been considered a proper 
surrogate of BC, particularly when focusing on BF distribution (139, 169, 188), and a risk factor for 
NAFLD (175). WC has also been found to be related with increased morbidity and mortality 
regardless of WC measuring site (23). In NAFLD patients WC has been found to be associated with 
several metabolic impairments including IR (183, 184) as well as liver fat (174) and NAFLD severity 
(185). Moreover, high WC was also found to be related to increased health-care costs (187). Even 
though widely used, there is currently no optimal and uniquely recommended WC measurement 
protocol (WCmp) to be used in clinical practice, either in the general population as in specific higher 
risk subpopulations. Several WCmp have been suggested but scientific rational is lacking to 
recommend one single protocol (23, 189). Recommended protocols differ mainly on the anatomical 
landmarks and correspondent measuring sites. The most commonly used WC measurement sites are 
the midpoint between the lowest rib and iliac crest, the umbilicus and the minimal waist, still a 
fourth measurement site has also been used and endorsed by the US National Institute of Health 
(NIH), which is the superior border of the iliac crest (23, 169). Nevertheless several other measuring 
sites have been sparsely used (23).     
To our knowledge this is the first study to look into the usefulness of commonly used WC 
measurements as surrogates of whole and central BF content in NAFLD patients. Therefore the aim 
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of the present study was to find which of the most used WCmp is the best for use in clinical settings 
with NAFLD patients, considering a threefold criteria: the WC most closely associated with whole and 
central BF content in NAFLD patients; the most precise WCmp; the most practical WCmp to use in 
clinical practice. 
5.2. Methods 
In the present study we analyzed two groups of variables (Table 5.1): BC variables, including 
whole and regional BF content, as assessed by DXA (as described in section 3.3.1); and WC 
measurements using different measurement protocols (as detailed in subsection 3.3.3), in the 
studied sample of 28 NAFLD patients (described in section 3.1).   
Table 5.1 – List of Studied variables in study 2 
Variable Unit of measurement Abbreviations Described in subsection 
Age Years -- 3.1 
Sex -- -- 3.1 
Anthropometry    
Weight Kg -- 3.3.3 
Height Cm -- 3.3.3 
Body mass index kg/m
2
 BMI 3.3.3 
Waist Circumference 1 Cm WC1 3.3.3 
Waist Circumference 2 Cm WC2 3.3.3 
Waist Circumference 3 Cm WC3 3.3.3 
Waist Circumference 4 Cm WC4 3.3.3 
Whole and Regional Body Composition    
Whole body fat Kg Whole BF 3.3.1 
Whole percentage of body fat % Whole %BF 3.3.1 
Trunk body fat Kg Trunk BF 3.3.1 
Trunk percentage of fat mass % Trunk %BF 3.3.1 
Appendicular body fat Kg Append BF 3.3.1 
Appendicular percentage of fat mass % Append %BF 3.3.1 
Abdominal body fat Kg Abd BF 3.3.1 
Abdominal percentage of body fat % ABD %BF 3.3.1 
Central Abdominal body fat Kg CAbd BF 3.3.1 
Central Abdominal percentage of body fat % CAbd %BF 3.3.1 
DXA – dual energy x-ray absorptionmetry; bpm – beats per minute; Max. GXT – maximal graded exercise test; ECG - electrocardiogram. 
Descriptive statistics are presented as mean ± sd and range for all analyzed variables. The 
Gaussian distribution of the data was assessed with the Shapiro-Wilk goodness-of-fit test. Levenne 
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test was used for assessing sample variance homogeneity. Paired-samples T test was used to 
compare WC results obtained with different WCmp. When homogeneity of variance was not present, 
the corrected significance values of T test were used. The association between whole and central BF 
and the results obtained with each WCmp was assessed using partial as well as part, also called 
semipartial (357), correlations, controlling for age and sex and body mass index (BMI). Only 
correlation coefficients equal or above 0.50 were considered to be significant at a significance level 
of 5% and a statistical power of 80%. Pairs of correlation coefficients obtained between each WC 
with each dependent variable were compared, using Z statistic, to find if any WC was more closely 
associated with whole and central BF. To evaluate the precision of the studied WCmp we calculated 
coefficients of variation for the repeated measurements, and compared them between WCmp using 
paired-samples T test. To respond to the third criteria, comprised in the aim of the present study, 
paired-samples T test was used to compare the time consumption of WC measurement between 
different measurement protocols. Statistical calculations were performed using the IBM SPSS 
Statistics version 19 (SPSS, inc, Chicago, IL, USA), except for z statistic which was performed using 
Medcalc version 11.1.1.0 (MedCalc Software, Mariakerke, Belgium). 
5.3. Results 
Mean values for all studied variables are presented in table 5.2. From among the 28 studied 
NAFLD patients obesity was present in 9 subjects (3 were female), according to BMI classification, yet 
mean BMI showed no differences between sexes (p=0.075 on independent samples t test) and was 
considered to be in the overweight category for the whole studied sample. BMI was also not related 
with subjects’ age (r= -0.22; p=0.266 on Pearson correlation). Results for WC measurements were 
considered to be different between all studied WCmp, for instance WC4 showed the highest values 
whereas WC1 showed the lowest, and WC3 was smaller than WC2, as shown in table 5.3. 
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Table 5.2 – Descriptive data of the studied sample in study 2. 
 NAFLD Patients (n=28) 
Variables Mean + sd *  Min. – Max. 
Age, yr (median, yr) 49.5 ± 12.8 (49)  25 – 68  
Sex, n female (% female)  9 (32,1)    
Anthropometry      
Weight, kg  87.6 ± 12.7   66.2 – 115.8  
Height, cm  167.2 ± 9.2   149.5 – 183.7  
BMI, kg/m2 (% obese) 29.1 ± 4.0 (32.1)  22.6 – 42.2  
WC 1, cm  100.7 ± 8.2   86.0 – 119.8  
WC 2, cm  104.8 ± 10.6   85.3 – 128.7  
WC 3, cm  103.7 ± 10.4   85.7 – 129.3  
WC 4, cm  106.3 ± 11.5   86.7 – 129.1  
Whole and Regional Body 
Composition 
     
BF, kg (%) 27.2 ± 9.3 (31.31 ± 8.20)  13.7 – 51.2 (18.84 – 46.28) 
FFM, kg (%) 58.7 ± 9.1 (68.69 ± 8.20)  39.6 – 77.7 (53.72 – 81.16) 
Trunk BF, kg (%) 15.2 ± 5.2 (33.15 ± 7.65)  7.4 – 25.0 (20.87 – 48.01) 
Trunk FFM kg (%) 29.9 ± 3.9 (66.85 ± 7.65)  21.1 – 38.6 (51.99 –79.13) 
Append BF, kg (%) 10.8 ± 4.8 (30.42 ± 10.39)  5.2 – 25.7 (13.63 – 50.40) 
Append FFM, kg (%) 24.5 ± 5.1 (69.58 ± 10.39)  14.9 – 34.8 (49.60 – 86.37) 
Abdominal BF, kg (%) 3.5 ± 1.2 (37.57 ± 6.59)  1.7 – 6.3 (26.09 – 49.40) 
Central Abdominal BF, kg (%) 2.9 ± 0.8 (35.82 ± 5.70)  1.6 – 5.0 (24.28 – 44.64) 
BMI – body mass index; WC1 – Waist circumference as measured at minimal waist; WC2 - Waist circumference as measured just above iliac 
crest; WC3 - Waist circumference as measured at the mid-distance between lowest rib and iliac crest; WC4 - Waist circumference as 
measured at the umbilicus; BF – body fat; FFM – fat free mass; * Results are presented as mean ± standard deviation, unless otherwise 
noted; Min. – lowest observed value; Max. – highest observed value; BMI – body mass index; BF – body fat; FFM – fat free mass. 
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Table 5.3 – Mean differences and P values from paired samples T test used in the 
comparison between waist circumference results obtained with different 
measurement protocols.    
Variables WC 1, cm   WC 2, cm   WC 3, cm  
 Dif † P  Dif † P  Dif † p 
WC2 4.1 0.000  -- --  -- -- 
WC3 3.0 0.000   -1.1 0.000  -- -- 
WC4 5.6 0.000  1.5 0.012  2.6 0.001 
WC1 – Waist circumference measured minimal waist; WC2 - Waist circumference measured just above 
iliac crest; WC3 - Waist circumference measured at mid-distance; WC4 - Waist circumference measured 
at the umbilicus; † - results from the WC protocols in the Left column subtracted by the results from 
the WC protocols in the top line. 
Table 5.4 shows the results for partial and semipartial correlations between each WC and 
each whole or central studied BF depot controlled for sex, age and BMI. All WC results were 
somewhat correlated with the overall studied DXA assessed BF depots, controlling for age, sex and 
BMI, often showing correlation coefficients above 0.5. Yet, only WC4 was correlated with both 
absolute and relative whole BF, in partial correlation. WC1, WC2 and WC3 were correlated only with 
the absolute values of whole BF, in partial correlations. All of the coefficients of correlation found in 
semipartial correlations for whole BF could not be considered significant. All studied WC were 
correlated with absolute and relative trunk BF, in partial correlations, however, in semipartial 
correlations, all WC only correlated significantly with absolute values of trunk BF. WC 1, WC2 and 
WC3 were associated with absolute and relative values of abdominal fat depots, comprising 
abdominal (Abd), Abd %BF, central abdominal (CAbd) BF and CAbd %BF, but WC4 was only 
correlated with Abd BF and Cabd BF, in partial correlations. Semipartial correlations only confirmed 
the correlation with Abd BF and CAbd BF, for all WC. Table 5.5 shows the results for the comparison 
between the correlation coefficients listed in table 5.4. Comparisons were made between pairs of 
competing WC correlations results with each dependent variable. No differences were found 
between all performed correlations with each studied BF depot. Nevertheless semipartial 
correlations, when the effect of age sex and BMI was removed, seem to show more constant 
correlation coefficients across different WCmp, for the same BF depot, than partial correlations, 
when results are only adjusted for age, sex and BMI. However, as stated, no differences were found 
across WC measuring sites, in the association with whole and central BF depots.  
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Table 5.4 – Partial and semipartial correlations between all studied circumferences and body composition variables 
of study 2. 
 WC 1, cm   WC 2, cm   WC 3, cm   WC 4, cm  
Variables r † r ‡  r † r ‡  r † r ‡  r † r ‡ 
Whole BF 0.63* 0.34  0.68* 0.37  0.66* 0.36  0.77* 0.35 
Whole %BF 0.46 0.23   0.45 0.22  0.46 0.22  0.54* 0.28 
Trunk BF 0.78* 0.52*  0.82* 0.54*  0.82* 0.54*  0.84* 0.51* 
Trunk %BF 0.56* 0.35  0.54* 0.34  0.56* 0.34  0.57* 0.30 
Abd BF 0.78* 0.68*  0.78* 0.69*  0.80* 0.70*  0.72* 0.66* 
Abd %BF 0.59* 0.49  0.57* 0.47  0.58* 0.48  0.47 0.44 
C Abd BF 0.76* 0.73*  0.77* 0.74*  0.78* 0.75*  0.68** 0.70* 
C Abd %BF 0.55* 0.48  0.53* 0.46  0.54* 0.47  0.48 0.44 
WC1 – Waist circumference measured minimal waist; WC2 - Waist circumference measured just above iliac crest; WC3 - Waist circumference 
measured at mid-distance; WC4 - Waist circumference measured at the umbilicus; BF – body fat; Abd BF – abdominal body fat; CAbd BF – Central 
abdominal body fat; † - partial correlations between studied circumferences and dependent variables, controlled for age, sex and body mass index; ‡ - 
semipartial correlations between studied circumferences and dependent variables, removing the effect of age, sex and body mass index; * - significant 
for p<0,05 and β=0.20. 
Table 5.6 shows both the coefficients of variation for the WC measurements according to the 
studied protocols, as well as the mean ± sd time spent for WC measurements using each of the 
studied WCmp. Coefficient of variation was not different irrespectively of the WCmp used. Time 
spent in each measurement was longer for WC3 as compared to all others. WC2 was more time 
consuming than both WC1 and WC4. The latest showed no differences between both mean time 
lengths of measurements. In summary time length of measurement of the studied protocols was as 
follows: WC1 ≈ WC4; WC1 and WC4 < WC 2 < WC3. 
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Table 5.5 – Z statistic P values for the comparison between correlation coefficients obtained in partial and semipartial 
correlations between all studied waist circumferences and the dependent variables, as expressed in absolute 
(lower left half of table) and relative (upper right half of the table) values. 
  WC1   WC2   WC3   WC4    
  p† p‡  p† p‡  p† p‡  p† p‡   
     0.954 0.982  0.971 0.988  0.874 0.841 Whole %BF WC1 
     0.923 0.962  0.980 0.990  0.715 0.853 Trunk %BF  
     0.886 0.920  0.949 0.963  0.747 0.836 Abd %BF  
     0.909 0.928  0.952 0.964  0.836 0.865 C Abd %BF  
WC2 Whole BF 0.744 0.907     0.982 0.994  0.920 0.824 Whole %BF WC2 
 Trunk BF 0.754 0.918     0.944 0.971  0.788 0.828 Trunk %BF  
 Abd BF 0.950 0.968     0.937 0.957  0.899 0.915 Abd %BF  
 C Abd BF 0.912 0.921     0.957 0.964  0.927 0.936 C Abd %BF  
WC3 Whole BF 0.828 0.939  0.913 0.968     0.902 0.830 Whole %BF WC3 
 Trunk BF 0.746 0.918  0.992 1.000     0.734 0.862 Trunk %BF  
 Abd BF 0.799 0.876  0.848 0.908     0.837 0.872 Abd %BF  
 C Abd BF 0.842 0.864  0.929 0.943     0.884 0.901 C Abd %BF  
WC4 Whole BF 0.881 0.958  0.859 0.948  0.946 0.981      
 Trunk BF 0.881 0.958  0.643 0.876  0.635 0.876      
 Abd BF 0.819 0.879  0.770 0.985  0.629 0.758      
 C Abd BF 0.849 0.862  0.763 0.784  0.697 0.730      
WC1 – Waist circumference measured minimal waist; WC2 - Waist circumference measured just above iliac crest; WC3 - Waist circumference measured at mid-
distance; WC4 - Waist circumference measured at the umbilicus; † - comparison between correlation coefficients obtained in partial correlations between 
waist circumferences and all dependent variables, controlled for age, sex and BMI; ‡ - comparison between correlation coefficients obtained in semipartial 
correlations between waist circumferences and all dependent variables, removing the effect of age, sex and BMI. 
 
Table 5.6 – Coefficient of variation and time length for measurement of 
each waist circumference protocol used in study 2. 
 WC 1  WC 2  WC 3  WC 4 
COV, % 0.45  0.49  0.47  0.73 
TLM, sec. 35±6*  44±4**  74±4**  34±5*** 
COV – mean coefficient of variation, TLM – mean±standard deviation time length of 
measurements, in seconds; WC1 – Waist circumference measured minimal waist; 
WC2 - Waist circumference measured just above iliac crest; WC3 - Waist 
circumference measured at mid-distance; WC4 - Waist circumference measured at 
the umbilicus; * - different from WC2 and WC3 (p<0-001) but not WC4 (P=0.522); ** - 
different from all other WC TLM (p<0.001); *** - different from WC2 and WC3 (p<0-
001) but not WC1 (P=0.522). 
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5.4. Discussion 
Even though WC has been a widely used measure in the subpopulation of NAFLD patients 
(174, 364), to our knowledge this is the first study to focus on the comparison of the usefulness of 
different WCmp based on a scientific and practical rational. The prevalence of high levels of BMI, 
including obese and morbidly obese patients, in the present sample was expected since obesity, 
along with insulin resistance, have been identified among the strongest risk factors for NAFLD, and 
therefore highly prevalent in this subpopulation (2-4, 6). WC results were also quite high which was 
consistent with sample levels of BMI. The magnitude of WC mean values was different according to 
the protocol in use meaning they are not interchangeable. This has large implications in all sorts of 
comparisons meaning that only one protocol should be used to permit within subjects comparison 
(pre - post), between groups comparisons and, most important, subjects results confrontation with 
normative charts or cut-off values because a dichotomous analysis may amplify even small absolute 
differences (365). To avoid misclassifications measurements should be made using the same protocol 
that was used to build the reference values. Several previous studies also reported WC magnitudes 
influenced by WCmp (365-367). However small or absent differences, particularly in men, between 
measurements of WC according to NIH (at the superior border of the iliac crest) and to WHO (at the 
midpoint between lowest rib and iliac crest) protocols have also been reported (365-367). 
Consequently, it has been suggested that current WC thresholds, generalized using WHO protocol, 
could be applied to NIH measurements (23). Even though the analysis of absolute values and 
classification of WC was not the aim of the present study our data do not support this generalization 
for NAFLD patients, but more research is needed to look into sex differences and other possible 
influencing variables that may help to endorse or reject an interchangeable use of both NIH and 
WHO WCmp in NAFLD patients. Moreover fairly recent studies reported differences in the 
prevalence of metabolic disorders as well as in the prevalence of metabolic syndrome, when 
comparing the same subjects grouped by results obtained with different WCmp using metabolic 
syndrome WC cutoff values (368, 369). These results reinforce the necessity for finding one single 
consensual standardized WCmp. 
In the present sample of NAFLD patients, as expected, WC results were highly associated 
with whole and central BF, adjusted for age, sex and BMI. Correlation coefficient magnitudes often 
revealed a large effect size (r>0.5). The association of WC with BC, particularly with central BF has 
long been reported (188, 370, 371). Equations using only age and WC, as measured midpoint 
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between lowest rib and iliac crest, were found to be among the best BC prediction equations (370). 
WC as measured midpoint between lower ribs and iliac crest was found highly related with intra-
abdominal fat, adjusted for age (371). In the present report, the results obtained in partial 
correlation may suggest that WC1, WC2 and WC3 are better associated with central BF, because they 
were related to both absolute and relative values of central BF depots, as opposed to WC4 which was 
the only related with both absolute and relative whole BF. However, when the results obtained in 
semipartial correlations are taken into consideration it is possible to notice that all coefficients of 
correlation were fairly reduced, as compared to those obtained in partial correlations. This means 
that the control variables, age, sex and BMI explained a considerable part of the variation of the 
studied DXA assessed BF depots, which is not explained by any of the tested WC. As a result, in 
semipartial correlations, all studied WC were similarly only correlated with trunk BF, Abd BF and 
CAbd BF, controlled for age, sex and BMI. Wang and colleagues (366) had already found stronger 
associations between WC and absolute central BF, as opposed to either whole BF mass or any 
percentage expressed BF depot, assessed by DXA. In the present study, WC appears to be a good BF 
surrogate, particularly for central BF which is the most hazardous BF, and may be an adequate 
procedure to assess BF accumulation in NAFLD patients for use in clinical practice, even after 
removing the effect of age, sex and BMI.   
Comparisons between pairs of competing WC correlations results with each dependent 
variable showed no differences meaning all WC results are similarly associated with the analysed BF 
depots, irrespectively of the WCmp used. Semipartial correlations, when the effect of age sex and 
BMI was removed, seem to show more constant correlation coefficients than partial correlations 
across different WCmp. This may indicate that the variation that may be found in the association 
between WC measured at different site and BC may be accounted by factors like subjects’ age, sex or 
BMI, other than the site of measurement alone. Nevertheless, in the present results, no differences 
were found between correlation coefficients across different WC measuring sites. Conflicting results 
can be found in general population (366, 367). A recent report focused on NIH (at the superior 
border of the iliac crest) and WHO (midpoint between lowest rib and iliac crest) recommended 
WCmp, as well as a third WC measurement that was not used in the present study (bellow the lowest 
rib), and found differences between correlation coefficients in partial correlations with abdominal 
adipose tissue assessed with magnetic resonance imaging, in women but not in men (367). Wang and 
colleagues (366) found correlation with both whole and trunk BF, though stronger with trunk BF, 
regardless of sex and WCmp (bellow lowest rib, at the superior border of the iliac crest, midpoint and 
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narrowest waist). In a sound review, by Ross and colleagues (23), it was concluded that the use of 
different WCmp do not change the well-established relationships between WC and morbidity of 
cardiovascular disease and diabetes and with cardiovascular and all-cause mortality. The present 
results are in agreement with the lack of biological rational described in previous reports, 
substantiating the difficulty in finding one single consensual standardized WCmp. Nevertheless there 
seems to be a relative consensus regarding the need to find a single consensual standardized WCmp.    
In the present sample of NAFLD patients all WC measurements, irrespective of WCmp, were 
similarly correlated with the studied BF depots, even after removing the effect of sex, age and BMI. 
The present findings confirm, in NAFLD patients, the findings reported on other populations 
regarding specific WCmp selection for the association with whole and central BF (366, 367). Despite 
conflicting results found in the literature (368) the differences in WCmp do not seem to influence the 
relationship between WC measurements and BC associated risk for cardiovascular and other 
hazardous outcomes (23, 369). In the absence of biological support identifying one preferable WCmp 
additional criteria have been suggested and may be used to substantiate the decision to use one 
particular WCmp: the use of bony landmarks and ease of measurement (23, 169, 189). It was argued 
that the use of bony landmarks could be preferable because of increased precision (169) or reliability 
(23, 189). WHO WCmp could also be expected to be less reliable than NIH protocol considering it is 
more exposed to error propagation effect caused by the identification of an additional landmark, 
measurement of the distance and calculation of the midpoint between the two. The present data do 
not confirm better precision of one single studied WCmp over another, as assessed by the 
comparison of coefficients of variation. Present results are in accordance to recent reported data, 
using exactly the same WCmps used in the present study (365). Other study analyzed measurement 
reproducibility and found no differences between studied WCmps (366). While the preference for 
bony landmarks when selecting a WCmp can be understandable because it appears to be less prone 
to variations or bias, particularly when monitoring changes in weight loss settings, more research is 
needed to support this argument. The second suggested criteria, ease of measurement, means that 
WCmp should be easily adopted by general public and practitioners to be elected and should also 
require less specific training and be less time consuming to be suitable for routine clinical practice 
(169). It has been suggested that WC measured at the superior border of the iliac crest would be 
more likely adopted by general public and practitioners as it requires only the palpation of one bony 
landmark whereas the protocol suggested by WHO (midpoint between lowest rib and iliac crest) 
requires the detection of two landmarks as well as the calculation of the midpoint between the two, 
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consequently NIH WCmp would also require less training (189). However published data show similar 
use among the most common WCmps (22 to 33% minimal waist, 26 to 29% midpoint and 27 to 28% 
umbilicus) (23, 169) and the identification of bony landmarks seem to require more training and 
experience for observers to locate then consistently, as subjectively reported by Mason and 
colleagues (365). Difficulties were also reported for measuring WC using external landmarks (minimal 
waist and umbilicus) (365). In the present study only the difficulties reported for WC using external 
landmarks were felt, with the exception of those found for quite thin subjects, as there were not any 
in the present sample, still lowest rib was the most demanding of bony landmarks to locate. Limited 
time availability has been suggested as one of the reasons for not using WC measurement in routine 
clinical practice (169). Manson and colleagues (365) also subjectively reported that WC measurement 
at the midpoint between lowest rib and iliac crest was more time consuming than when using other 
studied WCmp, although no quantitative data was shown. The present data confirm the findings that 
WHO WCmp is the most time consuming of all studied protocols (365). Also WCmp using external 
landmarks were less time consuming then those using bony landmarks.   
The present study confirms the strong association between WC and BF, especially central BF, 
even after controlling for the effect of age, sex and BMI. However, a preferable WCmp could not be 
established for the present sample of NAFLD patients based on biological criteria. There seem to be 
also no precision differences between different WCmp. Practical criteria may somewhat support a 
preferential use of WC measured at the superior border of the iliac crest, but additional research will 
be useful to confirm this conclusion regarding the association with other metabolic characteristics 
and outcomes in NAFLD patients. 
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Chapter 6 – Study 3:  
“Does Waist Circumference Measurement Protocol Influence the 
Relation Between Waist-to-Height Ratio and Body Composition in Non -
Alcoholic Fatty Liver Disease Patients?”3 
  
                                                          
3
 Pimenta, N, Santa-Clara, H, Cortez-Pinto, H, Silva-Nunes, J, Sardinha, L (2014) Clinical Nutrition 
(submitted). 
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Abstract 
Background: Body Fat (BF), particularly central fat accumulation, is related to Non-alcoholic 
Fatty Liver Disease (NAFLD), and is related also to increased cardiovascular morbidity and mortality, 
which is also increased in NAFLD patients. Waist-to-height ratio (WHtR) has been suggested to be the 
best clinical body index to predict cardiovascular risk. No single waist circumference measurement 
protocol (WCmp) is consensually accepted nor its effects on WHtR correlation have been assessed.  
Purpose: The aim of this study was to analyze the effect of using different WCmp on the 
strength of association between WHtR and both, whole and central BF in NAFLD patients.   
Methods: Whole and regional BF content were assessed with Dual Energy X-ray 
Absorptiometry (DXA) in 28 NAFLD patients (19 males, 51 ± 13 yrs, and 9 females, 47 ± 13 yrs) , who 
were diagnosed by liver biopsy or ultrasound, after exclusion of other potential causes of liver 
disease. All subjects also underwent anthropometric evaluation including the measurement of WC 
using four different WCmp (WC1: minimal waist; WC2: iliac crest; WC3: mid-distance between iliac 
crest and lowest rib; WC4: at the umbilicus) and WHtR was calculated using each of the WC 
measurements (WHtR1, WHtR2, WHtR3 and WHtR4, respectively). 
Results: All WHtR measurements were correlated particularly with central BF depots, 
including abdominal BF (r=0.80; r=0.84; r=0.84; r=0.78; respectively for WHtR1, WHtR2, WHtR3 and 
WHtR4) and central abdominal BF (r=0.72; r=0.77; r=0.76; r=0.71; respectively for WHtR1, WHtR2, 
WHtR3 and WHtR4), after controlling for age, sex and body mass index. There were no differences 
between the correlation coefficients obtained between all studied WHtR and each whole and central 
analyzed BF variable.  
Conclusions: The choice for a particular WCmp does not change the strength of relation 
between both, whole and central, BF depots in the present sample of NAFLD patients. This study may 
endorse an interchangeable use of different WCmp to identify subjects above suggested healthy 
boundary and therefore at higher risk.   
Keywords: Regional Body Fat; Dual Energy X-ray Absorptiometry; Hepatic Steatosis; Clinical 
Body Composition Assessment; Anthropometry. 
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6.1. Introduction 
Waist-to-height ratio (WHtR) is an index of abdominal obesity initially suggested by Hsieh and 
Yoshinaga in the mid-nineties (266, 267). By then WHtR was suggested to be a better predictor of 
multiple coronary heart disease risk factors than other obesity and body fat (BF) distribution indexes 
in both men (267) and women (266). WHtR was further suggested to be preferable to other indexes 
and clinical assessments, including body mass index (BMI), waist circumference (WC) and waist-to-
hip ratio (WHR), to predict cardiovascular risk factors, in different ethnic and age groups (129, 270). 
WHtR seems also to be at least similarly associated to abdominal fat as is WC, and better than both 
BMI and WHR (278, 279). To our knowledge only one study focused on non-alcoholic fatty liver 
disease (NAFLD) patients using WHtR (252). This study found WHtR to be higher in NAFLD patients 
but was not a better prognostic factor of NAFLD than were BMI or WHR. 
There is still some inconsistency considering the WC measurement protocol (WCmp) used to 
calculate WHtR (280). Several WCmp have been suggested but scientific rational is lacking to 
recommend one single protocol (23, 169, 189). The association of WC to cardiometabolic risk is 
independent of WCmp, however measurements using different WCmp have different magnitudes 
and therefore are not interchangeable (23). Suggested protocols differ mainly on the anatomical 
landmarks and correspondent measuring sites. WHtR was initially suggested using WC measured at 
the umbilicus (266, 267). In a fairly recent review on WHtR, WC measured midpoint between the 
lowest rib and iliac crest was found to be used in 50% of the reviewed papers, and for that reason its 
routine use was encouraged (280).   
To our knowledge it is unknown if the use of different commonly used WC, measured 
according to different WCmp, which differ mainly in the measuring sites, affects the relation between 
WHtR and both whole and central BF content. Therefore the aim of the present study was to analyze 
which of the most used WCmp is better to calculate WHtR for use in clinical practice with NAFLD 
patients as a surrogate for whole and central BF.   
6.2. Methods 
In the present study we analyzed two groups of variables (Table 6.1): whole and regional BF 
content, as assessed by DXA (as described in subsections 3.3.1); and WHtR as calculated using four 
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different WC measured according to different WCmp for each patient (as detailed in subsection 
3.3.3), in the studied sample of 28 NAFLD patients (described in section 3.1).   
Table 6.1 – List of Studied variables in Study 3 
Variable Unit of measurement Abbreviations Described in subsection 
Age Years -- 3.1 
Sex -- -- 3.1 
Anthropometry    
Weight kg -- 3.3.3 
Height cm -- 3.3.3 
Body mass index kg/m
2
 BMI 3.3.3 
Waist Circumference 1 cm WC1 3.3.3 
Waist Circumference 2 cm WC2 3.3.3 
Waist Circumference 3 cm WC3 3.3.3 
Waist Circumference 4 cm WC4 3.3.3 
Waist-to-height ratio 1 -- WHtR1 3.3.3 
Waist-to-height ratio 2 -- WHtR2 3.3.3 
Waist-to-height ratio 3 -- WHtR3 3.3.3 
Waist-to-height ratio 4 -- WHtR4 3.3.3 
Whole and Regional Body Composition    
Whole body fat kg Whole BF 3.3.1 
Whole percentage of body fat % Whole %BF 3.3.1 
Whole fat free mass kg Whole FFM 3.3.1 
Whole percentage of fat free mass % Whole %FFM 3.3.1 
Trunk body fat kg Trunk BF 3.3.1 
Trunk percentage of body fat % Trunk %BF 3.3.1 
Trunk fat free mass kg Trunk FFM 3.3.1 
Trunk percentage of fat free mass % Trunk %FFM 3.3.1 
Abdominal body fat kg Abd BF 3.3.1 
Abdominal percentage of body fat % ABD %BF 3.3.1 
Central Abdominal body fat kg CAbd BF 3.3.1 
Central Abdominal percentage of body fat % CAbd %BF 3.3.1 
Descriptive statistics are presented as mean ± sd and range, for all analyzed variables. The 
Gaussian distribution of the data was assessed with the Shapiro-Wilk goodness-of-fit test. Paired-
samples T test was used to compare the magnitude of the different WHtR mean values. Partial 
correlations, controlling for age and sex, and partial and part, also called semipartial (357), 
correlations, controlling for age and sex and BMI, were performed to assess the relations between 
dependent and independent variables. Only correlation coefficients equal or above 0.50 were 
considered to be significant at a significance level of 5% and a statistical power of 80% (357). Pairs of 
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correlation coefficients obtained between each WHtR with each dependent variable were compared, 
using Z statistic, to analyze if any WHtR was more closely associated with whole and central BF. 
Statistical calculations were performed using the IBM SPSS Statistics version 19 (SPSS, inc, Chicago, IL, 
USA), except for z statistic which was performed using Medcalc version 11.1.1.0 (MedCalc Software, 
Mariakerke, Belgium). 
6.3. Results 
Mean values for all studied variables are presented in table 6.2. From among the 28 studied 
NAFLD patients WHtR above the boundary value of 0.5 was present in nearly 100% of the sample, 
depending on the WCmp used. Results for WC measurements were considered to be different 
between all studied WCmp (WC4>WC2>WC3>WC1) and the magnitude of WHtR mean values were 
also different according to the WC used. Obesity was present in 9 subjects (3 were female), according 
to BMI classification, with no differences between sexes in mean BMI (p=0.075 on independent 
samples t test). 
Table 6.3 shows the results for partial correlations controlled for age and sex, as well as 
partial and semipartial correlations, controlled for sex, age and BMI, between each WHtR and each 
whole or central studied BF depot. All but WHtR1 were correlated with all studied BF depots, 
showing coefficients of correlation magnitudes that were most often above 0.5, in partial 
correlations controlled only for age and sex. When BMI was added as a control variable in partial 
correlations, all WHtR were no longer correlated with whole BF and %BF, and WHtR4 was also not 
correlated with Trunk %BF. In semipartial correlations, controlled for age, sex and BMI, all WHtR 
were only correlated only with both absolute and relative values of abdominal (Abd) BF and central 
abdominal (CAbd) BF, except for WHtR4 which was not correlated with Abd %BF.  
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Table 6.2 – Descriptive data of the studied sample in study 3 
 NAFLD Patients (n=28) 
Variables Mean + sd *  Min. – Max. 
Age, yr (median, yr) 49.5 ± 12.8 (49)  25 – 68  
Sex, n female (% female)  9 (32.1)    
Anthropometry      
Weight, kg (COV, %) 87.6 ± 12.7 (0.07)  66.2 – 115.8  
Height, cm (COV, %) 167.2 ± 9.2 (0.03)  149.5 – 183.7  
BMI, kg/m2 (% obese) 29.1 ± 4.0 (32.1)  22.6 – 42.2  
WC 1, cm (COV, %) 100.7 ± 8.2# (0.45)  86.0 – 119.8  
WC 2, cm (COV, %) 104.8 ± 10.6# (0.49)  85.3 – 128.7  
WC 3, cm (COV, %) 103.7 ± 10.4# (0.47)  85.7 – 129.3  
WC 4, cm (COV, %) 106.3 ± 11.7# (0.73)  86.7 – 129.1  
WHtR 1 (≥0.5, %) 0.60 ± 0.07† (96.4)  0.48 – 0.75  
WHtR 2 (≥0.5, %) 0.63 ± 0.08† (100.0)  0.50 – 0.82  
WHtR 3 (≥0.5, %) 0.62 ± 0.08† (96.4)  0.49 – 0.81  
WHtR 4 (≥0.5, %) 0.64 ± 0.09† (100.0)  0.50 – 0.85  
Whole and Regional Body 
Composition 
     
Whole BF, kg (%) 27.2 ± 9.3 (31.31 ± 8.20)  13.7 – 51.2 (18.84 – 46.28) 
Whole FFM, kg (%) 58.7 ± 9.1 (68.69 ± 8.20)  39.6 – 77.7 (53.72 – 81.16) 
Trunk BF, kg (%) 15.2 ± 5.2 (33.15 ± 7.65)  7.4 – 25.0 (20.87 – 48.01) 
Trunk FFM kg (%) 29.9 ± 3.9 (66.85 ± 7.65)  21.1 – 38.6 (51.99 –79.13) 
Append BF, kg (%) 10.8 ± 4.8 (30.42 ± 10.39)  5.2 – 25.7 (13.63 – 50.40) 
Append FFM, kg (%) 24.5 ± 5.1 (69.58 ± 10.39)  14.9 – 34.8 (49.60 – 86.37) 
Abdominal BF, kg (%) 3.5 ± 1.2 (37.57 ± 6.59)  1.7 – 6.3 (26.09 – 49.40) 
Central Abdominal BF, kg (%) 2.9 ± 0.8 (35.82 ± 5.70)  1.6 – 5.0 (24.28 – 44.64) 
COV – coefficient of variation; BMI – body mass index; WC1 – Waist circumference as measured at minimal wait; WC2 - Waist 
circumference as measured just above iliac crest; WC3 - Waist circumference as measured at mid distance between lowest rib and iliac 
crest; WC4 - Waist circumference as measured at the umbilicus; WHtR1 – waist-to-height ratio using WC1; WHtR2 – waist-to-height ratio 
using WC2; WHtR3 – waist-to-height ratio using WC3; WHtR4 – waist-to-height ratio using WC4; BF – body fat; FFM – fat free mass; * 
Results are presented as mean ± standard deviation, unless otherwise noted; Min. – lowest observed value; Max. – highest observed value; 
BMI – body mass index; BF – body fat; FFM – fat free mass; # - different from all other WC mean values, p < 0.05 in paired samples t-test; † 
- different from all other WHtR mean values, p < 0.05 in paired samples t-test.   
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Table 6.3 – Partial and semipartial correlations between all studied waist-to-height ratios and body fat content variables. 
Variables  Whole BF Trunk BF Abd BF C Abd BF Whole %BF Trunk %BF Abd %BF C Abd %BF 
WHtR 1  † 0.49 0.63* 0.81* 0.72* 0.51* 0.56* 0.65* 0.63* 
 § 0.41 0.58* 0.80* 0.72* 0.45 0.51* 0.66* 0.63* 
 ¶ 0.22 0.38* 0.70* 0.69* 0.22 0.32 0.54* 0.55* 
WHtR 2 † 0.61* 0.73* 0.82* 0.74* 0.56* 0.59* 0.61* 0.61* 
 ‡ 0.48 0.64* 0.84* 0.77* 0.46 0.52* 0.66* 0.63* 
 # 0.26 0.43 0.74* 0.74* 0.23 0.32 0.54* 0.55* 
WHtR 3 † 0.60* 0.72* 0.83* 0.74* 0.55* 0.59* 0.62* 0.61* 
 ‡ 0.48 0.64* 0.84* 0.76* 0.46 0.52* 0.66* 0.62* 
 # 0.25 0.42 0.74* 0.73* 0.22 0.32 0.54* 0.54* 
WHtR 4 † 0.59* 0.68* 0.76* 0.68* 0.51 0.53* 0.56* 0.57* 
 ‡ 0.44 0.58* 0.78* 0.71* 0.42 0.45 0.62* 0.60* 
 # 0.23 0.38 0.68* 0.67* 0.20 0.27 0.49 0.50* 
WHtR 1 – Waist-to-height ratio calculated using waist circumference measured at narrowest torso; WHtR 2 - Waist-to-height ratio 
calculated using waist circumference measured at iliac crest; WHtR 3 - Waist-to-height ratio calculated using waist circumference 
measured at midpoint between lowest rib and iliac crest; WHtR 4 - Waist-to-height ratio calculated using waist circumference measured at 
the umbilicus; BF – body fat; Trunk BF – Trunk body fat; Abd BF – Abdominal body fat; C Abd BF – Central abdominal body fat; † - partial 
correlations between studied WHtR and dependent variables, controlled for age and sex; ‡ - partial correlations between studied WHtR 
and dependent variables, controlled for age, sex and BMI; # - semipartial correlations between studied WHtR and dependent variables, 
adjusted for age, sex and BMI; * - significant for p<0.05 and β=0.20. 
Table 6.4 shows the results for the comparison (p-values) between pairs of competing WHtR 
coefficients of correlation with each dependent variable. No differences were found between all 
compared coefficients of correlation.   
6.4. Discussion 
To our knowledge this is the first report to focus on the strength of correlation between 
WHtR and BF in NAFLD patients, and on the variation of such relation associated to different WCmp 
used to calculate WHtR. Mean WHtR was reasonably high and the prevalence of elevated WHtR, 
considering the 0.5 boundary value, was very high in the present sample. This was expected since it 
has been shown that NAFLD patients have higher values of WHtR (252). The magnitude of WHtR 
mean values were different according to the WC used in its calculation (WHtR4 > WHtR2 > WHtR3 > 
WHtR1) meaning they are not interchangeable. This may have large implications in clinical practice 
and data collection for longitudinal assessment of subjects (pre - post) as well as between groups 
comparisons  
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Table 6.4 – Z statistic P values for the comparison between the coefficients of correlation obtained in partial and 
semipartial correlation between the studied waist-to-height ratios and all dependent variables. 
  WHtR 1   WHtR 2   WHtR 3   WHtR 4    
  p† p‡  p† p‡  p† p‡  p† p‡   
     0.975 0.991  0.989 0.997  0.892 0.929 Whole %BF WHtR 1 
     0.989 0.994  0.969 0.984  0.758 0.856 Trunk %BF  
     0.995 1.000  0.995 0.996  0.806 0.802 Abd %BF  
     0.981 0.988  0.991 0.992  0.861 0.841 C Abd %BF  
WHtR 2 Whole BF 0.731 0.872     0.986 0.994  0.868 0.920 Whole %BF WHtR 2 
 Trunk BF 0.717 0.856     0.981 0.991  0.747 0.850 Trunk %BF  
 Abd BF 0.663 0.799     0.990 0.996  0.801 0.802 Abd %BF  
 C Abd BF 0.705 0.740     0.972 0.980  0.843 0.830 C Abd %BF  
WHtR3 Whole BF 0.790 0.902  0.938 0.970     0.882 0.926 Whole %BF WHtR 3 
 Trunk BF 0.740 0.866  0.976 0.990     0.729 0.840 Trunk %BF  
 Abd BF 0.646 0.793  0.981 0.994     0.811 0.805 Abd %BF  
 C Abd BF 0.743 0.775  0.960 0.963     0.870 0.849 C Abd %BF  
WHtR4 Whole BF 0.880 0.964  0.847 0.907  0.908 0.937      
 Trunk BF 0.983 0.980  0.701 0.837  0.724 0.847      
 Abd BF 0.716 0.872  0.538 0.677  0.522 0.671      
 C Abd BF 0.948 0.900  0.658 0.647  0.695 0.680      
WHtR 1 – Waist-to-height ratio calculated using waist circumference measured at minimal waist; WHtR 2 - Waist-to-height ratio calculated 
using waist circumference measured at iliac crest; WHtR 3 - Waist-to-height ratio calculated using waist circumference measured at 
midpoint between lowest rib and iliac crest; WHtR 4 - Waist-to-height ratio calculated using waist circumference measured at the 
umbilicus; BF – body fat; Trunk BF – Trunk body fat; Abd BF – Abdominal body fat; C Abd BF – Central abdominal body fat; † - comparison 
between correlation coefficients obtained in partial correlations between different WHtR and all dependent variables, controlled for age, 
sex and BMI; ‡ - comparison between correlation coefficients obtained in semipartial correlations between different WHtR and all 
dependent variables, removing the effect of age, sex and BMI. 
and, most important, subjects results confrontation with normative charts and cut-off or boundary 
values because dichotomous analysis may amplify even small absolute differences (365). Several 
previous studies also reported WC magnitudes (the changeable component of WHtR) to be 
influenced by WCmp (365-367). Still it have been advocated that current WC thresholds, generalized 
using WHO protocol (at the midpoint between lowest rib and iliac crest), could be applied to NIH 
measurements (at the superior border of the iliac crest) (23) because of small or absent differences 
found between measurements using these WCmp, particularly in men (365, 366). Even though we 
found differences between all studied WHtR mean values, both WHtR1 and WHtR3 only misclassified 
1 subject (3.6%) at elevated risk as compared to WHtR2 and WHtR4, when a dichotomous approach 
was applied based on the boundary value of 0.5. Though this was not the aim of the present study, 
WHtR2 and WHtR4 may be considered preferable for diagnosing increased WHtR, considering they 
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were able to identify 100% of the studied NAFLD patients, which is a population with increased 
cardiovascular risk. This may suggest high sensitivity of WHtR for detecting patients with NAFLD 
though both WHtR’ sensitivity and specificity for detecting NAFLD needs to be properly assessed and 
warrants further investigation.    
In the present sample of NAFLD patients WHtR was highly associated with whole and central 
BF, controlled for age and sex. But when BMI was introduced as a control variable, WHtR was only 
correlated with central BF, meaning BMI overlaps the explanation of whole BF accounted by the 
variation of WHtR. When semipartial correlations were used, controlled for sex, age and BMI, WHtR 
were only correlated with absolute and relative values of the studied abdominal fat depots, meaning 
that control variables were explaining part of the variation of both trunk BF and trunk %BF that could 
not be explained by WHtR. Correlation coefficient magnitudes were particularly high for central BF 
depots, but WHtR4 correlations seem to be somewhat less consistent than those observed for the 
other WHtRs and therefore may be considered disadvantageous, as compared to the others. WHtR2 
and WHtR3 seem slightly more consistently associated with NAFLD patients body composition (BC) 
than the other, but differences are minor. The association of WHtR with BC, particularly with central 
BF, has been reported in diverse groups (278, 279) but not until now in NAFLD patients. WHtR was 
also shown to predict higher cardiometabolic risk better than WC and BMI (129). The present study 
showed consistent coefficients of correlation of WHtR and central fat depots, even after controlling 
for age, sex and BMI, suggesting that WHtR explains the variation of abdominal fat far beyond BMI. 
Abdominal adipose tissue is known to be highly related to metabolic abnormalities and increased 
cardiometabolic risk, therefore it is reasonable to assume that WHtR may be highly related to the 
same metabolic abnormalities and increased cardiometabolic risk, in NAFLD, as already observed in 
other subpopulations, thought such hypothesis needs confirmation.  
Comparisons between pairs of competing WHtR correlations results with each dependent 
variable showed that all studied WHtR are similarly associated with the analyzed BF depots, 
irrespectively of the WC used for its calculation. Previous studies have already found no differences 
in the association of WC alone, measured at different sites, with BF depots (366, 367). In a sound 
review, by Ross and colleagues (23), it was concluded that the use of different WCmp did not 
changed the well-established relationships between WC and morbidity of cardiovascular disease and 
diabetes and with cardiovascular and all-cause mortality. Since WHtR have proven highly sensitive in 
the prediction of cardiovascular risk (129), the absence of WCmp influence in risk prediction should 
be confirmed in future studies, using WC measured at different sites, to calculate WHtR.  
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The present study confirms the strong association between WHtR and BF, specially central 
BF, even after controlling for age, sex and BMI, in NAFLD patients. No change in the strength of 
relation between WHtR and both whole and central BF depots was found in the present study, 
regardless of the WCmp used, and a preferable WCmp to calculate WHtR could not be clearly 
established. The results of the present study may endorse an interchangeable use of different WCmp 
to identify subjects above boundary value and therefore at higher risk. Additional research is needed 
to confirm the influence of different WCmp on the variation of WHtR associations with 
cardiometabolic risk factors, in NAFLD patients. 
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Chapter 7 – Study 4:  
“Does Waist Circumference Measurement Protocol Used Influences the 
Relation Between Waist-to-hip Ratio and Body Fat Content and Distribution 
in Non-Alcoholic Fatty Liver Disease Patients?”4 
  
                                                          
4
 Pimenta, N, Santa-Clara, H, Cortez-Pinto, H, Silva-Nunes, J, Sardinha, L (2013) Clinical Nutrition 
(Submitted). 
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Abstract 
Background: Body Fat (BF), particularly central fat accumulation, is related to Non-alcoholic 
Fatty Liver Disease (NAFLD), and is related also to increased cardiovascular morbidity and mortality, 
which is also increased in NAFLD patients. Waist-to-hip ratio (WHR) has been suggested to be a 
clinical marker of BF distribution capable of diagnosing adverse and pathogenic BF distribution 
profiles. No single waist circumference measurement protocol (WCmp) is consensually accepted nor 
its effects on WHR correlation have been assessed.  
Purpose: The aim of this study was to analyze whether the most used WCmp affect the 
strength of association between WHR and BF content and BF distribution, in NAFLD patients.   
Methods: Whole and regional BF content were assessed with Dual Energy X-ray 
Absorptiometry (DXA) in 28 NAFLD patients (19 males, 51 ± 13 yrs, and 9 females, 47 ± 13 yrs) , who 
were diagnosed by liver biopsy or ultrasound, after exclusion of other potential causes of liver 
disease. Ratios between DXA assessed BF depots were used to assess BF distribution. 
Anthropometric evaluation included the measurement of WC using four different WCmp (WC1: 
minimal waist; WC2: iliac crest; WC3: mid-distance between iliac crest and lowest rib; WC4: at the 
umbilicus) and WHR was calculated using each of the WC measurements (WHR1, WHR2, WHR3 and 
WHR4, respectively). 
Results: No correlations were found with whole BF, trunk BF and appendicular BF. Only 
WHR2, WHR3 and WHR4 were correlated with Abdominal BF (r=0.59; r=0.59; r=0.58; respectively), 
Central Abdominal BF (r=0.61; r=0.60; r=0.58; respectively), trunk-to-appendicular BF (r=0.56; r=0.56; 
r=0.51; respectively) and Abdominal BF-to-whole BF ratio (r=0.51; r=0.53; r=0.54; r=0.53; 
respectively), controlled for age, sex and body mass index.  
Conclusions: The present study confirms the strong relation of WHR and a central 
distribution of BF, regardless of WCmp used, in NAFLD patients. WHR1 seemed, at least, less 
consistent as a central BF surrogate. WHR2 and WHR3 may used interchangeably for the diagnosis of 
high WHR and, may be considered preferable for use in clinical practice, for the calculation of NAFLD 
patients WHR. 
Keywords: Body Fat; Hepatic Steatosis; Body Composition; Anthropometry, body fat 
distribution. 
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7.1. Introduction 
Body composition (BC) has an important role in the etiology of non-alcoholic fatty liver 
disease (NAFLD) (9). Both central body fat (BF) and insulin resistance have been found to increase the 
risk of NAFLD (363), yet whole and particularly central BF may further increase the risk for NAFLD by 
its strong association with insulin resistance (5, 183), as well as with other disturbances (60-65) 
Accordingly waist-to-hip ratio (WHR) was shown to be closely related to the occurrence of NAFLD 
(252). WHR is assumed to reflect the distribution of fat throughout the body and a high WHR should 
represent a preferential abdominal or central accumulation of BF (128) and it has generally proven to 
be so (91, 138, 139) yet conflicting results have also been found (263). WHR was initially suggested to 
be calculated using measurements of waist circumference (WC) at the minimal waist (261) but WC 
measured at the mid distance between lowest rib and iliac crest has been the most used protocol 
(179). The considerable variation in methodology and results found in the literature may be limiting a 
wider usage of this body index.  The importance of using one consensual standardized measurement 
protocol to calculate WHR was recognized (264, 265). Yet no single consensual measurement 
protocol in consensually accepted and a wide diversity of methods for the measurement and calculus 
of WHR can be found in the literature (179). 
To our knowledge it is unknown if the use of different commonly used WC, with different 
measuring sites, affect the relation between WHR and both whole and central BF content and BF 
distribution. Therefore the aim of the present study was to analyze which of the most used WC 
measurement protocol (WCmp) is better to calculate WHR for use in clinical practice with NAFLD 
patients as a surrogate of whole and central BF content and BF distribution.   
7.2. Methods 
In the present study we analyzed two groups of variables (Table 7.1): whole and regional BF 
content, as assessed by DXA (as described in subsections 3.3.1); BF distribution assessed using ratios 
between different DXA assessed BF depots (as described in subsections 3.3.2) and WHR as calculated 
using four different WC measured according to different WCmp for each patient (as detailed in 
subsection 3.3.3), in the studied sample of 28 NAFLD patients (described in section 3.1).   
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Table 7.1 – List of Studied variables in study 4 
Variable Unit of measurement Abbreviations Described in subsection 
Age Years -- 3.1 
Sex -- -- 3.1 
Anthropometry    
Weight kg -- 3.3.3 
Height cm -- 3.3.3 
Body mass index kg/m
2
 BMI 3.3.3 
Waist Circumference 1 cm WC1 3.3.3 
Waist Circumference 2 cm WC2 3.3.3 
Waist Circumference 3 cm WC3 3.3.3 
Waist Circumference 4 cm WC4 3.3.3 
Waist-to-hip ratio 1 -- WHR1 3.3.3 
Waist-to-hip ratio 2 -- WHR2 3.3.3 
Waist-to-hip ratio 3 -- WHR3 3.3.3 
Waist-to-hip ratio 4 -- WHR4 3.3.3 
Whole and Regional Body Composition    
Whole body fat kg Whole BF 3.3.1 
Whole percentage of body fat % Whole %BF 3.3.1 
Trunk body fat kg Trunk BF 3.3.1 
Trunk percentage of fat mass % Trunk %BF 3.3.1 
Appendicular body fat kg Append BF 3.3.1 
Appendicular percentage of fat mass % Append %BF 3.3.1 
Abdominal body fat kg Abd BF 3.3.1 
Abdominal percentage of body fat % ABD %BF 3.3.1 
Central Abdominal body fat kg CAbd BF 3.3.1 
Central Abdominal percentage of body fat % CAbd %BF 3.3.1 
Body fat distribution variables    
Trunk BF-to-Appendicular BF -- -- 3.3.2 
Abdominal BF-to-whole BF -- -- 3.3.2 
Abdominal BF-to-trunk BF -- -- 3.3.2 
Descriptive statistics are presented as mean ± sd and range for all analyzed variables. The 
Gaussian distribution of the data was assessed with the Shapiro-Wilk goodness-of-fit test. Paired-
samples T test was used to compare the magnitude of the different WHR mean values. Partial and 
part, also called semipartial (357), correlations, controlling for age and sex and body mass index 
(BMI), were performed to assess the relations between dependent and independent variables. Only 
correlation coefficients equal or above 0.50 were considered to be significant at a significance level 
of 5% and a statistical power of 80% (357). Pairs of correlation coefficients obtained between each 
WHR with each dependent variable were compared, using Z statistic, to analyze if any WHR was 
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more closely associated with whole and central BF. Statistical calculations were performed using the 
IBM SPSS Statistics version 19 (SPSS, inc, Chicago, IL, USA), except for z statistic which was performed 
using Medcalc version 11.1.1.0 (MedCalc Software, Mariakerke, Belgium). 
7.3. Results 
Mean values for all studied variables are presented in table 7.2. High WHR was present in 
about 70 to over 80%, according to the WHR used, yet WHR2 and WHR3 diagnosed exactly the same 
prevalence of high WHR in the studied sample. Results for WHR were considered to be different 
when using different WC (WHR4>WHR2>WHR3>WHR1). 
The results for partial and semipartial correlations, controlled for sex and age (table 7.3), 
showed all WHR to be preferentially correlated with central BF. Partial correlations, controlled for 
age and sex, show WHR1 to only correlated only with abdominal BF-to-whole BF ratio. All other 
studied WHR correlate also with abdominal (Abd) BF, central abdominal (CAbd) BF and trunk BF-to-
appendicular BF ratio. However, the only significant coefficients of correlation found in semipartial 
correlations, also controlled only for sex and age, were found between WHR1, WHR2 and WHR3 and 
both Abd BF and CAbd BF.  
The results for partial and semipartial correlations, controlled for sex, age and BMI (table 
7.4), showed that only WHR1, WHR2 and WHR3 were correlated with any of the studied BF depots or 
BF distribution ratios. WHR 2,WHR 3 and WHR4 were all correlated with Abd BF, CAbd BF, trunk BF-
to-appendicular BF ratio and abdominal BF-to-whole BF ratio, in partial correlations controlled for 
age, sex and BMI. In semipartial correlations, controlled also for age, sex and BMI, WHR1, WHR2 and 
WHR3 were only found to be associated with Abd BF and CAbd BF. 
Coefficients of correlation tended to increase when BMI was added as control variable, even 
in semipartial correlations, but this increase was not significant (p>0.05 in all coefficient of 
correlation comparisons by Z statistics, using Medcalc version 11.1.1.0 [MedCalc Software, 
Mariakerke, Belgium], data not shown). All coefficients of correlation remained relatively stable 
either when using partial as in semipartial correlations. Also no differences were found in the 
comparison between any pair of coefficients of correlation obtained between competing WHR with 
each dependent variable (listed in table 7.3 and 7.4), using Z statistics (p>0.05 in all comparisons, 
data not shown). 
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Table 7.2 – Descriptive data of the studied sample in study 4. 
 NAFLD Patients (n=28) 
Variables Mean + sd *  Min. – Max. 
Age, yr (median, yr) 49.5 ± 12.8 (49)  25 – 68  
Sex, n female (% female)  9 (32.1)    
Anthropometry      
Weight, kg (COV, %) 87.6 ± 12.7 (0.07)  66.2 – 115.8  
Height, cm (COV, %) 167.2 ± 9.2 (0.03)  149.5 – 183.7  
BMI, kg/m2 (% obese) 29.1 ± 4.0 (32.1)  22.6 – 42.2  
WC 1, cm (COV, %) 100.7 ± 8.2# (0.45)  86.0 – 119.8  
WC 2, cm (COV, %) 104.8 ± 10.6# (0.49)  85.3 – 128.7  
WC 3, cm (COV, %) 103.7 ± 10.4# (0.47)  85.7 – 129.3  
WC 4, cm (COV, %) 106.3 ± 11.7# (0.73)  86.7 – 129.1  
Hip-C, cm (COV, %) 107.6 ± 12.0 (0.38)  92.3 – 138.3  
WHR 1 (high WHR, %) 0.94 ± 0.07† (69.2)  0.75 – 1.03  
WHR 2 (high WHR, %) 0.98 ± 0.07† (76.9)  0.85 – 1.11  
WHR 3 (high WHR, %) 0.97 ± 0.07† (76.9)  0.82 – 1.09  
WHR 4 (high WHR, %) 0.99 ± 0.06† (84.6)  0.88 – 1.10  
Whole and Regional Body Fat      
Whole BF, kg (%) 27.2 ± 9.3 (31.31 ± 8.20)  13.7 – 51.2 (18.84 – 46.28) 
Trunk BF, kg (%) 15.2 ± 5.2 (33.15 ± 7.65)  7.4 – 25.0 (20.87 – 48.01) 
Append BF, kg (%) 10.8 ± 4.8 (30.42 ± 10.39)  5.2 – 25.7 (13.63 – 50.40) 
Abdominal BF, kg (%) 3.5 ± 1.2 (37.57 ± 6.59)  1.7 – 6.3 (26.09 – 49.40) 
Central Abdominal BF, kg (%) 2.9 ± 0.8 (35.82 ± 5.70)  1.6 – 5.0 (24.28 – 44.64) 
Body Fat distribution, ratios      
Trunk BF/ Append BF ratio 1.477 ± 0.371   0.958 – 2.547  
Abdominal BF / BF ratio 0.130 ± 0.025   0.045 – 0.185  
Abdominal BF / Trunk BF ratio 1.231 ± 0.039   0.095 – 0.299  
COV – coefficient of variation; BMI – body mass index; WC1 – minimal waist circumference measured at the narrowest part of the torso; 
WC2 – waist circumference measured just above the iliac crest; WC3 – waist circumference measured at the mid-distance between lowest 
rib and iliac crest; WC4 - Waist circumference at the umbilicus; WHR 1 – waist-to-hip ratio using WC1; WHR 2 – waist-to-hip ratio using 
WC2; WHR 3 – waist-to-hip ratio using WC3; WHR 4 – waist-to-hip ratio using WC4; BF – body fat; FFM – fat free mass; * Results are 
presented as mean ± standard deviation, unless otherwise noted; Min. – lowest observed value; Max. – highest observed value; BMI – body 
mass index; BF – body fat; FFM – fat free mass; # - different from all other WC mean values, p < 0.05 in paired samples t-test; † - different 
from all other WHR mean values, p < 0.05 in paired samples t-test. 
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Table 7.3 – Partial and semipartial correlations between all studied waist-to-hip ratios and body composition, controlled 
for age and sex. 
Variables WHR1   WHR2   WHR3   WHR4  
 † §  † §  † §  † § 
Whole BF  - 0.17 - 0.12    0.13   0.09    0.09   0.06    0.10   0.07 
Whole %BF - 0.02 - 0.02    0.15   0.08    0.13   0.07    0.12   0.06 
Trunk BF   0.05   0.04    0.35   0.27    0.31   0.25    0.31   0.25 
Trunk %BF   0.12   0.08    0.29   0.19    0.29   0.19    0.24   0.16 
Append BF - 0.42 - 0.28  - 0.16 - 0.11  - 0.21 - 0.13  - 0.17 - 0.11 
Append %BF - 0.18 - 0.08  - 0.06 - 0.03  - 0.08 - 0.04  - 0.05 - 0.02 
Abd BF   0.37   0.33    0.57*   0.51*    0.56*   0.50*  0.57*   0.51* 
Abd %BF   0.34   0.28    0.44   0.36    0.44   0.36    0.42   0.35 
CAbd BF   0.40   0.39    0.60*   0.58*    0.58*   0.56*    0.57*   0.56* 
CAbd %BF   0.25   0.22    0.40   0.32    0.36   0.31    0.34   0.30 
Trunk BF/ Append BF   0.45   0.37    0.56*   0.46    0.56*   0.46    0.51*   0.42 
Abdominal BF/ whole BF   0.52*   0.47    0.51*   0.46    0.54*   0.49    0.52*   0.47 
Abdominal BF/ Trunk BF   0.38   0.37    0.30   0.29    0.32   0.32    0.33   0.33 
WHR 1 – Waist-to-Hip ratio calculated using waist circumference measured at narrowest torso; WHR 2 - Waist-to-Hip ratio calculated using 
waist circumference measured at iliac crest; WHR 3 - Waist-to-Hip ratio calculated using waist circumference measured at midpoint between 
lowest rib and iliac crest; WHR 4 - Waist-to-Hip ratio calculated using waist circumference measured at the umbilicus; BF – body fat; Trunk 
BF – Trunk body fat; Abd BF – Abdominal body fat; CAbd BF – Central abdominal body fat; † - partial correlations between studied WHR and 
dependent variables, controlled for age and sex; § - semipartial correlations between studied WHR and dependent variables, controlled for 
age and sex ; * - significant for p<0.05 and β=0.20. 
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Table 7.4 – Partial and semipartial correlations between all studied waist-to-hip ratios and body composition, controlled 
for age, sex and BMI. 
Variables WHR1   WHR2   WHR3   WHR4  
 † §  † §  † §  † § 
Whole BF    0.06   0.03    0.19   0.13    0.18   0.10    0.15   0.08 
Whole %BF   0.13   0.06    0.17   0.08    0.18   0.09    0.13   0.06 
Trunk BF   0.29   0.19    0.43   0.28    0.43*   0.28    0.38   0.25 
Trunk %BF   0.27   0.17    0.33   0.20    0.34   0.21    0.26   0.16 
Append BF - 0.29 - 0.14  - 0.19 - 0.09  - 0.20 - 0.10  - 0.22 - 0.11 
Append %BF - 0.08 - 0.03  - 0.06 - 0.02  - 0.05 - 0.02  - 0.05 - 0.02 
Abd BF   0.47   0.41    0.59**   0.52**    0.59**   0.52**    0.58**   0.51** 
Abd %BF   0.39   0.32    0.45   0.37    0.44   0.37    0.42   0.35* 
CAbd BF   0.48   0.46    0.61**   0.58**    0.60**   0.58**    0.58**   0.56** 
CAbd %BF   0.31   0.27    0.37   0.32    0.37   0.32    0.35   0.30 
Trunk BF/ Append BF   0.45   0.38    0.56**   0.46    0.56**   0.46    0.51*   0.42 
Abdominal BF/ whole BF   0.48   0.43    0.510*   0.46    0.53**   0.48    0.53*   0.47 
Abdominal BF/ Trunk BF   0.32   0.30    0.300   0.28    0.32   0.30    0.34   0.32 
WHR 1 – Waist-to-Hip ratio calculated using waist circumference measured at narrowest torso; WHR 2 - Waist-to-Hip ratio calculated using waist 
circumference measured at iliac crest; WHR 3 - Waist-to-Hip ratio calculated using waist circumference measured at midpoint between lowest 
rib and iliac crest; WHR 4 - Waist-to-Hip ratio calculated using waist circumference measured at the umbilicus; BF – body fat; Trunk BF – Trunk 
body fat; Append – Appendicular; Abd BF – Abdominal body fat; C Abd BF – Central abdominal body fat; † - partial correlations between studied 
WHR and dependent variables, controlled for age, sex and BMI; § - semipartial correlations between studied WHR and dependent variables, 
controlled for age, sex and BMI; * - significant for p<0.05 and β=0.20. 
7.4. Discussion 
Mean WHR was somewhat high and the prevalence of elevated WHR, was also rather high in 
the present sample. This was expected as NAFLD patients have shown to have higher values of WHR 
(252). The differences observed in the magnitude of WHR mean values, calculated using different 
WC, suggest they are not interchangeable, which may have important implications in clinical practice 
and data collecting, advising a careful and consistent choice of the WCmp used for the calculation of 
WHR. But the literature is neither consistent nor consensual regarding which WCmp should be used 
for the calculation of WHR. Several previous studies have reported WC magnitudes to be influenced 
by WCmp (365, 366). Still it has been suggested that WC measured at the midpoint between lowest 
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rib and iliac crest or at the superior border of the iliac crest could be used interchangeably for the 
diagnosis of obesity (23). Even though the present study shows differences between all WHR, both 
WHR2 and WHR3 diagnosed exactly the same prevalence of high WHR, using recommended cut-off 
values (261), suggesting they could be used interchangeably, in the present sample, for the diagnosis 
of high WHR.  
The results concerning the correlations with whole and regional BF content suggests that 
WHR1 (calculated using WC measured at minimal waist) cannot be accepted as a proper surrogate. 
Albeit WHR was initially suggested to be calculated using WC measured at minimal waist (261), this 
was the least useful protocol in the present study. WHR2, WHR3 and WHR4 had a similar 
performance in the relation with the studied BF content variables. These WHRs were found to be 
particularly related with central BF, in the studied NAFLD patients. Though not consensually, the 
association between WHR and central BF was previously reported (91, 139) but not until now in 
NAFLD patients. Adding BMI as a control variable had little or no effect on the coefficients of 
correlation of the three most useful WHR with both Abd BF and CAbd BF, either in partial as in 
semipartial correlations, meaning BMI does not relate to dependent variables beyond that already 
accounted by the other control variables (sex and age). In fact BMI has been suggested to be more 
related to overall BF (122, 123), particularly with whole and subcutaneous adipose tissue (124), and 
does not take into account regional BF deposition (140) which has been identified as an important 
correlate leading to CVD (13) and possibly to NAFLD (5, 16). Therefore, when assessing obesity, BMI 
may be deceptive (17). The present results underlies the assumption that WHR, particularly WHR1, 
WHR2 or WHR3, may be of utmost importance in the clinical assessment of BC of NAFLD patients. 
When semipartial, instead of partial, correlations were used, the coefficients of correlation between 
WHR2, WHR3 and WHR4 and both Abd BF and CAbd BF were fairly unchanged, meaning that three 
mentioned WHRs were strongly associated with the studied abdominal fat depots, regardless of age, 
sex and BMI. Considering that the studied abdominal BF depots have been shown to be closely 
related to visceral adipose tissue (79, 80) which, in turn, was found to be a risk factor for the 
presence of NASH (46), it is reasonable to suggest that WHR assessment may be fundamental in the 
clinical assessment of NAFLD patients. WHR, using WC measured at mid-distance, was shown to be 
positively correlated with abdominal adipose tissue compartments, as assessed by magnetic 
resonance imaging (MRI) in free-living men (139). Coefficients of correlation over 0.70 were also 
found between WHR, using WC measured at the umbilicus, and both visceral and subcutaneous 
adipose tissue, as assessed by MRI at the level of the fourth lumbar vertebra (L4) (91). Even though 
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these results are in accordance to the findings of the present study, there are considerable 
differences in the methodology, including considerable sample differences, therefore extended 
interpretations are restrained. Thus opposing results were also found both in men and women when 
correlating WHR, using WC measured at the umbilicus, with DXA assessed BF depots similar to the 
present study, including central BF (r<0.28) and peripheral BF (r<0.16) (263). But the mentioned 
contradictions may rely on significant sample differences, as compared to the present study. The 
mentioned study included only subjects in the mid-thirties with completely different health status 
(263). Bottom line, WHR1, WHR2 and WHR3 seem useful in the assessment of central BF 
accumulation, which is more strongly related with adverse outcomes than whole BF, and therefore 
considered to be useful alternatives in the assessment of BC of NAFLD patients, in clinical settings. 
When focusing on BF distribution, all WHR were positively correlated with BF distribution 
variables, as observed by the significant coefficients of correlation of all studied WHR with 
Abdominal BF-to-whole BF ratio, but only WHR2, WHR3 and WHR4 were correlated also with trunk 
BF-to-appendicular BF ratio, in partial correlations controlled for age and sex. As mentioned, BMI has 
been suggested to be more related to overall subcutaneous adipose tissue (124) and provides only a 
crude measurement of total adiposity (126, 130), therefore, it was not thoroughly surprising to find 
that adding BMI as controlling variable had a rather small impact on the studied coefficients of 
correlation, even though WHR1 was no longer related with any BF distribution variable, confirming 
the limited usefulness of the WHR calculated using minimal waist. Fully opposite results were found 
in other study, reporting high coefficients of correlation between WHR using minimal waist, and both 
DXA derived trunk-to-leg BF ratio (r=0.62) and waist-to-hip BF ratio (r=0.78) (138). The mentioned 
study was conducted on a sample of healthy white women which is profusely different form the 
sample analyzed in the present study. The results from the present study are in agreement with 
previous findings showing WHR, calculated using WC measured at the umbilicus, not correlated to 
trunk BF-to-appendicular BF ratio (263). Yet this was also conducted in a sample of adolescent girls. 
In semipartial correlations no significant associations were found between any studied WHR and any 
BF distribution variable. This underlies the importance of age and sex, more than BMI, in the 
variation of BF distribution, and raises questions about the usefulness of WHR as a BF distribution 
surrogate in NAFLD patients.  
The present study confirms the strong association between WHR and central BF, even after 
controlling for age, sex and BMI, in NAFLD patients. However WHR using WC measured at minimal 
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waist does not seem useful as a BF content and/or distribution surrogate in NAFLD. In NAFLD 
patients WHR seems a good surrogate of only central BF and not of BF distribution, as has been 
advocated. The results of the present study may endorse an interchangeable use of WHR2 and WHR3 
to identify subjects with high WHR and therefore at higher risk. Based on present results both WHR2 
and WHR3 seem preferable to use in NAFLD patients. Additional research is needed to confirm the 
influence of different WCmp in the relation of WHR with other NAFLD and cardiometabolic risk 
factors.   
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Abstract 
Background: Body composition (BC), particularly central body fat (BF), is a major concern in 
Non-alcoholic Fatty Liver Disease (NAFLD). Body mass index (BMI) limitations are well known and 
several other body indexes are gaining importance.   
Purpose: The aim of the present investigation was twofold: to analyze how body 
circumferences and indexes perform as surrogate of whole and regional BF content and BF 
distribution in NAFLD patients, and to find if any specific body index and/or circumference perform 
better than the commonly used BMI as surrogate of BC in NAFLD patients. 
Methods: Absolut and relative whole BF, trunk BF, appendicular BF, abdominal (Abd) BF 
(measured between the upper edge of L2 and the lower edge of L4) and central abdominal (CAbd) BF 
(measured as abdominal BF but limited to the lateral sides of rib cage) were assessed with Dual 
Energy X-ray Densitometry (DXA) in 28 NAFLD patients (19 males, 51 + 13 yrs, and 9 females, 47 + 13 
yrs), who were diagnosed through liver biopsy or ultrasound, after exclusion of other potential 
causes of liver disease. Body circumferences included waist (WC), hip (Hip-C), arm (Arm-C), thigh 
(Thigh-C) and calf (Calf-C) measurements, and indexes included the calculation of BMI, body 
adiposity index (BAI = [Hip-C / height^1.5]-18), Waist-to-height ratio (WHtR = WC / height) and waist-
to-hip ratio (WHR=WC / Hip-C). 
Results: Partial correlations showed that, whole BF was significantly associated with nearly 
all independent variables, including Arm-C (r=0.76), WC (0.79), Hip-C (r=0.88), Thigh-C (r=0.74), Calf-C 
(r=0.79), BMI (r=0.65), BAI (r=0.58) and WHtR (r=0.63), controlled for age and sex. However, when 
controlled also for BMI only WC was associated with Trunk BF (r=0.87); WC, WHtR and WHR were 
associated with Abd BF (r=0.78; r=0.84 and r=0.59, respectively) and CAdb BF (r=0.77; r=0.76 and 
r=0.61, respectively); WHtR was related with Abdominal BF-to-whole BF ratio and arm circumference 
was inversely related with abdominal BF-to-trunk BF ratio (r=-0.53), consistently. Only WC, WHtR and 
WHR were found better surrogates than BMI for some of the mentioned dependent variables. 
Conclusions: Most body circumferences and both BMI and BAI were found limited in the 
assessment of both central BF accumulation and BF distribution. BMI is neither superior to other 
tested BF surrogates, nor independent of WC in the assessment of BF in NAFLD patients. The present 
study supports the inclusion WC and/or WHtR, as good alternative methods to BMI, to assess BC of 
NAFLD patients in clinical settings. 
Keywords: Hepatic Steatosis; DXA, Body Composition; Anthropometry, Body Mass Index. 
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8.1. Introduction 
Body composition (BC) has been suggested to have an important role in the etiology of non-
alcoholic fatty liver disease (NAFLD) (9). Central body fat (BF) accumulation seems even more related 
to NAFLD and its related features than whole BF (5, 16, 46). Sound evidence has been showing the 
importance of centrally accumulated BF for the development of NAFLD (46, 60, 61).  
NAFLD is a common cause of liver disease encompassing two basic histological lesions: (I) 
hepatic steatosis (fat accumulation in hepatocytes), and (II) non-alcoholic steatohepatitis 
(characterized by hepatic steatosis and inflammation along with a constellation of other 
disturbances) (30-32). Ultimately NAFLD can lead to advanced fibrosis, cirrhosis, liver failure and 
death (16, 30). NAFLD patients often present high levels of BF accumulation and obesity, as 
compared to the general population (44). BC has been suggested to have an important role in the 
etiology of NAFLD (9). Central BF accumulation seems even more related to NAFLD, and its related 
features, than whole BF (5, 16, 46). Sound evidence has been showing the importance of centrally 
accumulated fat for the development of NAFLD (46, 60, 61). BF, besides being an important 
independent risk factor for NAFLD, is also strongly associated with other risk factors for NAFLD, such 
as insulin resistance (5). Additionally, excess both whole and central BF accumulation, or central BF 
distribution, are also known cardiovascular risk factors.  
Body mass index (BMI) is recommended to assess obesity status is general population (100) 
as well as in specific higher risk sub-populations (372) and has been widely used in NAFLD patients, 
along with other anthropometric measures (137, 175, 183, 252, 363). However BMI limitations have 
long been identified and are well known (21, 22) and other body indexes, such as waist-to-height 
ratio (WHtR) and waist-to-hip ratio (WHR) are gaining importance (24, 129, 252). Waist 
circumference (WC) has been suggested as a preferable method to determine obesity in coronary 
artery disease patients (373), however waist-to-height ratio has been recently shown to more 
strongly identify coronary risk in middle aged men (247). WHtR has also been suggested as a 
preferable central obesity marker in the general population, along with an appealing public health 
message: “keep your waist circumference to less than half your height” (129). A novel body index 
named Body Adiposity Index (BAI) was argued as a better index of adiposity (24). To our knowledge 
the relation of BMI and other clinical BC surrogates with whole and regional BC have not been tested 
in NAFLD patients. Recently WHR ratio was considered to be the most important tested BC marker 
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for the prediction NAFLD, as compared to BMI or waist-to height-ratio (WHtR), however the 
prediction of either whole or regional BC, as well as BF distribution, was not tested (252).  
To our knowledge the usefulness of some body circumferences and indexes as surrogates of 
BF content and distribution in NAFLD patients, is unknown. BMI limitations are well known, yet no 
alternative have been largely accepted and BMI is still the reference method for the diagnosis of 
obesity and  obesity related risks and is the most used BC marker in clinical practice. There are strong 
arguments supporting the routine use of BMI, however the BMI arguments may be common to 
several alternatives. Therefore the aim of the present investigation was twofold: (I) to analyze how 
body circumferences and indexes perform as surrogate of whole and regional BF content and BF 
distribution in NAFLD patients, and (II) to find if any specific body index and/or circumference 
perform better than the commonly used BMI as surrogate of BC in NAFLD patients. 
8.2. Methods 
In the present study we analyzed two groups of variables (Table 8.1): whole and regional BF 
content, as assessed by DXA (as described in subsections 3.3.1); BF distribution assessed using ratios 
between different DXA assessed BF depots (as described in subsections 3.3.2) and body indexes and 
circumferences (as detailed in subsection 3.3.3), in the studied sample of 28 NAFLD patients 
(described in section 3.1). In the present study, based on the results from the previous studies in the 
present thesis, we used WC assessed at the level of the iliac crest (102, 171, 189, 190). The 
mentioned was the WC used to calculate both WHtR and WHR.  
Descriptive statistics are presented as mean ± sd and range for all analyzed variables. The 
Gaussian distribution of the data was assessed with the Shapiro-Wilk goodness-of-fit test. Partial and 
part, also called semipartial (357), correlations were performed to assess the relations between 
dependent and independent variables controlling for age, sex and BMI. When BMI was an 
independent variable the correlation was controlled for age, sex and WC. Considering the size of the 
studied sample, to attain a statistical power of 80% (β = 0.20) at a statistical significance level of 5% 
(α=0.05), only coefficients of correlation equal or superior to 0.50, corresponding to a large effect 
size, were considered significant (357). To observe if any of the studied body circumferences or 
indexes performed better than the commonly used BMI as surrogate of whole and central BF content 
and BF distribution, in NAFLD patients, the correlation coefficients obtained between BMI and each  
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Table 8.1 – List of Studied variables in study 5 
Variable Unit of measurement Abbreviations Described in subsection 
Age Years -- 3.1 
Sex -- -- 3.1 
Anthropometry    
Weight Kg -- 3.3.3 
Height Cm -- 3.3.3 
Arm Circumference Cm Arm-C 3.3.3 
Waist Circumference Cm WC 3.3.3 
Hip Circumference Cm Hip-C 3.3.3 
Thigh Circumference Cm Thigh-C 3.3.3 
Calf Circumference Cm Calf-C 3.3.3 
Body Indexes    
Body mass index kg/m
2
 BMI 3.3.3 
Body Adiposity index -- BAI 3.3.3 
Waist-to-height ratio -- WHtR 3.3.3 
Waist-to-hip ratio -- WHR 3.3.3 
Whole and Regional Body Composition    
Whole body fat Kg Whole BF 3.3.1 
Whole percentage of body fat % Whole %BF 3.3.1 
Whole fat free mass Kg Whole FFM 3.3.1 
Whole percentage fat free mass % Whole %FFM 3.3.1 
Trunk body fat Kg Trunk BF 3.3.1 
Trunk percentage of body fat % Trunk %BF 3.3.1 
Trunk fat free mass Kg Trunk FFM 3.3.1 
Trunk percentage fat free mass % Trunk %FFM 3.3.1 
Appendicular body fat Kg Append BF 3.3.1 
Appendicular percentage of body fat % Append %BF 3.3.1 
Appendicular fat free mass Kg Append FFM 3.3.1 
Appendicular percentage of fat free mass % Append %FFM 3.3.1 
Abdominal body fat Kg Abd BF 3.3.1 
Abdominal percentage of body fat % ABD %BF 3.3.1 
Central Abdominal body fat Kg CAbd BF 3.3.1 
Central Abdominal percentage of body fat % CAbd %BF 3.3.1 
Body fat distribution variables    
Trunk BF-to-Append BF ratio -- -- 3.3.2 
Abdominal BF-to-whole BF ratio -- -- 3.3.2 
Abdominal BF-to-trunk BF ratio -- -- 3.3.2 
dependent variable were compared with the coefficients of correlation obtained by all other 
Independent variable for the same dependent variable using Z statistic. The level of significance was 
set at P<0.05 (two-tailed). Statistical calculations were performed using the IBM SPSS Statistics 
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version 19 (SPSS, inc, Chicago, IL, USA), except for z statistic which was performed using Medcalc 
version 11.1.1.0 (MedCalc Software, Mariakerke, Belgium).  
8.3. Results 
Mean values for all studied variables are presented in Table 8.2. From among the 28 studied 
NAFLD patients, 78.6% had excessive weight, including 32.1 % who were obese, and high levels of 
WC, WHtR and WHR were present in 57.1 %, 100% and 67.8 % of the patients, respectively. Mean 
BMI of the studied sample was in the overweight category. BMI and WHR were not different 
between both sexes (p=0.067 and p=0.058 obtained in an independent samples t test comparison, 
respectively), but female patients had higher WC (112.1 cm vs 102.1 cm, p=0.030), Hip-C (120.7 cm vs 
102.9 cm, p=0.014) and Tight (56.6 cm vs 51.5 cm, p=0.038) as well as BAI (43.2 vs 21.2, p<0.001) and 
WHtR (0.71 vs 0.60, p<0.001).  In Pearson correlation WHR (r=0.543, p=0.004), arm (Arm-C) (r=-
0.476, p=0.014), thigh (Thigh-C) (r=0.713, p<0.001) and calf (Calf-C) (r=-0.540, p=0.004) 
circumferences were associated with patients’ age. 
Table 8.3 shows the results for partial and semipartial correlations between each 
independent variable (clinical markers of BF content and distribution) and each dependent variable 
(DXA assessed BF content and distribution), controlled for sex and age. All but WHR are associated 
with whole BF and trunk BF in partial correlations controlled for age and sex. Appendicular BF was 
only consistently predicted by Hip-C, Thigh-C and Arm-C. Other markers were also associated with 
appendicular BF but these were critically affected by age and sex, as observed in semipartial 
correlation results. BF in the abdomen seems to be particularly associated to WC, WHtR and WHR, 
but only WHtR showed a strong association with all absolute and relative variables from both 
abdominal (Abd) BF and central abdominal (CAbd) BF, unaffected by age and sex. Both BAI was also 
somewhat correlated with Abd BF, controlled for age and sex. 
A consistent inverse relation between arm-C and Abd BF-to-trunk BF ratio was also found. 
WHR was also correlated with DXA derived BF distribution markers, but only in partial correlations 
controlled for age and sex. 
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Table 8.2 – Descriptive data of the studied sample study 5 
 NAFLD Patients (n=28) 
Variables Mean + sd *  Min. – Max. 
Age, yr (median, yr) 49.5 ± 12.8 (49)  25 – 68  
Sex, n female (% female)  9 (32,1)    
Anthropometry      
Weight, kg (COV, %) 87.6 ± 12.7 (0,07)  66.2 – 115.8  
Height, cm (COV, %) 167.2 ± 9.2 (0,03)  149.5 – 183.7  
WC, cm (COV, %) 104.8 ± 10.6 (0,49)  85.3 – 128.7  
Hip-C, cm (COV, %) 107.6 ± 12.0 (0,38)  92.3 – 138.3  
Thigh-C, cm (COV, %) 52.9 ± 5.7 (0,47)  44.5 – 67.5  
Calf-C, cm (COV, %) 39.3 ± 3.4 (0,44)  32.9 – 46.4  
Arm-C, cm (COV, %) 34.0 ± 3.6 (0,64)  29.3 – 44.6  
Body Indexes      
BMI, kg/m2 (% obese) 29.1 ± 4.0 (32.1)  22.6 – 42.2  
BAI 32.2 ± 8.2   21.0 – 51.0  
WHtR  (% High WHtR) 0.63 ± 0.08 (100.0)  0.50 – 0.82  
WHR (% High WHR) 0.98 ± 0.07 (67.9)  0.85 – 1.11  
Whole and Regional Body 
Composition 
     
Whole BF, kg (%) 27.2 ± 9.3 (31.31 ± 8.20)  13.7 – 51.2 (18.84 – 46.28) 
Whole FFM, kg (%) 58.7 ± 9.1 (68.69 ± 8.20)  39.6 – 77.7 (53.72 – 81.16) 
Trunk BF, kg (%) 15.2 ± 5.2 (33.15 ± 7.65)  7.4 – 25.0 (20.87 – 48.01) 
Trunk FFM kg (%) 29.9 ± 3.9 (66.85 ± 7.65)  21.1 – 38.6 (51.99 –79.13) 
Append BF, kg (%) 10.8 ± 4.8 (30.42 ± 10.39)  5.2 – 25.7 (13.63 – 50.40) 
Append FFM, kg (%) 24.5 ± 5.1 (69.58 ± 10.39)  14.9 – 34.8 (49.60 – 86.37) 
Abd BF, kg (%) 3.5 ± 1.2 (37.57 ± 6.59)  1.7 – 6.3 (26.09 – 49.40) 
CAbd BF, kg (%) 2.9 ± 0.8 (35.82 ± 5.70)  1.6 – 5.0 (24.28 – 44.64) 
Body Fat Distribution (ratios)      
Trunk BF-to-Append BF ratio  1.477 ± 0.371   0.958 – 2.547  
Abdominal BF-to- whole BF ratio 0.130 ± 0.025   0.045 – 0.185  
Abdominal BF-to-Trunk BF ratio 1.231 ± 0.039   0.095 – 0.299  
COV – coefficient of variation; WC - waist circumference measured just above the iliac crest; Hip-C – hip circumference; Thigh-C – thigh 
circumference; Calf-C – calf circumference; Arm-C – arm circumference; BMI – body mass index; BAI – body adiposity index; Append – 
Appendicular;  WHtR – weight-to-height ratio; WHR – weight.-to-hip ratio; BF – body fat; FFM – fat free mass; * Results are presented as 
mean ± standard deviation, unless otherwise noted; Min. – lowest observed value; Max. – highest observed value; BMI – body mass 
index; BF – body fat; FFM – fat free mass. 
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Table 8.3 – Partial and semipartial correlations between circumferences and body indexes and body fat content and 
distribution, controlled for age and sex. 
Variables    Circumferences    Body Indexes  
  Arm-C WC Hip-C Thigh-C Calf-C  BMI BAI WHtR WHR 
Whole BF r † 0.76* 0.79* 0.88* 0.74* 0.79*  0.65* 0.58* 0.63* 0.13 
 r ‡ 0.54* 0.55* 0.62* 0.53* 0.56*  0.45 0.41 0.45 0.09 
Whole %BF r † 0.45 0.56* 0.59* 0.40 0.49  0.40 0.54* 0.56* 0.15 
 r ‡ 0.24 0.30 0.31 0.21 0.26  0.21 0.29 0.30 0.08 
Trunk BF r † 0.64 0.87* 0.81* 0.64* 0.73*  0.52 0.56* 0.73* 0.35 
 r ‡ 0.51* 0.68* 0.64* 0.50* 0.58*  0.40 0.44 0.58* 0.27 
Trunk %BF r † 0.39 0.62* 0.54* 0.34 0.46  0.35 0.48 0.59* 0.29 
 r ‡ 0.26 0.41 0.36 0.23 0.30  0.23 0.32 0.39 0.19 
Append BF r † 0.78* 0.56* 0.84* 0.77* 0.74*  0.65* 0.52* 0.41 -0.16 
 r ‡ 0.52* 0.36 0.55* 0.50* 0.48  0.46 0.34 0.27 -0.11 
Append %BF r † 0.41 0.37 0.51* 0.35 0.42  0.35 0.52* 0.41 -0.06 
 r ‡ 0.18 0.17 0.23 0.16 0.19  0.17 0.24 0.19 -0.03 
Abd BF r † 0.09 0.75* 0.45 0.14 0.35  0.17 0.57* 0.82* 0.57* 
 r ‡ 0.08 0.67* 0.40 0.13 0.31  0.15 0.51* 0.73* 0.51* 
Abd %BF r † -0.03 0.51* 0.27 -0.01 0.14  0.06 0.44 0.61* 0.44 
 r ‡ -0.03 0.42 0.23 -0.01 0.12  0.05 0.37 0.51* 0.36 
C Abd BF r † 0.13 0.72* 0.43 0.26 0.36  0.11 0.48 0.74* 0.60* 
 r ‡ 0.13 0.70* 0.42 0.25 0.35  0.10 0.47 0.72* 0.58* 
C Abd %BF r † 0.06 0.51* 0.35 0.11 0.21  0.10 0.51* 0.61* 0.36 
 r ‡ 0.06 0.44 0.30 0.09 0.18  0.09 0.45 0.53* 0.32 
Trunk BF-to-Append BF ratio r † -0.03 0.39 0.06 0.04 0.05  -0.08 -0.02 0.31 0.56* 
 r ‡ -0.03 0.32 0.05 0.04 0.05  -0.06 -0.02 0.25 0.46 
Abd BF-to- whole BF ratio r † -0.48 0.18 -0.21 -0.38 -0.21  -0.21 0.20 0.39 0.51* 
 r ‡ -0.43 0.16 -0.19 -0.35 -0.19  -0.20 0.18 0.36 0.46 
Abd BF-to-Trunk BF ratio r † -0.56* -0.05 -0.33 -0.49 -0.33  -0.27 0.13 0.21 0.30 
 r ‡ -0.54* -0.05 -0.32 -0.48 -0.32  -0.26 0.12 0.20 0.29 
Arm-C – arm circumference; WC – waist circumference ; Hip-C – hip circumference; Thigh-C – thigh circumference; Calf-C – calf circumference; BMI – body 
mass index; BAI – body adiposity index; WHtR – waist to height ratio; WHR – Waist-to-Hip ratio; Whole BF – whole body fat; Trunk BF – trunk body fat; 
Append BF – appendicular body fat; Abd BF – abdominal body fat; CAbd BF – central abdominal body fat; † - partial correlations between studied body 
circumferences or indexes and the studied BF content or distribution variables, controlled for age and sex; ‡ - semipartial correlations between studied 
body circumferences or indexes and the studied BF content or distribution variables, controlled for age and sex ; * - significant for p<0.05 and β=0.20. 
Table 8.4 shows the results for partial and semipartial correlations between each 
independent and dependent variables, controlled for sex, age and BMI (except when BMI was an 
independent variable, in this case, control variables were age, sex and WC). When BMI was added 
has a control variable, all coefficients of correlation between clinical markers and whole BF were 
slightly reduced showing that BMI explained a some variation of the dependent variables already 
accounted for by the studied independent variables (the body circumferences and indexes). However 
BMI, together with sex and age, explained a more considerable amount of the variation of the 
dependent variables that could not be explained by the tested clinical markers, as can be confirmed 
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by the considerable drop in all coefficients of correlation obtained in semipartial correlations, as 
opposed to partial correlation, which resulted non-significant. 
Table 8.4 – Partial  and semipartial correlations between circumferences and body indexes and body fat content and 
distribution, controlled for age, sex, and body mass index. 
Variables    Circumferences    Body Indexes  
  Arm-C WC Hip-C Thigh-C Calf-C  BMI BAI WHtR WHR 
Whole BF r † 0.58* 0.68* 0.79* 0.58* 0.62*  0.43 0.35 0.48 0.19 
 r ‡ 0.31 0.37* 0.42 0.31 0.34  0.19 0.19 0.26 0.10 
Whole %BF r † 0.27 0.45 0.48 0.22 0.33  0.13 0,42 0,46 0,17 
 r ‡ 0.13 0.22 0.23 0.11 0.16  0.06 0.21 0.23 0.08 
Trunk BF r † 0.45 0.82* 0.71* 0.46 0.59*  0.19 0.37 0.64* 0.43 
 r ‡ 0.29 0.54* 0.47 0.30 0.39  0.07 0.24 0.43 0.28 
Trunk %BF r † 0.22 0.54* 0.44 0.17 0.31  0.03 0.36 0.52* 0.33 
 r ‡ 0.14 0.34 0.27 0.11 0.19  0.02 0.22 0.32 0.20 
Append BF r † 0.64* 0.32 0.70* 0.62* 0.53*  0.51* 0.26 0.15 -0.19 
 r ‡ 0.32 0.16 0.35 0.30 0.26  0.27 0.13 0.07 -0.09 
Append %BF r † 0.24 0.23 0.40 0.19 0.27  0.19 0.41 0.30 -0.06 
 r ‡ 0.10 0.10 0.17 0.08 0.11  0.08 0.18 0.13 -0.02 
Abd BF r † -0.06 0.78* 0.45 0.03 0.31  -0.39 0.57* 0.84* 0.59* 
 r ‡ -0.05 0.69* 0.29 0.03 0.27  -0.23 0.49 0.74* 0.52* 
Abd %BF r † -0.11 0.57* 0.32 -0.06 0.14  -0.29 0.49 0.66* 0.45 
 r ‡ -0.09 0.47 0.26 -0.05 0.11  -0.21 0.40 0.54* 0.37 
C Abd BF r † 0.04 0.77* 0.46 0.21 0.36  -0.41 0.48 0.77* 0.61* 
 r ‡ 0.04 0.74* 0.44 0.20 0.35  -0.28 0.46 0.74* 0.68* 
C Abd %BF r † -0.02 0.53* 0.37 0.04 0.17  -0.21 0.53* 0.63* 0.37 
 r ‡ -0.02 0.46 0.32 0.04 0.15  -0.16 0.47 0.55* 0.32 
Trunk BF-to-Append BF ratio r † 0.01 0.50* 0.13 0.10 0.13  -0.34 0.01 0.38 0.56* 
 r ‡ 0.01 0.41 0.11 0.08 0.11  -0.26 0.01 0.31 0.46 
Abd BF-to- whole BF ratio r † -0.46 0.35 0.09 -0.33 -0.09  -0.37 0.38 0.57* 0.51* 
 r ‡ -0.42 0.31 -0.08 -0.29 -0.08  -0.33 0.34 0.51* 0.46 
Abd BF-to-Trunk BF ratio r † -0.53* 0.11 -0.21 -0.43 -0.22  -0.28 0.34 0.39 0.30 
 r ‡ -0.50* 0.11 -0.20 -0.41 -0.20  -0.27 0.32 0.36 0.28 
Arm-C – arm circumference; WC – waist circumference ; Hip-C – hip circumference; Thigh-C – thigh circumference; Calf-C – calf circumference; BMI – body 
mass index; BAI – body adiposity index; WHtR – waist to height ratio; WHR – Waist-to-Hip ratio; Whole BF – whole body fat; Trunk BF – trunk body fat; 
Append BF – appendicular body fat; Abd BF – abdominal body fat; CAbd BF – central abdominal body fat; † - partial correlations between studied body 
circumferences or indexes and the studied BF content or distribution variables, controlled for age, sex and BMI; ‡ - semipartial correlations between studied 
body circumferences or indexes and the studied BF content or distribution variables, controlled for age, sex and BMI; * - significant for p<0.05 and β=0.20. 
The same occurred when BMI was the independent variable controlled for age, sex and WC. The 
same was also true for the prediction of trunk BF, except for WC which revealed to be consistently 
and strongly associated with trunk BF, and rather unaffected by controlling also for BMI. The relation 
between WC, WHtR and WHR with Abd BF and CAbd BF depots, did not seem to be influenced by the 
introduction of BMI as a control variable as well. Tough, again only WHtR was consistently and 
strongly associated with both absolute and relative values of both abd BF and CAbd. With the 
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introduction of BMI as a control variable WHtR was found to be correlated to Abd BF-to-whole BF 
ratio. The associations between WHR and arm-C with DXA derived BF distribution ratios remained 
fairly unchanged, when adding BMI as a control variable. 
The coefficients of correlation obtained in partial and semipartial correlations between BMI 
and the studied DXA derived BF content and distribution variables were compared with similar 
coefficients of correlation obtained between all other independent variables (body circumferences 
and indexes) and the same studied dependent variables, as can be observed in tables 8.5 and 8.6. 
The correlation of WC and WHtR with Abd BF and CAbd BF was significantly superior, as compared to 
BMI, either when using only age and sex as controlling variables as when adding BMI to the control 
variables. WC is also consistently superior to BMI in the association with trunk BF. WHR seem 
particularly better surrogate of BF distribution than is BMI. WHtR was also found to be consistently 
superior to BMI in the prediction of Abd BF-to-whole BF, for a given BMI. BMI was found superior in 
the correlation with whole BF and appendicular BF, only when compared with WHR.  
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Table 8.5 – Z statistic P values for the comparison between the correlation coefficients obtained in partial and 
semipartial correlations, controlled for age and sex, between body mass index and all dependent variables, 
and between all studied body circumferences and indexes and the same dependent variables 
Variables    Circumferences   Body Indexes  
BMI  Arm-C   WC   Hip-C Thigh-C Calf-C    BAI  WHtR  WHR 
Whole BF r † 0.414 0.308 0.030* 0.661 0.287  0.670 0.924 0.023* 
 r ‡ 0.677 0.619 0.384 0.724 0.605  0.862 0.989 0.165 
Whole %BF r † 0.816 0.444 0.367 0.997 0.669  0.516 0.453 0.247 
 r ‡ 0.911 0.731 0.690 0.991 0.840  0.766 0.737 0.640 
Trunk BF r † 0.521 0.008** 0.058 0.553 0.212  0.865 0.209 0.432 
 r ‡ 0.628 0.141 0.244 0.648 0.400  0.857 0.400 0.615 
Trunk %BF r † 0.870 0.213 0.406 0.965 0.663  0.590 0.264 0.822 
 r ‡ 0.898 0.470 0.612 1.000 0.773  0.731 0.513 0.909 
Append BF r † 0.253 0.629 0.113 0.384 0.521  0.498 0.240 0.001** 
 r ‡ 0.790 0.672 0.690 0.861 0.927  0.600 0.421 0.032* 
Append %BF r † 0.817 0.926 0.471 0.990 0.758  0.465 0.791 0.132 
 r ‡ 0.953 0.997 0.808 0.977 0.927  0.805 0.942 0.485 
Abd BF r † 0.757 0.005** 0.277 0.908 0.493  0.096 <0.000*** 0.090 
 r ‡ 0.799 0.020* 0.336 0.934 0.536  0.150 0.006** 0.142 
Abd %BF r † 0.737 0.076 0.272 0.799 0.772  0.142 0.022* 0.145 
 r ‡ 0.785 0.159 0.527 0.837 0.809  0.238 0.074 0.241 
C Abd BF r † 0.934 0.004** 0.207 0.578 0.333  0.143 0.003** 0.040* 
 r ‡ 0.923 0.006** 0.215 0.576 0.339  0.152 0.004** 0.046* 
C Abd %BF r † 0.875 0.113 0.374 0.997 0.725  0.109 0.035* 0.345 
 r ‡ 0.901 0.172 0.436 0.992 0.751  0.168 0.076 0.406 
Trunk BF-to-Append BF ratio r † 0.882 0.085 0.645 0.674 0.648  0.845 0.167 0.013* 
 r ‡ 0.899 0.158 0.700 0.723 0.700  0.865 0.254 0.047* 
Abd BF-to- whole BF ratio r † 0.290 0.160 0.974 0.650 0.982  0.140 0.026* 0.006** 
 r ‡ 0.350 0.197 0.968 0.569 0.977  0.175 0.042* 0.013* 
Abd BF-to-Trunk BF ratio r † 0.207 0.436 0.789 0.347 0.795  0.157 0.090 0.041* 
 r ‡ 0.227 0.447 0.805 0.367 0.805  0.170 0.100 0.047* 
Arm-C – arm circumference; WC – waist circumference ; Hip-C – hip circumference; Thigh-C – thigh circumference; Calf-C – calf circumference; BMI – 
body mass index; BAI – body adiposity index; WHtR – waist to height ratio; WHR – Waist-to-Hip ratio; Whole BF – whole body fat; Trunk BF – trunk 
body fat; Append BF – appendicular body fat; Abd BF – abdominal body fat; CAbd BF – central abdominal body fat; † - Comparison between coefficients 
of correlation obtained in partial correlations, controlled for age and sex; ‡ - Comparison between coefficients of correlation obtained in semipartial 
correlations, controlled for age and sex; * - significant for p<0.05; ** - significant for p<0.01; ***- significant for p<0.001. 
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Table 8.6 – Z statistic P values for the comparison between the correlation coefficients obtained in partial and semipartial 
correlations between all studied body circumferences and indexes and all dependent variables, controlled for age, sex 
and body mass index, and the coefficients obtained in partial and semipartial correlations between body mass index 
and the same dependent variables, controlled for age and sex. 
Variables    Circumferences   Body Indexes  
BMI  Arm-C   WC   Hip-C Thigh-C Calf-C    BAI  WHtR  WHR 
Whole BF r † 0.696 0.840 0.295 0.692 0.887  0.156 0.392 0.042* 
 r ‡ 0.567 0.725 0.913 0.565 0.633  0.303 0.445 0.179 
Whole %BF r † 0.619 0.809 0.717 0.483 0.800  0.916 0.778 0.386 
 r ‡ 0.785 0.962 0.926 0.711 0.869  0.994 0.950 0.654 
Trunk BF r † 0.361 0.048* 0.280 0.751 0.743  0.492 0.517 0.670 
 r ‡ 0.679 0.522 0.757 0.378 0.731  0.545 0.905 0.651 
Trunk %BF r † 0.619 0.395 0.722 0.488 0.877  0.965 0.470 0.917 
 r ‡ 0.748 0.673 0.865 0.662 0.906  0.997 0.719 0.929 
Append BF r † 0.962 0.127 0.701 0.860 0.523  0.074 0.029* 0.001** 
 r ‡ 0.536 0.228 0.626 0.508 0.406  0.186 0.130 0.036* 
Append %BF r † 0.681 0.651 0.831 0.534 0.749  0.791 0.843 0.138 
 r ‡ 0.818 0.804 0.991 0.749 0.846  0.977 0.882 0.494 
Abd BF r † 0.413 0.002** 0.275 0.616 0.601  0.099 <0.001*** 0.074 
 r ‡ 0.481 0.015* 0.595 0.669 0.646  0.167 0.005** 0.136 
Abd %BF r † 0.554 0.041* 0.345 0.661 0.794  0.095 0.009** 0.141 
 r ‡ 0.630 0.109 0.443 0.721 0.828  0.182 0.048* 0.238 
C Abd BF r † 0.806 0.001** 0.164 0.700 0.335  0.143 0.001** 0.035* 
 r ‡ 0.823 0.003** 0.180 0.701 0.349  0.158 0.003** 0.009** 
C Abd %BF r † 0.645 0.090 0.326 0.817 0.823  0.085 0.025* 0.332 
 r ‡ 0.694 0.151 0.395 0.851 0.838  0.145 0.064 0.400 
Trunk BF-to-Append BF ratio r † 0.774 0.028* 0.465 0.540 0.471  0.755 0.095 0.013* 
 r ‡ 0.807 0.075 0.542 0.608 0.547  0.791 0.171 0.048* 
Abd BF-to-whole BF ratio r † 0.316 0.039* 0.285 0.663 0.656  0.029* 0.002** 0.006** 
 r ‡ 0.394 0.063 0.660 0.718 0.675  0.050* 0.007** 0.014* 
Abd BF-to-Trunk BF ratio r † 0.258 0.175 0.845 0.500 0.851  0.028* 0.016* 0.040* 
 r ‡ 0.315 0.192 0.829 0.558 0.834  0.037* 0.023* 0.051 
Arm-C – arm circumference; WC – waist circumference ; Hip-C – hip circumference; Thigh-C – thigh circumference; Calf-C – calf circumference; BMI – 
body mass index; BAI – body adiposity index; WHtR – waist to height ratio; WHR – Waist-to-Hip ratio; Whole BF – whole body fat; Trunk BF – trunk 
body fat; Append BF – appendicular body fat; Abd BF – abdominal body fat; CAbd BF – central abdominal body fat; † - Comparison between coefficients 
of correlation obtained in partial correlations, controlled for age, sex and BMI; ‡ - Comparison between coefficients of correlation obtained in 
semipartial correlations, controlled for age, sex and BMI; * - significant for p<0.05; ** - significant for p<0.01; ***- significant for p<0.001. 
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8.4. Discussion 
To our knowledge the usefulness of some body circumferences and indexes in NAFLD 
patients, is unknown. The characteristics of the studied patients could be considered quite common 
for NAFLD patients, particularly the high levels of BMI, including obese and morbidly obese patients, 
because obesity have been identified as a strong risk factor for NAFLD and therefore highly prevalent 
in this sub-population (2-4, 6, 26). Some discrepancies were found in the diagnosis of adverse BC 
profiles, including excess BF, when using different methods and respective cutoff values. High WHtR 
was present in 100% of the patients meaning this may be more sensitive to identify patients with 
NAFLD even in those with normal BMI. All alternative methods identified higher prevalence of 
subjects considered to have a more adverse BC profile than did BMI. The high level found for WHtR, 
WHR and WC are consistent with the higher risk of comorbidities present in NAFLD patients, and 
therefore, though this was not the aim of the present study, our preliminary results suggest a 
preferable usage of the alternative methods in this population. Yet both sensitivity as well as 
specificity of these clinical markers and respective cutoffs should be thoroughly studied in NAFLD 
patients, in future studies.  
About all of the studied body circumferences and indexes were strongly associated with 
whole BF but all seem to be particularly influenced by control variables age and sex, and particularly 
by BMI. BMI seems to slightly overlap the explanation of the dependent variables by the studied 
body circumferences and indexes, as can be interpreted from confronting coefficients of correlation 
obtained with and without using BMI as a control variable. Moreover BMI seems to considerably 
explain some variation of the dependent variables that could not be explained by the studied clinical 
markers, as can be inferred from the opposition of coefficients of correlation obtained in partial 
correlations to those obtained in semipartial correlations, both controlled for age, sex and BMI. Thus, 
when WC was included as controlling variable in the correlation between BMI and whole BF, the 
coefficient of correlation dropped quite significantly, particularly in semipartial correlation. This 
means WC explains very meaningfully the variation of BF and partially overlaps that explained by 
BMI. This was expected as all tested independent variables are known BC surrogates and, to some 
extent, may overlap and explained the same body component. However they have been shown to be 
related differently with different fat depots meaning that, though all being related to whole BF, they 
can explain partly different aspects of BF content (124). Appendicular and hip-C have been shown to 
be clearly more related to subcutaneous fat, while WC, WHtR and BMI have been found to be also 
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significantly related with visceral fat, in healthy adults (124, 208). BAI, advocated to be a superior 
marker of adiposity, particular related to whole %BF (24, 284, 285), did not stand out from the other 
markers, in the present sample of NAFLD patients.  
Similar results to those found for the associations with whole BF were also found for the 
correlations with trunk BF, but in this case WC was always found consistently, independently and 
strongly associated with trunk BF, and exceptionally this association was found to be rather 
unaffected by controlling also for BMI. Therefore WC was considered to be the best marker of trunk 
BF between all tested. These results contrast with previous findings that showed, BMI and WHtR, in 
addition to WC, strongly related to trunk BF (263). However these previous findings, besides being 
collected from a sample of healthy adults, were not controlled for any covariates and therefore may 
be neither comparable to ours nor assumed to represent NAFLD sub-population specificity. WC was 
expected to be a good surrogate of trunk BF because it measures the circumference of the trunk, at 
the level of a specific abdominal landmark, and also because DXA assessed trunk BF has been shown 
to be highly related to visceral adipose tissue, assessed by MRI (91). Therefore our results are also in 
accordance to those observations showing WC to be highly related to visceral adipose tissue (124) 
and may increase the rational for the relation between WC and central obesity related metabolic 
abnormalities in NAFLD patients, as described for other populations (17, 23). The only consistent 
associations with appendicular BF were with Hip-C, Thigh-C and Arm-C. These results are in 
accordance to preferential relation of these body circumferences with subcutaneous adipose tissue 
rather than with visceral adipose tissue, which is only present in the trunk (124, 208). These results 
also support the inverse relation observed between these clinical markers and the risk of adverse 
outcomes (195, 213, 227). Yet, in the present study, these associations were not independent of BMI. 
Also in accordance to previous findings, in healthy adults (263), other markers in the present study, 
such as WC, BMI and WHtR, were also somewhat associated with appendicular BF, but the 
controlling variables age and sex seemed to be explaining a considerable part of the variation of the 
appendicular BF that was not explained by these clinical markers. This could be observed when the 
variation of appendicular BF accounted by the controlling variables was included in the correlation 
(semipartial correlation), resulting in coefficients of correlation that could not be found significant. 
BF in the abdomen seems to be particularly associated to WC, WHtR and WHR, however only 
WHtR showed a strong association with all absolute and relative variables from both Abd BF and 
CAbd BF, unaffected by age, sex and BMI. Therefore WHtR was considered the best marker of 
abdominal fat accumulation in the present study. Both studied Abd BF and CAbd, as assessed by DXA, 
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were shown to be highly related to visceral adipose tissue, assessed by MRI (79, 80). Therefore our 
results suggest that WHtR may be an important tool to assess central obesity in clinical settings to 
help preventing and managing related metabolic risk, as have been described in other populations 
(17). This is consistent with the strong relation found between WHtR and the risk of hazardous 
metabolic outcomes, frequently associated with central obesity, including CVD and death (129, 254). 
Interesting is the fact that both sex and age unexpectedly did not explain much of the variation of the 
these central BF depots, confirmed by the rather small change observed between coefficients of 
correlation obtained from both partial and semipartial correlations, this may suggest a NAFLD 
subpopulation phenotype and warrants further investigation.  
Concerning BF distribution, a rousing result is the consistent and independent inverse 
relation between arm-C and Abd BF-to-Trunk BF ratio, meaning that low arm-C may indicate more of 
trunk BF centered in the abdominal region. This is in accordance to the hazardous associations 
already found for low arm-C (226, 227). WHR was also correlated with DXA derived BF distribution 
markers, but only in partial correlations controlled for age and sex, meaning control variables explain 
a considerable amount of the variation of BF distribution that was not explained by WHR. These 
however contrasts with previous findings showing rather modest correlation coefficients in Pearson 
correlations between WHR and trunk BF-to-appendicular BF, consistently in both healthy men and 
women (263). In the present study the relation of WHR with BF distribution markers seems rather 
unaffected by BMI. Nonetheless, WHR was the only studied clinical marker to show any kind of 
relation with trunk BF-to-appendicular BF in the present study. We have showed that trunk BF-to-
appendicular BF ratio was the best DXA assessed correlate with parasympathetic nervous system 
reactivation (data presented in study 1). Despite being a strong risk factor for metabolic and 
cardiovascular hazardous outcomes (18, 298, 299, 305-309, 312), the mentioned autonomic nervous 
system marker is linked to adipocyte functioning (326, 335, 342) and may have a role in BC 
abnormalities, either as a cause or as a consequence, however this needs further supporting basic 
and clinical evidences. Surprisingly, the tested clinical markers were not acceptable independent 
predictors of trunk BF-to-appendicular BF. 
The comparison of coefficients of correlation obtained in partial and semipartial correlations 
between BMI and the studied DXA derived BF content and distribution variables with similar 
coefficients of correlation obtained between all other independent variables (circumferences and 
indexes) and the same studied dependent variables, as observed in tables 8.5 and 8.6,  confirmed WC 
and WHtR as the best alternatives to BMI in the clinical assessment of BC, considering they are not 
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inferior to BMI in assessing whole BF but seem far superior in assessing central BF content and 
distribution. Not surprisingly WHR seems particularly superior to BMI in assessing BF distribution. 
WHR was the only tested clinical marker associated with trunk BF-to-appendicular BF which we have 
showed to be the best predictor of cardiac autonomic control variation and therefore more related 
with autonomic nervous system functioning (data from study 1), thus WHR has been assumed as 
beneficial for the diagnosis of NAFLD (252) reinforcing the beneficial use of WHR in clinical setting to 
improve patients BF distribution profile assessment, which is known to be associated with health 
risks, beyond overall adiposity . 
The present study confirms the usefulness of BMI as a surrogate of whole BF however it 
emphasizes also its limitations in the assessment of both central BF accumulation and BF distribution, 
and also underscores that BMI neither superior to other tested BF surrogates, nor independent of 
WC in assessing nearly all BF depots in NAFLD patients. The present study also supports the usage of 
both WC and WHtR, as good alternative methods to BMI, to assess BC profile of NAFLD patients in 
clinical settings. Both arm-C and WHR may add information concerning BF distribution. The use of a 
simple measuring tape can be an inexpensive, simple and preferable way of assessing sound BC 
information in routine clinical appraisals in NAFLD patients, even when compared to commonly used 
BMI. 
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Chapter 9 – Conclusions 
“Overall conclusions and recommendations to be drawn from this 
thesis”  
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In this chapter all five studies are linked as one single research and the overall final 
conclusions, supported by the finding of the present thesis, are presented. The chapter is divided in 
three sections: the first section of final conclusions regards what were considered to be the main 
strengths and limitations of the present thesis and the comprised studies; a second section of the 
present chapter highlights the main findings; ultimately we will point some final recommendations 
and future directions of research.   
9.1. Strengths and limitations 
There are several strengths and limitations to this thesis. We consider the link between 
science and practice sought by the present thesis to be a major strength of this work. This is intended 
to be supportive of clinical practice and, to that extent, we think that intention may have been 
achieved, with strong evidence and scientific support. The used body composition (BC) assessment 
reference method (DXA) albeit considered a gold standard instrument to assess BC in a three 
compartment model (24), is unable to determine visceral adiposity independently from 
subcutaneous body fat (BF). Nevertheless, recent studies indicate strong correlation between 
abdominal BF estimated from selected ROI, assessed by DXA, and visceral BF quantified by magnetic 
resonance imaging (79) and computed tomography (90, 374). The study design, cross-sectional, does 
not permit to establish the usefulness of the studied clinical variables in monitoring BF content and 
distribution changes over time, or to establish causal relationships between studied variables, based 
on the present results. These results represent, however, a preliminary analysis to establish the 
usefulness of some clinical BC surrogates, particularly body circumferences and indexes, as 
surrogates of BF content and distribution in non-alcoholic fatty liver disease (NAFLD) patients. Also, 
the size of the sample did not allow for the identification of significant associations lower than 
r=0.50, in order to attain minimal statistical power of 80% and statistical significance of 5%. Even 
though results seem fairly unexposed to type 1 and type 2 errors, the ability of detecting lower, still 
important, significant associations between variables was limited. However the aim of the present 
study does not seem to have been overlooked, because it sought to find the best clinical markers, 
which are found at the higher end of correlational range. Also, the recruitment strategy used to 
constitute the studied sample limits the external validity of our results, therefore, even though these 
results may constitute important preliminary findings in the population of NAFLD patients, they can 
only be applied to patients with the same characteristics to those included in the studied sample.  
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9.2. Main Findings 
The main overall conclusions to be drawn from the present work can be divided into three 
sets. The first set of conclusions regards the first listed purpose of the present thesis: to determine if, 
and to what extent, specific markers of BC and BF distribution, are related with a selected mortality 
and cardiovascular risk related autonomic nervous system (ANS) marker in NAFLD patients. We could 
observe in the present thesis that increased BF content, particularly central BF, was associated with 
slow heart rate recovery (HRR) in NAFLD patients. BF distribution appears to be more important than 
overall BF accumulation in explaining the variation of HRR. Considering these observations we could 
conclude that the accumulation of central BF is somewhat linked to ANS decline though the 
cause/effect direction remains to be clarified. There appears to be also a particular BF distribution 
phenotype, regardless the amount of BF, that  is related as well to ANS decay, hence again it remains 
to be disclosed if it is a specific centrally distributed BF phenotype that leads to altered ANS 
functioning, or if it is the other way around. In any case, both central BF accumulation and centrally 
distributed BF can both be related to higher cardiovascular risk in NAFLD patients, resulting from 
their inverse association with HRR, which, when under specific cutoffs, is a known strong risk factor 
for metabolic and cardiovascular abnormalities as well as cardiovascular and all-cause mortality.    
A second set of conclusions to drawn from the present thesis is related to listed purposes 2 
to 4: (purpose 2) to find which of the most used waist circumference measurement protocol (WCmp) 
is preferable to be used in clinical practice with NAFLD patients; (purpose 3) to analyze whether the 
most used WCmp affect the strength of association between waist-to-height ratio and both, whole 
and central BF in NAFLD patients; (purpose 4) to analyze whether the most used WCmp affect the 
strength of association between waist-to-hip ratio (WHR) and BF content and distribution in NAFLD 
patients. All studied waist circumferences performed similarly well in relating with analyzed BF 
depots, particular with more central accumulated BF, which endows waist circumference (WC) as an 
important risk assessment tool in NAFLD patients, considering central BF is known to be particular 
important in developing NAFLD and other metabolic and cardiovascular diseases, and was shown to 
be related with slow HRR as mentioned in the previous set of conclusions. The WC that was found 
most suitable for generalization in routine clinical appraisals was that measured just above the iliac 
crest. This protocol was quite similar to the others tested when analyzing the relations with whole 
and central BF content but it demonstrated three main advantages: it uses a bony landmark which 
has been considered an important feature for standardization, therefore is preferable to the WC 
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measured at the minimal torso, also called minimal waist, as well as to the WC measured at the 
umbilicus; it uses only one landmark, which has been sensed to be more practical and easy to 
identify and measure, in opposition to the WC measured at the mid distance between lowest rib and 
iliac crest, which has two landmarks and demands the calculation and identification of a third 
landmark; and finally the measurement is less time consuming in comparison to the other tested WC 
that used bony landmarks. WC measured just above the iliac crest also performed well when used to 
calculate both WHtR and WHR (purposes 3 and 4). It allowed strong associations between those 
body indexes, particularly with central BF and was found to be among the preferable solutions for 
both mentioned indexes. So, base only on these practical criteria we conclude that this should be the 
preferable WC to be included in routine clinical practice. Both WHtR and WHR performed well in the 
association with BF, particularly with central BF. As WC alone, also both WHtR and WHR seem good 
markers of metabolic and cardiovascular risk, and may be related to increased cardiovascular and all-
cause mortality, given the inverse association of central BF with slow HRR. We conclude also that the 
WC measured just above the iliac crest should be the WCmp used to calculate both WHtR and WHR, 
considering the following four reasons: when using WC alone, WC measured just above the iliac crest 
was considered to be the preferred protocol; this preferred WCmp performed well when used to 
calculate both WHtR and WHR; WC measured just above the iliac crest was always found among the 
preferred solutions for the calculation of both mentioned body indexes and was never considered 
inferior to the other tested protocols in any criteria; and also standardization is an important purpose 
when the goal is to accomplish generalization, so it would be a strong barrier to generalization if one 
used different WCmp for each body index.  
The third set of conclusions drawn from the present thesis regards the listed purposes 5 and 
6: (purpose 5) to analyze how body circumferences and indexes perform as surrogate of whole and 
regional BF content and BF distribution in NAFLD patients; and (purpose 6) to find if any specific body 
index and/or circumference perform better than the commonly used body mass index (BMI) as 
surrogate of BC in NAFLD patients. The present thesis confirms the usefulness of BMI as a surrogate 
of whole BF however it emphasizes also its known limitations in the assessment of both central BF 
accumulation and BF distribution, and also underscores that BMI is neither superior to other tested 
BF surrogates, nor independent of WC in assessing nearly all BF depots in NAFLD patients. Among all 
tested body circumferences only WC was found to be a useful marker of BC, particularly of Central 
BF, in NAFLD patients. WHtR was the body index most related with BC, particularly with central BF 
and BF distribution, in the studied NAFLD patients. These were already reported in the present 
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thesis, except for BF distribution, and reinforce the usefulness of both WC and WHtR as risk 
assessment tools in NAFLD patients. Based on the results reported in the present thesis we are to 
conclude that both WC and WHtR are preferred alternative methods to BMI, to assess BC profile of 
NAFLD patients in clinical settings. Both arm circumference (Arm-C) and WHR may add information 
concerning BF distribution however this needs confirmation.  
9.3. Recommendations for future research 
Future studies should account for the limitations found in the present thesis, particularly that 
related with the sample size, in order to increase statistical power and to be able to detect 
meaningful results of smaller dimension. An increased sample would allow also testing differences 
between subgroups (e.g. men vs women; fit vs unfit; obese vs overweight vs normal weight; High 
HRR vs Low HRR, and other). The chosen marker of ANS functioning is known to be indicator of 
parasympathetic reactivation after maximal exercise, yet, in future studies it would be interesting to 
assess also the relation with both sympathetic and parasympathetic functioning using other 
methods. In the results from the present thesis both sex and age unexpectedly did not affect much of 
the associations with the central BF depots, and this was mentioned to possibly suggest a NAFLD 
subpopulation phenotype, though this need to be addressed in future research also. The 
continuation of this research should also focus on further associations with two main groups of 
variables: one group intends to deepen the present research and consists of assessing BC with 
different reference methods (e.g. magnetic resonance spectroscopy) to study other BF depots, 
including the liver itself, and BF distribution variables to test which are the best clinical surrogates to 
use in clinical settings with NAFLD; another group aims to broaden the present research and consists 
of testing other associations with different risk factors to find the best clinical marker of BC to use in 
clinical settings with NAFLD. Finally, a longitudinal approach may help clear some questions rose by 
the reported results, particularly the cause/effect relation of the reported association of central BF 
and BF distribution with ANS function, in other words, which abnormalities occur first and which 
follows. A longitudinal approach could also help to establish the best clinical marker to monitor 
changes in BC and associated risk profiles. Most important would be to test interventions in the 
population of NAFLD patients, particularly that focusing on lifestyle approaches, including increased 
physical activity, looking at specific health benefits related to BC changes as well as the benefits that 
are independent of BC changes resulting from increased physical activity or other features of the 
interventions to be studied. 
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